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ABSTRACT 
E3 ubiquitin ligases are key regulatory enzymes of the ubiquitination pathway as they are 
responsible for substrate specificity. This thesis aimed at deciphering the molecular 
mechanisms through which two different E3 ligases, Nedd4 and Rabex-5, exert their 
activity. Nedd4 is the prototype for HECT-E3 ligase while Rabex-5, containing an A20 
zinc finger domain (ZnF_A20) instead of a canonical RING, could be defined as an 
atypical RING-E3 ligase. 
In the case of Nedd4, we provided the first crystal structure of the catalytic 
intermediate of HECTNedd4~Ub in complex with Ub non-covalently bound to the UBD 
present in the N-lobe of HECTNedd4. Our structure represents the next step of the transfer of 
UbD from the catalytic cysteine of E2 to the one of E3 in which the UbD C-terminal tail is 
in an extended conformation primed for catalysis. Our data strongly supports the sequential 
addition model proposed for HECT proteins. 
 Within this study we also clarified some aspects of Rabex-5 as E3 ligase. By yeast-
two-hybrid, GST-pull-down assays and ITC analysis, we identified specific E2 partners, 
Ube2D and Ube2E families, that bind Rabex-5 only when in their active Ub-loaded state. 
Performing in vitro auto-ubiquitination assay and disulfide stability assay we confirmed 
that ZnF_A20 is the minimal domain responsible for the catalytic activity. To obtain the 
structure of the Rabex-51-74:E2-Ub complex, we tested, unfortunately without success, 
crystallization trials and SAXS analysis with various samples. 
 We also analyzed Rabex-5 catalytic activity towards on H-Ras, which is the unique 
substrate of Rabex-5 so far identified, and we disproved that H-Ras is a Rabex-5 substrate. 
To identify candidate substrates we profiled 20.000 human proteins using a microarray-
based ubiquitination screening. A list of 67 proteins represent the most statistically 
stringent and conservative estimate for Rabex-5 substrates that we are going to validate in 
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the nearest future, starting from the ones involved in the endocytic pathway. 
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INTRODUCTION 
1. Ubiquitin and Ubiquitin-like proteins  
Cells use different kind of post-translational protein modifications to generate and transmit 
signals regulating cellular functions. Among the numerous post-translational 
modifications, a key role is played by the covalent attachment of one or more ubiquitin 
(Ub) molecules to epsilon-amino groups of protein lysines (Dye and Schulman, 2007).  
Ub is a relatively small polypeptide of 76 amino acids, highly conserved in all 
eukaryotic cells (Pickart, 2001). This protein is extremely stable and adopts a compact β-
grasp fold with the six residues at the C-terminal tail very flexible (Vijay-Kumar et al., 
1987) (Figure 1A). It is an abundant protein present both in the cytoplasm and in the 
nucleus, in a free monomeric and target-conjugated form (Dantuma et al., 2006). In 
mammals, Ub is encoded by a multigene family; UBB and UBC encode Ub polyproteins 
with three and nine Ub coding units respectively, while UBA52 and UBA80 encode fusion 
between Ub and two ribosomal proteins (L40 and S27, respectively). The translation 
occurs from precursor proteins that are then processed into Ub monomers (Finley et al., 
1989; Redman and Rechsteiner, 1989).  
Ub is a family member of Ub-like modifiers (Ubls) together with Nedd8, SUMO 
and ISG15. The conjugation reaction to the specific substrate occurs through analogous but 
specific enzymes cascade determining the involvement in different cellular process (van 
der Veen and Ploegh, 2012). They are all very similar in structure with a common C-
terminal glycine involved in the formation of the isopeptide bond with the substrate 
(Figure 1B). SUMO (small Ub-like modifier) is involved in nuclear transport and 
organization, transcription, chromatin remodeling, ribosome biogenesis and DNA repair 
(Gareau and Lima, 2010). Nedd8 (neuronal precursor cell-expressed developmentally 
downregulated) is a well-defined modifier of all members of Cullin family, able to activate 
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their ubiquitin ligase activity (Huang et al., 2009). Autophagy 12 (Atg12p) and autophagy 
8 (Atg8p) are two Ubls involved in autophagy (Ohsumi and Mizushima, 2004). ISG15 
(interferon-stimulated gene 15) is involved in the activation of antiviral immune response 
through IFN response (Zhao et al., 2005) and broadly targets newly synthesized proteins 
(Durfee et al., 2010).	   
Interestingly, recent data demonstrated that Ub could be itself modified by post-
translational modification such as acetylation and phosphorylation, increasing the signaling 
repertoire of this multifunctional protein (Herhaus and Dikic, 2015). Among the various 
residues of Ub that can be phosphorylated, Ser65 residue has been extensively studied in 
the context of mitochondrial autophagy (mitophagy). This modification, not only changes 
the Ub surface properties adding a negative charge, but can also alter the activity of several 
E2 enzymes, E2/E3 complexes (Wauer et al., 2015) and impairs the activity for several 
deubiquitinating enzymes (Ordureau et al., 2015; Swaney et al., 2015). Alterations in 
PARKIN pathway are found in neurodegenerative disease such as in Parkinson. Recently it 
was demonstrated that PARKIN binding to the p-Ser65-Ub determines its conformational 
changes causing an increase of its E3 ligase activity (Kazlauskaite et al., 2015; Kumar et 
al., 2015; Ordureau et al., 2015).  
 
Figure 1. Structures of ubiquitin-like 
modifiers  (adapted from Dye BT, Annu Rev 
Biophys Biomol Struct. 2007). (A) Ub posses a 
compact β-grasp structure with a flexible C-
terminal tail. (B) Structures of some 
characterized Ubls. They adopt similar 
tridimensional conformation. SUMO and Nedd8 
are composed by only one Ub-like unit respect 
ISG15 that is composed by two units. 
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1.1 Monoubiquitination and ubiquitin chains  
Ub can be attached to the substrate as a single molecule (monoubiquitination or multi-
monoubiquitination) or as a polymer composed by multiple Ub molecules called Ub chains 
(polyubiquitination).  
Monoubiquitination usually determines a change in the interaction ability or in the 
localization of the target proteins (Hicke, 2001) and acts preferentially as a non-proteolytic 
signal to control gene expression, viral budding, DNA repair and endocytosis (Ramanathan 
and Ye, 2012).  
Ub chains can be of different topology depending on how Ub molecules are 
connected. The linkage between Ubs can be through the N-terminus or through one of its 
seven lysines (Lys6, 11, 27, 29, 33, 48 e 63) (Figure 2A). These chains are considered 
homogenous if on each moiety the same residue is modified, or branched if different 
linkages are used (Figure 2B). Chains display distinct structural conformations depending 
on the linkage (Kulathu and Komander, 2012). The canonical Lys48-linked chains adopt 
compact conformation (Eddins et al., 2007), with those adjacent moieties interacting with 
each other. Other linkages, such as Lys6 and Lys11, cause Ub dimers to adopt a similar 
compact conformation (Matsumoto et al., 2010). In contrast, N-terminus and Lys63- chains 
display an open conformation, with no contact surfaces except for the linkage site (Datta et 
al., 2009; Komander et al., 2009b) (Figure 3). Recently, the crystal structure of the Lys33-
linked diUb was solved showing that it adopts a symmetric compact conformation. In 
contrast, the Lys33-linked triUb in crystal structure shows an open extended conformation 
(Kristariyanto et al., 2015). Another group demonstrated that in solution the Lys33-linked 
and Lys29-linked diUb adopt an open conformation (Michel et al., 2015). Interestingly, 
also other Ub chains can adopt multiple conformations in solution (Varadan et al., 2002), 
highlighting the fact that the structural conformations are not a unique but rather a 
	   18	  
preferred state of the chains that are indeed very flexible. The receptor proteins carrying 
the ubiquitin binding domains (UBDs, see below) exploited this flexibility.  
From the functional point of view, two chains have been extensively studied: 
Lys48-linked polyubiquitin chains are involved in targeting proteins for degradation by 
26S proteasome (Hershko and Ciechanover, 1998), and Lys63-linked polyubiquitin chains 
promote cell signaling, membrane protein trafficking or DNA damage response (Chen and 
Sun, 2009). Only recently a functional role also for other Ub chains linkages has been 
established. Lys11-linked Ub chains have recently been linked to the proteosomal 
degradation of cell-cycle proteins. The anaphase-promoting complex (APC/C), the E3 
ligase critical for the mitotic degradation of cyclin B and securin, has been shown to act in 
concert with the E2 Ube2S generating Lys11-linked Ub chains on its substrates (Jin et al., 
2008; Wickliffe et al., 2011). Linear-linked chains are involved in nuclear factor-κB (NF-
κB) signalling and cell death and dysfunction in linear ubiquitination underlie chronic 
inflammation (Iwai et al., 2014). Lys33-Ub chains appear to have non-degradative 
functions working as negative regulator of T-cell antigen receptor (Huang et al., 2010) and 
of AMPK (AMP-activated protein kinase)-related protein kinase (Al-Hakim et al., 2008). 
Finally, branched chain with mixed linkages can be formed in vitro (Ben-Saadon et 
al., 2006) and their role in vivo was established in recent work (Meyer and Rape, 2014). 
Rape and colleagues identified substrates that are specifically modified by branched 
ubiquitin chains and showed that these conjugates provide an improved signal for 
proteasomal degradation (Meyer and Rape, 2014).  
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Figure 2. Ub chains (adapted from Kulathu, Nat. Rev. Mol. Cell Biol., 2012). (A) The Ubiquitin 
molecule. The N-terminus and all the lysine residues involved in chains formation are highlighted. 
(B) Schematic representation of all different types of substrate ubiquitination such as mono, multi-
monoubiquitination and homogeneous or mixed in the case of Ub chains. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Structures of some Ub chains with different linkages (adapted from Kulathu, Nat. 
Rev. Mol. Cell Biol., 2012). Depending on the type of linkages, every Ub chains adopt different 
tridimensional structures that determine different functions. Ub chains with K48-, K6- and K11-
linkage display a compact conformation instead of K63- and N-terminus adopt an open 
conformation. The hydrophobic patch centered on Ile44 is represented in blue and the interaction 
patch centered on Ile36 is represented in green. 
 
A! B!
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1.2 Ubiquitin binding domain (UBD) 
As stated before, each chain may assume distinct structure and function in the cell and this 
selective function is mediated by Ub receptors, proteins that contain Ub binding domains 
(UBDs) (Husnjak and Dikic, 2012). 
UBDs are small domains (20-150 aa) able to bind non-covalently Ub (Hicke et al., 
2005). A large amount of proteins (around 150 by a rough estimation) possess UBDs 
through which they can interact with ubiquitinated substrates. The abundance and 
localization of ubiquitin receptors is crucial for the generation of an ubiquitin network 
where the ability of ubiquitin to act as an interaction module works as a signalling cascade.  
The binding affinity of single UBD is very low, with a dissociation constant (KD) 
around 10-500 µM (Dikic et al., 2009); this is advantageous for the cell because it creates a 
dynamic network allowing rapid assembly and disassembly of the complexes. 
The most common surface of interaction between UBDs and Ub involves the 
solvent-exposed hydrophobic patch of Ub, which includes Leu8, Ile44 and Val70. 
However, other UBDs interact with different residues of Ub, determining a large amount 
of structural folds and unique binding modes (Dikic et al., 2009). Few examples are: the 
ZnF_A20 of Rabex-5 binds Ub to a polar surface centered on Asp58 (Penengo et al., 
2006), the ZnF UBP of DUB isopeptidase T interacts with the C-terminal Gly of Ub 
(Reyes-Turcu et al., 2006), the UEV (Ubc E2 variant) domain contacts a hydrophilic site 
centered on Gln62 of Ub (Sundquist et al., 2004). In addition, single UBDs can have 
multiple ubiquitin binding surfaces. For example DUIM, which possess one α-helix UIM 
domain, is able to interact simultaneously with two Ub molecules using opposite surface 
on the same α-helix (Hirano et al., 2006). 
Binding to UBDs can modify Ub chains topology generating a range of inter-
moiety arrangements as demonstrated for Ub chains Lys48-linked, Lys63-linked and N-
terminus-linked (Dikic et al., 2009). For example, Lys63-linked diUb is usually present in 
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open conformation with the linker region that connects the two Ub moieties very flexible. 
However, it assumes an extended conformation when in complex with the UBD of the 
endosome-associated Ub isopeptidase AMSH (associated molecule with the SH3 domain 
of STAM) to facilitate the cleavage of the isopeptide bond (Sato et al., 2008). By contrast, 
Lys63-linked diUb can assume a more compact conformation when it interacts with 
specific antibodies able to recognize it (Newton et al., 2008).  
The number of identified UBDs are constantly growing and now includes at least 
twenty domains: UBA, UIM, MIU, DUIM, CUE, GAT, NZF, ZnF_A20, UBP, UBZ, Ubc, 
UEV, UBM, GLUE, Jab1/MPN, VHS, PRU, SH3, UBAN and PFU (Table 1).  
 
Table 1: Summary of ubiquitin binding domains and their main characteristics (adapted from 
Husnjak and Dikic, Annu. Rev. Biochem. 2012).  
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UBD abbreviations Structure
Ubiquitin
surface
Type of ubiquitin
binding Proteins with speci!c UBDs
UBA Three-helix bundle Ile44 mUb
polyUb ( > K48)
UBL
PLIC1/2, HHR23A/B, Ddi1,
p62/SQSTM1, NBR1, Cbl-b, USP5,
UBC1, HERC2
CUE Three-helix bundle Ile44 mUb Cue2 (monomeric), Vps9 (dimeric)
UIM Single α -helix, often present in tandem Ile44 mUb
pUb (K48, K63)
UBL
S5a, Vps27, USP28, ataxin-3, EPS15,
STAM, RAP80
MIU/IUIM Single α -helixb Ile44 mUb Rabex-5
DUIM Single α -helix, binds two ubiquitin moleculesc Ile44 mUb Hrs
VHS Superhelix of eight α -helices Ile44 mUb STAM, Hrs
GAT Three-helix bundle Ile44 mUb GGA3, TOM1
NZF Zinc !nger, four β -strands Ile44 mUb
pUb (K63) d
Npl4, VPS36, TAB2, TAB3, HOIP,
HOIL-1L
ZnF A20 Zinc !nger Asp58e mUb (Rabex-5)
Lys63 (A20)
A20, Rabex-5
ZnF UBP Zinc !nger, a globular fold with a deep cleft
and pocket to accommodate ubiquitin’s tail
Leu8, Ile36,
tail
pUb (unanchored) USP5, HDAC6, BRAP2
UBZ Zinc !nger, ββα -fold Ile44 mUb
pUb
Polymerase η , polymeraseκ , FAN1,
NDP52, TAX1BP1, WRNIP1
UBC β -sheet Ile44 mUb UbcH5C
UEV αβ -sequence, lacks E2 catalytic Cys Ile44 mUb VPS23, TSG101
UBM Helix turn helix, helices separated by an
invariant Leu-Pro motif
Leu8 mUb Polymerase ι , polymerase Rev1
GLUE Split-pleckstrin homology domain Ile44 mUb EAP45
PRU Pleckstrin homology domain, three loops bind
ubiquitin
Ile44 mUb (Ile44)
pUb (K48 linker)
UBL
Rpn13
Jab1/MPN Inactive variant of Jab1/MPN domain lacking key
residues in the motif
Ile44 mUb Prp8p
PFU Four β-strands and two α-helices Ile44 mUb
pUb
Doa1, PLAA
SH3, variant β-barrel fold, hydrophobic groove binds ubiquitin Ile44 mUb Sla1, CIN85, amphiphysin
UBAN Parallel coiled-coil dimer Ile44
Phe4
linker
Met1-diUb NEMO, optineurin, ABIN1-3
WD40 repeat β -propeller Top surface of WD40 repeatβ -propeller Ile44 mUb Doa1/UFD3
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Most UBDs bind the hydrophobic patch of Ub through an α-helical-based 
structure. Some UBDs such as ubiquitin-interacting motif (UIM), inverted UIM (MIU), 
double-sided ubiquitin-interacting motif (DUIM) are composed by a single α-helix, others 
such as ubiquitin-associated domain (UBA) and CUE domain bind Ub through two 
discontinuous α-helices(Hurley et al., 2006)(Figure 4A).   
 The second largest family of UBDs is represented by ZnFs and this family is 
composed by NZF domain, A20_ZnF domain, ZnF UBP and UBZ domains. They use a 
single zinc-binding site that coordinates a zinc atom (Figure 4B). 
 
Figure 4. Structures of different ubiquitin binding domains (adapted from Hurley, Biochem J. 
2006). (A) Representation of some UBDs characterized by the α-helix. Ub molecule is represented 
in yellow and the helical domain in blue. The canonical hydrophobic patch involved in the binding 
is depicted as green spheres. (B) Representation of three UBDs, shown in blue, those possess the 
ZnF domain where the zinc ions are highlighted as red sphere. Ub is depicted in yellow and the 
canonical hydrophobic patch in green spheres to show that they recognize different surface on Ub. 
 
These zinc-finger-based structures possess more diversity in recognition and affinity than 
the α-helix domains because they recognize different surfaces on the Ub. An example is 
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represented by the ZnF4 domain which is able to bind three separate Ub molecules using 
unique interaction interface (Bosanac et al., 2010).  
Many proteins carry more than one UBD (tandem UBDs), either of the same or of 
different structure, causing specific network (Husnjak and Dikic, 2012) (Figure 5). An 
example of tandem UBDs is Rabex-5 that is composed by the N-terminal ZnF_A20 
domain fused to the MIU domain, a zinc finger and α-helix domains respectively (Lee et 
al., 2006a; Penengo et al., 2006).  
Proteins containing tandem UBDs can interact each other through their UBDs 
forming multi-protein complexes. This process can also determine an increase in the Ub 
binding affinity due to the avidity effect, promoting the Ub:UBD interaction. Many 
endocytic proteins possess multiple UIMs such as epidermal growth factor receptor protein 
substrate 15 (Eps15) and Eps15R that have double-sided UIMs. UIMs bind to mono-Ub 
with low affinity however multiple UIMs cooperate to increase the affinity and could bind 
multiple monoubiquitinated proteins (Hofmann and Falquet, 2001). 
Tandem UBDs can also define the interaction with Ub chains of specific linkage, 
such as RAP80 (receptor associated protein 80) that specifically binds Lys63-linked but 
not Lys48-linked Ub chains through its two UIMs (Sims and Cohen, 2009). 
In the case of the transcriptional activator Met4, the two tandem UBDs, UIM and 
UIM-like domains (Tyrrell et al., 2010) exert a different function regulating the enzyme 
activity. Preventing its proteasomal degradation, these two UBDs interact with the Lys48-
linked Ub chains blocking the interaction of Met4 with the promoter (Kaiser et al., 2000).  
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Figure 5. Models of possible role of tandem UBDs (adapted from Husnjak and Dikic, Ann. Rev. 
Biochem. 2012). (A) Tandem UBDs can help the formation of multi-protein complex causing an 
increase in the binding affinity to an avidity effect. (B) Binding with specific Ub chains or mono-
Ub can positively or negatively regulate the protein activity. (C) Tandem UBDs can discriminate 
between different Ub chains conferring linkage specificity of the protein. 
 
2. The Ubiquitin Machinery  
The ubiquitin pathway is comprised of many enzymes and regulators that process, activate, 
attach and detach ubiquitin to substrates. In the ubiquitination cascade three different 
enzymes are involved: Ub-activating enzymes (E1s), Ub-conjugating enzymes (E2s) and 
Ub-ligases (E3s). The cascade mechanism allows the prompt modification of a large 
number of diverse substrates, in many distinct ways (Scheffner et al., 1995). For covalent 
conjugation to occur, the ubiquitin C-terminus has to be activated. This happens through 
the action of an activating enzyme (E1), that forms a thioester with the carboxyl group of 
the C-terminal Ub residue, Gly76. Subsequently, this transient thioester is transferred to 
the cysteine of a conjugating enzyme (E2). This second enzyme carries the activated Ub to 
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a third enzyme, the ubiquitin ligase (E3), which catalyzes the transfer of Ub to the lysine 
residue of the substrate, generating a stable isopeptide bond (Figure 6).  
In the ubiquitin pathway two E1 enzymes are involved in the activation and transfer 
of Ub to a limited number of E2s, which interact with several E3s determining an increase 
in specificity along the cascade. Indeed each E3 recognizes and ubiquitinates a panel of 
substrates with high specificity (Hershko and Ciechanover, 1998).  
 
 
 
 
 
 
 
Figure 6. Schematic representation of the ubiquitin 
pathway (adapted from Woelk, Cell Div. 2007). 
Substrate ubiquitination occurs via the stepwise transfer 
of Ub moieties from Ub-activating enzyme (E1), to an 
Ub-conjugating enzyme (E2) and finally to the protein 
substrate in a ligation reaction catalyzed by the E3 
ligase. The two major classes of E3 ligases are depicted. 
 
 
 
 
 
 
 
2.1 Ub-activating enzyme (E1) 
In mammals there are two E1 (UBA1 and UBA6) involved in the ubiquitin activation 
(Pelzer et al., 2007). Structural studies have shown that E1s contain at least three distinct 
regions involved in the biochemical activities of the enzyme: two pseudosymmetric 
adenylation domains that are involved in ATP-Mg2+ and Ub binding, a catalytic cysteine 
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domain (Cys domain) that is involved in the E1~Ub thioester bond formation and a Ub 
fold domain (UFD) important for the E2 interaction (Lee and Schindelin, 2008).  
The enzyme undergoes remarkable conformational changes during the process of 
activation. The first step of the reaction is guided by the binding of ATP- Mg2+ and Ub in 
the adenylation domain that adenylates the C-terminal glycine of Ub. Once the Ub is 
adenylated the E1 releases the pyrophosphate, generating an 130° rotation of the Cys 
domain. Cys domain rotation facilitates the nucleophilic attack and the transfer of Ub from 
the adenylation site to the catalytic site with the formation of a thioester bond. Once the 
thioester bond is formed, the AMP is released and another conformational change occurs. 
This favours a second cycle of adenylation starting from the binding of ATP- Mg2+-Ub 
(Olsen and Lima, 2013) (Figure 7). A fully loaded E1 carries two Ub molecules, one as 
thioester and the second as adenylate. The thiol-linked Ub is then transferred from the E1 
to the second enzyme of the ubiquitination cascade, the E2. 
 
 
 
 
Figure 7. Schematic representation of the first 
step of ubiquitination (adapted from Kleiger, 
Trends Cell Biol. 2014). First step of the process 
is the activation of Ub through its adenylation 
mediated by the E1 using a molecule of ATP. 
Second step is the formation of the thiolester bond 
between Ub and the catalytic cysteine of the E1. 
Next, Ub is transferred from the E1 to the E2.  
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2.2 Ub-conjugating enzyme (E2) 
E2s are functionally defined for their capability to accept the Ub thioester from the E1 
ternary complex and to transfer ubiquitin to either an E3 or a substrate (Figure 8). There 
are 11 E2s in Saccharomyces cerevisiae and more than 40 in higher organisms (Metzger et 
al., 2012). This class of enzymes carries out distinct biological functions and their 
specificity of function is mainly related to their interactions with distinct E3s (Pickart, 
2001).  
 
Figure 8. Functions of E2 (adapted from 
Kleiger, Trends Cell Biol. 2014). E2 enzymes 
interacting with RING/RING-like E3s can 
directly transfer the Ub to the substrate as in 
(i). E2s that interact with E3s containing the 
HECT or RBR domain, as in (ii), require an 
additional trans-thioesterification step.    
 
All E2s have a common conserved UBC core domain of ~150 residues important 
for the E1 recognition, for the binding and transfer of the activated Ub (Pickart, 2001). 
Depending on the domains that they possess, E2s can be divided in four major classes: 
Class I (e.g.Ube2D, UbcH7, Ubc13) possess only the UBC core domain, Class II (e.g. 
Ube2k) and Class III (e.g. UbcH6 and Ube2e2) possess a C-terminal and N-terminal 
extension from the UBC core domain respectively, Class IV possess both extensions. 
These amino acidic sequences contribute for the substrate specificity, as they can modulate 
both E3 interactions and cellular localization (Christensen et al., 2007). 
It is known that the E2 binding to E1 and to E3 is mutually exclusive, as their 
binding sites on the E2 are partially overlapping. Thus, the E2-E3 interaction happens only 
when the E2 is disengaged from the E1. In addition, E1 preferentially associates with free 
E2s while E3 preferentially associates with Ub-thioester E2s, thus ensuring sequentiality in 
the cascade (Eletr et al., 2005). A recent analysis based on structural and computational 
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approach revealed that on the interaction surface there are structurally conserved residues 
among E2 proteins which appear to be essential for all E2−E3 interactions despite E3 
characteristics (RING or HECT type E3s), while a particular loop in the structure likely 
plays important roles in E3 selectivity (Kar et al., 2012).  
A specific HPN motif surrounding the active site of the E2 has a crucial role in 
isopeptide bond formation, positioning the incoming lysine and generating an environment 
that lowers the pKa of the lysine to promote the nucleophilic attack (Bernier-Villamor et 
al., 2002). In different E2s (e.g. Ube2D2) the conserved asparagine of the HPN motif can 
form an oxyanion intermediate interacting with the last glycine at the C terminus of Ub 
(Wu et al., 2003). During the nucleophilic attack of the thioester bond, the oxyanion 
intermediate facilitates the Ub transfer (Sakata et al., 2010) (Figure 9). In addition, the 
asparagine side chain has a structural role and it is required to maintain the correct 
tridimensional rearrangement of the active site loop (Berndsen et al., 2013). 
 
 
 
 
 
 
 
 
Figure 9. Role of the Asparagine in HPN motif (adapted from Sakata, Structure. 2010). (A) 
Model of oxyanion intermediate for nucleophilic attack on E2~Ub. (B) Schematic representation of 
the binding interface between Ub and E2 (e.g. Ube2D3) around the catalytic site. Black dashed 
lines represent hydrogen bonds and pink dashed lines are hydrophobic interactions. 
 
Some members of E2 families, i.e. Ube2D3, have a non-covalent Ub-binding 
domain on the “back side” of the E2, centered on Ser22. Through this surface they interact 
Ube2D2 
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with Ub via the canonical hydrophobic patch of Ub composed by L8, I44 and V70 (Figure 
10A). The Ub conjugated to the active site of the E2 cannot bind the backside UBD present 
in the same E2 molecule. Thus, each E2 can bind two different Ub molecules 
simultaneously: one non-covalently to the UBD and the other covalently linked to the 
catalytic cysteine (Figure 10B). It was initially proposed that this UBD is important for the 
processivity in Ub chain formation, as it creates E2~Ub self-associated oligomers that 
increase the local concentration of E2~Ub around the E3 (Brzovic et al., 2006). Indeed, the 
S22R mutation, which disrupts the interaction on the “back side”, impaired the ability of 
E2s to form poly-Ub chains but not to monoubiquitinate (Brzovic et al., 2006; Buetow et 
al., 2015). More recently, it was proposed that the Ub, bound to the “back side” might have 
a positive allosteric activity on the E3-mediated Ub transfer. Indeed, it appears to stabilize 
the E3-E2~Ub complex in a catalytically favorable conformation (Buetow et al., 2015). 
 
Figure 10. UBD in the E2. (A) (adapted from Sakata, Structure. 2010) Schematic representation of 
the non-covalent interaction between UBD of the E2 (e.g. Ube2D2) and Ub where residue S22 of 
E2 has a critical role. Black dashed lines represent hydrogen bonds and pink dashed lines are 
hydrophobic interactions. (B) (adapted from Brzovic, Mol Cell. 2006) Cartoon depicting the self-
assembly of activated E2~Ub through the non-covalent interaction UBD:Ub that is important for 
the processivity. Each E2 interacts with two different Ub molecules.  
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2.3 Ub-ligase enzyme (E3) 
The last enzymes of the ubiquitination machinery are the Ub-ligase E3s that in humans are 
estimated to be more than 600.  
According to their properties, E3 ligases could be divided in three major classes: 
HECT, RING and RING-in-between-RING (RBR) domain-containing E3s. E3 ligases 
containing the HECT (homologous to the E6AP carboxyl terminus) domain (Rotin and 
Kumar, 2009) form an obligate thioester intermediate via a catalytic cysteine and 
subsequently transfer the Ub to the lysine of the substrate (Figure 11A). The vast majority 
of E3 ligases belong to the group of Really Interesting New Gene (RING) and RING-
related E3s – such as plant homeodomain (PHD) and members of the U-box family 
(Deshaies and Joazeiro, 2009). 
These enzymes do not contain catalytic cysteines but simultaneously bind the E2~Ub and 
the substrate to allosterically activate the donor Ub carried by the E2 enzyme (Dou et al., 
2012; Plechanovova et al., 2012) and subsequently transfer it to the substrates (Deshaies 
and Joazeiro, 2009)(Figure 11B). The last class of E3 ligases is represented by the RBR, 
defined as RING-HECT hybrid, because it possesses both a RING-type domain and an 
atypical RING domain (RING2) containing a catalytic cysteine (Metzger et al., 2012; 
Wenzel and Klevit, 2012) (Figure 11C). 
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Figure 11. Mechanisms of Ub transfer for different E3s (adapted from Wenzel, BMC Biol. 
2012). (A) E3 ligases containing the HECT domain bind the E2~Ub and the Ub is transferred to the 
catalytic cysteine forming a thioester intermediate. Next the E3s transfer Ub to the lysine of the 
substrate. (B) RING-E3 ligases act as scaffold facilitating the transfer of Ub from the E2~Ub to the 
lysine. (C) RBR domains act as RING-HECT hybrids. The E2~Ub binds the RING1 domain and 
Ub is transferred to the catalytic cysteine of the RING2 domain. Next Ub is transferred to the 
lysine of the substrate.  
 
E3 ligases confer specificity in the ubiquitination reaction since they recognize specific 
target substrates and determine - alone or in combination with their cognate E2 - whether 
the substrate will be mono- or polyubiquitinated and the type of linkages that are formed 
(Christensen et al., 2007).  
Little is known about how these enzymes can determine the linkage specificity 
during Ub-chains elongation. With few remarkable exceptions (Jin et al., 2008; Petroski 
and Deshaies, 2005; Wickliffe et al.) even if various models have been proposed 
(Hochstrasser, 2006) the mechanisms of Ub-chain assembly have not been clarified yet 
(Figure 12).  
	  
	  
	   32	  
Figure 12. Models for synthesis of polyubiquitin chain (adapted from Hochstrasser, Cell 2005). 
(A) Sequential addition model in which a RING E3 (here depicted) attaches one Ub at a time, 
starting from the lysine of the substrate and then to the specific lysine on the distal Ub of the 
growing chain. (B) Indexation model in which the entire Ub chain is first built on the catalytic 
activity of the HECT E3 and then transferred to the lysine of the substrate. (C) Seesaw model 
shows a possible mechanism in which a pair of E2s (homo- or heterodimer) can built Ub chain 
prior the transfer to the substrate. The growing Ub chain passes back and forth between the two 
E2s. (D) In the hybrid model Ub chain is formed on the catalytic cysteine of the E3 but an 
additional step is necessary. The free end of the Ub chain has to be activated by the E1 then 
transferred to the cysteine of the E2 before the final transfer to the substrate.  
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2.3.1. HECT 
The HECT E3s are enzymes characterized by the presence of a well-conserved catalytic 
domain, the HECT domain, a 350 residues module first characterized in the human 
ubiquitin protein ligase E6-associated protein E6AP (Huibregtse et al., 1995).  
In mammals there are ~30 HECT domain E3s and they are divided in subfamilies, depicted 
in Figure 13, according to their protein-protein interaction domain architecture: the 
HERCs contain RCC1 (regulator of chromosome condensation 1)-like domains (RLDs); 
the Nedd4 family ligases contain a C2 and several WW domains, and HECT E3s that 
neither contain C2, RLDs nor WW domains (Rotin and Kumar, 2009; Scheffner and 
Kumar, 2014). They have different roles and functions in protein trafficking, immune 
response and different signaling pathways. Their deregulation is associated with several 
human diseases, including cancer (Rotin and Kumar, 2009; Scheffner and Kumar, 2014).  
HECT-domain E3 ligases catalyze two distinct reactions: a transthiolation reaction, 
in which ubiquitin is transferred from the E2 to an active site cysteine in the HECT 
domain, and a subsequent attack on the HECT~Ub thioester by a substrate lysine 
(Huibregtse et al., 1995) (Figure 11A). For both reactions, the HECT domain is necessary 
and sufficient. 
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Figure 13: Domain architecture of mammalian HECT E3s (adapted from Rotin and Kumar, 
Nat. Rev. Mol. Cell Biol. 2009). In all cases the HECT domain is present at the C-terminus. The 
HERC family members can be divided in two group: the small HERCs contain only one regulator 
of chromosome condensation 1 (RCC1)-like domains (RLDs), the large HERCs contain more than 
one RLD and additional domains. Nedd4 family members shared common domain architecture, 
composed by an amino-terminal C2 domain and two to four WW domains. The other HECT family 
contains proteins composed by various domains (as shown). PABC, PABP (Poly (A)-binding 
protein) C terminus; ANK, ankyrin; UBA, ubiquitin-associated; ZnF, zinc finger. Not all these 
proteins have an E3 ligase activity, even if they possess the HECT domain, as it was proposed for 
G2E3 (Brooks et al., 2008).  
 
From the structural point of view, the HECT domain is a bilobal structure composed by an 
N-terminal region (N-lobe) important for the E2 binding and a C-terminal region (C-lobe) 
that contains the conserved catalytic cysteine involved in thioester formation (Scheffner et 
al., 1995). The C- and N- lobes are connected by a hinge loop whose flexibility determines 
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the various conformations observed in the different solved structures (Huang et al., 1999) 
(Figure 14).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Different orientation of the C-lobe in the structures of HECT domains (adapted 
from Maspero E., EMBO Rep., 2011). Structures of the different HECT domains show that the C-
lobe may assume different orientation respect the N-lobe. N-lobes are in light blue, while C-lobes 
are in a colour gradient, ranging from blue (residue linked to the N-lobe) to red (C-terminus of the 
HECT domains). The position of the catalytic cysteine is highlighted as yellow ball, representing 
the sulphur atom. 
 
The flexibility of the hinge loop has a critical role in the ligase activity. It is required to 
bring in close proximity the cysteine residues of the E2 and the E3 during Ub transfer and 
for the nucleophilic attack of the target lysine to the HECT~Ub (Kamadurai et al., 2013; 
Kamadurai et al., 2009; Verdecia et al., 2003) (Figure 15).  
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Figure 15. Model of the catalytic activity of the HECT 
domain (adapted from Kipreos E., WormBook 2005). 
The mechanism of the Ub-conjugation to the substrate by 
the HECT domain is shown. The E2~Ub binds the N-lobe 
of the HECT domain and transferred Ub to the catalytic 
cysteine of the C-lobe. The C-lobe rotates on the flexible 
hinge loop and catalyzes the transfer of Ub to the lysine of 
the substrate. 
 
 
 
 
 
E3 ligases containing the HECT domain possess a wide range of linkage specificity: yeast 
Rsp5 and human Nedd4 synthesize Lys63-chains (Kim and Huibregtse, 2009; Maspero et 
al., 2011), E6AP assembles Lys48 and KIAA10/UBE3C promotes chains formation with 
Lys29 and Lys48 linkages (Wang and Pickart, 2005). The apoptosis-resistant E3 ubiquitin 
ligase (AREL1) is instead able to synthesize predominantly atypical Lys33-linked chains 
with a little percentage of Lys11-chains (Michel et al., 2015). For HECT-E3 ligases the 
linkage specificity is an inherent property of the HECT domain itself and does not depend 
on the interacting E2. It was demonstrated that the last C-terminal 60 amino acids of the C-
lobe contain the critical determinant for the linkage specificity (Kim and Huibregtse, 
2009). Our lab has recently demonstrated that the partial substitution of the last four 
residues of the HECT domain of Nedd4-1 with residues of E6AP produced a partial 
changing in linkage specificity from Lys63 to Lys48-linked Ub chains (Maspero et al., 
2013). The last three or four residues present in the C-terminal part of the HECT domain 
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are important for the chain specificity, however other determinants present in the C-lobe 
might participate. 
2.3.2. RING 
The mammalian genome encodes for more than 600 potential RING finger E3s (Deshaies 
and Joazeiro, 2009). They regulate crucial cellular functions such as cell cycle, DNA 
repair, cell signaling and responses to hypoxia (Deshaies and Joazeiro, 2009).  
In these enzymes, the catalytically critical domain is the RING. Thanks to the 
coordination of two structural Zn2+ ions through eight Cys and His residues, the RING 
domain assumes a globular conformation similar to a cross brace structure (Petroski and 
Deshaies, 2005). The RING E3 has a dual role in substrate ubiquitination. First, it acts as a 
scaffold between the E2~Ub and the substrate and brings them together in close proximity 
(Figure 11B). Second, it induces conformational changes in the complex that allosterically 
activates the E2~Ub and correctly orients the thioester bond. Structural studies in which 
E2~Ub loaded form is captured in complex with RING domain E3, RNF4 (Plechanovova 
et al., 2012) or BIRC7 (Dou et al., 2012) show that the RING domain contacts an 
hydrophobic patch on the loaded ubiquitin. This contact immobilizes the C-terminus of the 
ubiquitin moiety in a structurally conserved groove in the E2, favoring a conformation that 
facilitates the lysine attack of the substrate lysine to the thioester bond (Dou et al., 2012; 
Plechanovova et al., 2012). Members of RING ligases can work as monomers, dimers or 
multi-subunit complexes (Figure 16).  
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Figure 16: RING E3s arrangement (adapted from Lipkowitz, 2011). RING finger E3s can be 
single subunit in which the RING finger (RF) is surrounded by protein interacting motifs (shown in 
dark blue) or homodimers/heterodimers where the RING finger and/or surrounding regions serve 
as the site of dimerization. Finally they can exist as multisubunits E3s, which include a scaffold to 
assemble multiple proteins (as the Cullin protein) such as adaptor proteins and substrate targeting 
proteins. 
 
Dimerization of RINGs often occurs through surrounding regions of the RING domain 
itself, forming homodimers or heterodimers (Lipkowitz and Weissman, 2011). One 
example of homodimers is represented by the Rnf8 E3 ubiquitin-protein ligase complex 
that plays a key role in DNA damage signaling (Nakada et al., 2012; Peuscher and Jacobs, 
2011). In the case of heterodimers, generally one RING is not active and is involved in the 
stabilization of the active E2 binding RING domain. A well-studied example is given by 
E3 ligase Mdm2 that can function as homodimer or heterodimer with MDMX in regulating 
the tumor suppressor p53 (Linke et al., 2008). Another example is Brca1-Bard1, a RING 
finger complex where the two proteins are associated through the N-terminal regions. In 
this complex, only Brca1 has a role in E2 binding and E3 activity, instead Bard1 has only a 
structural role as it does not even contact the E2 (Brzovic et al., 2003). 
Examples for multi-subunit RING ligases are the APC/C (anaphase-promoting 
complex/cyclosomes) and the Cullin family ligases (Culling-RING ligases, CRLs) (Hua 
and Vierstra, 2011). The APC/C has a critical role in the correct progression of the cell 
cycle. It is composed of several subunits including co-activators that confer substrate 
specificity and associate with the APC/C at specific stages of the cell cycle (Buschhorn 
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and Peters, 2006). Cell cycle regulation depends also on the action of another family of 
multi-subunit E3s, the SCF (Skp1-Cul1-F-box) (Lydeard et al., 2013). The SCF is a 
modular class of E3 ubiquitin ligases that use an interchangeable set of substrate adaptors 
termed F box proteins (Bai et al., 1996). The SCF complex is the prototypic Cullin E3 
where a Cullin protein serves as a scaffold to assemble multiple proteins, including a small 
RING finger protein (RBX1), adaptor proteins (such as SKP1) (Feldman et al., 1997) and 
substrate targeting proteins (such as F-box) (Deshaies, 1999). 
In addition to the classical RING domain other similar domains were demonstrated 
to have similar E3 properties. U-box proteins are an evolutionary variant of the RING 
domain, with similar folding and function but with a hydrophobic core in place of 
structural metal ions (Ohi et al., 2003). 
The PHD domain represents another variant of the RING finger that includes a 
cysteine rather than a histidine in the fourth coordinating position and an invariant 
tryptophan before the seventh zinc-binding residue (Aravind and Koonin, 2000; Capili et 
al., 2001). Another variation of the theme is represented by proteins that contain a zinc 
finger (ZnF) domain. Among them, the ZnF_4 of the A20 protein (Bosanac et al., 2010) 
and the ZnF_A20 of Rabex-5, have been shown to possess catalytic activity (Lee et al., 
2006a; Xu et al., 2010).  
 
2.3.3. RING in between RING (RBR) 
The RING-between-RING E3s family has only recently burst upon the scene as a 
mechanistically distinct class of E3s that shares features of both RING and HECT E3s, yet 
catalyze ubiquitination and auto-regulate their activity in a distinct manner. These E3 
ligases contain RING and RING-like domains separated by a conserved sequence called 
in-between-RING (IBR) (Aguilera et al., 2000). The first RING domain is important to 
recruit the E2 and the second RING possesses the catalytic cysteine to form a thioester 
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intermediate in a HECT-like mechanism (Wenzel et al., 2011) (Figure 11C). The presence 
of the second RING, which acts as an HECT domain, determines the linkage specificity. 
Members of this E3 family mediate diverse processes as regulation of post-
translation modifications and protein stability, cellular and stress signaling, cell-cycle 
control, transcription, RNA metabolism and translation (Eisenhaber et al., 2007). 
The most studied RBR enzymes are Parkin, whose mutations in the RBR domain 
are associated with Parkinson’s disease (Shimura et al., 2012), and HOIP (HOIL-1 
interacting protein) that is a component of the complex LUBAC (linear ubiquitin chain 
assembly complex). The LUBAC complex regulates the translation and activates the NF-
kB signaling (Wenzel and Klevit, 2012). These proteins are regulated in different ways like 
intramolecular auto-inhibition or they are potential targets of protein kinase (Spratt et al., 
2014). As example, phosphorylation of residue Ser65 on Parkin Ub-like (Ubl) domain, 
mediated by PINK1 (PTEN-induced putative kinase protein 1) (Kazlauskaite et al., 2014), 
has a critical role in Parkin activation (Kumar et al., 2015). This modification increases the 
affinity for p-Ser65-Ub by 20-fold determining an increase in Parkin activation 
(Kondapalli et al., 2012; Ordureau et al., 2015). 
 
2.4. De-ubiquitinating enzymes (DUBs) 
Ubiquitination is a reversible and dynamic process thanks to the action of deubiquitinating 
enzymes (DUBs). These enzymes specifically cleave the isopeptide bond between the ε-
amino group of lysine side chains of target proteins and the C-terminal group of ubiquitin 
or disassemble Ub-chains. Human genome encodes for about 100 DUBs and more than 
60% of these DUBs are not well characterized. 
The critical role of DUBs is to maintain the pool of free-Ub by processing linear 
fusion products (UBC and UBB), ubiquitin precursors (Clague et al., 2012), Ub chains 
preformed or Lys48-Ub chains to rescue the Ub from proteasomal degradation (Hanpude 
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et al., 2015)(Figure 17a, e, b). They have an additional role in non-proteasomal 
degradation pathway by removing Ub signal and by editing the Ub chains and generating 
alternative Ub signaling (Chen and Sun, 2009)(Figure 17c, f). These proteins are 
composed of multi-domains as the catalytic DUB domain and the UBDs involved in the 
binding of ubiquitinated-substrate and/or subcellular localization domains (Hanpude et al., 
2015).  
DUBs can be classified into 5 distinct families: ubiquitin C-terminal hydrolases 
(UCH), the ubiquitin specific proteases (USP/UBPs), Otubain domain ubiquitin binding 
proteins (OTU), Machado-Joseph domain-containing (MJD) proteases, Jab1/Pab1/MPN 
domain-containing (JAMM) protease (Nijman et al., 2005). All DUBs families are cysteine 
proteases, except for protease containing the JAMM domain that are the only DUBs 
classified as Zn metalloproteases because required a Zn2+ ion for their function (Nijman et 
al., 2005).  
 A large group of DUBs, i.e. most of USP family members, disassemble Ub chains 
independently of the linkage (Komander et al., 2009a). Other DUBs display specificity 
toward one or few linkages. Examples include Cezanne that specifically cleaves Lys11-
linked Ub chains (Bremm et al., 2010) and OTUB1 that is specific for Lys48-linkages 
(Mevissen et al., 2013). A20 acts as DUB removing Lys63-linkage Ub chains from the 
substrate thanks to the N-terminal ovarian tumor (OTU) domain (Bosanac et al., 2010; 
Wertz et al., 2004).   
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Figure 17. General cellular role of DUBs (adapted from Komander, Nat Rev Mol Cell Biol. 
2009). (a) Ub is formed as a fused precursor protein consisting in multiple copies of Ub and DUBs 
which help in the formation of monomeric Ub. (b) Elimination of degradation signals from proteins 
by cleaving Ub chains. (c) DUBs can remove non-degradative Ub signal. (d) DUBs prevent Ub 
proteasome degradation with conjugated proteins. (e) Disassembling Ub chains to form monomeric 
Ub and increase the free Ub pool. (f) By editing Ub chains DUBs can generate other Ub signaling. 
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3. NEDD4 
3.1 Domain description 
The Nedd4 (neuronal precursor cell-expressed developmentally downregulated gene 4) 
family of HECT domain E3 ligases is a well-characterized class of enzymes and conserved 
from yeast to mammals. In humans there are 9 members (Nedd4-1, Nedd4-2, ITCH, 
Smurf1, Smurf2, WWP1, WWP2, NEDL1 and NEDL2) of this family and all of these 
proteins share common domains (Ingham et al., 2004; Rotin and Kumar, 2009) (Figure 
18A). 
They present a conserved modular organization with an N-terminal C2 domain 
critical for membrane localization, between two and four WW domains that recognize 
substrates and adaptor proteins that contain PY motif or phosphoserine/threonine residues 
and a C-terminal HECT catalytic domain always positioned at the C-terminus of the 
protein (Figure 18B). 
The C2 domain, folded in an eight-stranded β-sandwich structure, is a calcium-
binding domain. Upon Ca2+ binding the C2 domain interacts with phospholipids and 
mediates intracellular targeting to the plasma membrane, endosomes and multivescicular 
bodies (Dunn et al., 2004). In addition, the C2 domain has a critical role; it exerts the auto-
inhibitory function through the binding to the HECT domain (Mari et al., 2014; Wiesner et 
al., 2007). 
The name of WW domain derives from the presence of two highly conserved 
tryptophan residues and a conserved proline residue in a sequence of ~35 amino acids 
(Harvey et al., 1999). This domain is composed by a hydrophobic core surrounded by three 
stranded antiparallel β-sheets and binds proteins that contain small proline-rich sequences, 
called PY motif (Huang et al., 2000; Sudol, 1996).  
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Figure 18. Schematic representation of the structure of Nedd4 family (adapted from An H, Mol 
Biosyst. 2014). (A) All 9 members of Nedd4 family shared common domains. (B) Nedd4 family 
members have N-terminal C2 domain involved in membrane binding and auto-inhibitory function, 
from 2 to 4 WW domains involved in substrate binding and the catalytic HECT domain at the C-
terminal. 	  
3.2 Functional role of Nedd4  
Each members of Nedd4 family are diversely implicated in a wide range of biological 
processes such as endocytosis, protein trafficking, viral budding, signaling, cellular growth 
and proliferation (Rotin and Kumar, 2009; Yang and Kumar, 2010). They modulate 
important cellular functions and their alterations play a critical role in cancer (Scheffner 
and Kumar, 2014). 
Nedd4-1 is widely expressed in mammalian tissues and has a conserved function in 
endocytosis and sorting of numerous proteins through mono- (Polo et al., 2002; Woelk et 
al., 2006) and Lys63-linked polyubiquitination (Rotin and Kumar, 2009). 
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The first Nedd4’s polyubiquitinated substrate identified was the epithelial Na+ 
channel (Katz et al., 2002) that is involved in the maintenance of salt (Na+) and fluid 
balance in cells (Harvey et al., 2001; Kamynina et al., 2001). Nedd4 (and even better 
Nedd4-2) through their WW domains, directly bind the PY motif present at the C-terminal 
tail of ENaC. Subsequently, ENaC ubiquitination caused by these ligases promotes its 
endocytosis and degradation (Rotin et al., 2001; Staub et al., 1996). Mutations or deletions 
of PPxY motif determined the disruption of the interaction between Nedd4 and ENaC 
causing the Liddle’s syndrome, a severe disorder that consists of sodium retention and 
hypertension (Lifton et al., 2001). 
A possible oncogenic role of Nedd4 was ascribed to its effect on the tumor 
suppressor proteins PTEN. It was published that Nedd4 mediates the polyubiquitination of 
PTEN in the cytosol determining its proteasomal degradation (Wang et al., 2007). 
However, the role of Nedd4 on PTEN fate was not validated in Nedd4 knockout studies 
(Fouladkou et al., 2008), leaving a controversy in the field.  
Nedd4 has been implicated in the down-regulation of different receptors like 
epidermal growth factor receptor (EGFR) (Katz et al., 2002). EGFR trafficking is 
modulated by a variety of endocytic adaptors (i.e. eps15, eps15R and epsins) that interact 
through their UIM with the ubiquitinated receptor and through other domains with 
different components of the endocytic machinery, like clathrin and adaptor protein-2 (AP-
2) (Acconcia et al., 2009). In particular, Eps15 contains two copies of UIM. Upon EGF 
stimulation, the second UIM is involved in the recruitment of Nedd4, which then leads to 
Eps15 monoubiquitination via a process called coupled monoubiquitination (Polo et al., 
2002; Woelk et al., 2006). Using Eps15 as a model system our lab clarified the molecular 
mechanism of coupled monoubiquitination. This involves the interaction between a 
“competent” UIM in the Ub receptor and a HECT-type E3 ligase (Nedd4, in the case of 
eps15), which has itself been covalently modified by ubiquitination. This modified E3 
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enzyme is then able to transfer another thiolester-conjugated Ub from the catalytic Cys 
residue to the Lys acceptor site in the substrate (Woelk et al., 2006). 
 
3.3 Characteristics of the HECT domain of Nedd4 
The HECT domain is the minimal region of the HECT-E3 enzymes that is necessary and 
sufficient to promote ubiquitination. As described in paragraph 2.3.1, the HECT domain is 
divided in two structural lobes tethered by a flexible linker. In the N-terminal N-lobe 
resides the E2 binding domain that is critical for the interaction with active E2~Ub, while 
the C-terminal C-lobe contains the catalytic cysteine critical for the enzymatic activity.  
Several studies have demonstrated that members of the Nedd4 family possess two 
Ub-interaction surfaces within the HECT domain. A study published by Schulman and co-
workers provided the crystal structure of Ube2D2~Ub in complex with the HECT domain 
of Nedd4-2 giving insights into how Ub, covalently bound to the E2, is correctly 
positioned to be transferred to the catalytic cysteine of the HECT domain (Kamadurai et 
al., 2009). This study discovered the first non-covalent ubiquitin-binding surface in the C-
lobe. This surface is essential for the Ub transfer from the E2 to the E3 (Kamadurai et al., 
2009). Several hydrophobic contacts involve an Ub surface centered on Ile36, Leu71 and 
Leu73.  
Other studies identified a different ubiquitin-binding surface present in the N-lobe 
of the HECT domain. This was first identified in Rsp5 (French et al., 2009), the yeast 
homologue of Nedd4, and subsequent in Smurf2 (Ogunjimi et al., 2010), another member 
of Nedd4 family. However, these two studies reached different conclusions on about the 
role of this Ub-binding surface. In the case of Rsp5, it was proposed that the UBD acted to 
restrict polyubiquitination (French et al., 2009), while for Smurf2 the UBD was shown to 
facilitate the substrate polyubiquitination (Ogunjimi et al., 2010).   
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Our lab characterized the UBD in the N-lobe of Nedd4 through the crystal structure 
of HECTNedd4:Ub complex (Maspero et al., 2011). We demonstrated that only a subset of 
Nedd4 family members binds Ub, namely Nedd4, Nedd4-2 and Smurf2 (Maspero et al., 
2011).  
Our results confirmed the essential role of the non-covalent binding surface in the 
N-lobe for enzyme processivity. Indeed a point mutation in the UBD, capable of 
abrogating the Ub interaction, impaired the polyubiquitination of known Nedd4 substrates 
but not their monoubiquitination. Kim et al. reached similar conclusions solving the 
structure of Rsp5 in complex with Ub (Kim et al., 2011). 
Based on these results we proposed a model in which once the first Ub moiety is 
attached to the substrate, the Ub occupies the UBD present in the N-lobe and this 
interaction is essential for the retention of the ubiquitinated substrate to the E3, keeping the 
correct conformation of the N-lobe that favors enzyme processivity (Maspero et al., 2011) 
(Figure 19). 
Figure 19. Model of the role of UBD of the HECT domain in enzyme processivity. Model for 
substrate polyubiquitination, in pink is depicted the substrate, in yellow ubiquitin, the WW and N-
lobe of the HECT domain in blue while in green the C-lobe. We demonstrated that the UBD 
present in the N-lobe of the HECT domain is not essential for the first cycle of substrate 
ubiquitination while it has a critical role for the enzyme processivity. Our model proposed that the 
UBD kept in close proximity the lysine of Ub to the catalytic cysteine. Mutation of the UBD 
impaired substrate polyubiquitination but not the monoubiquitination. 
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3.4 Regulation of Nedd4 ligase activity 
The ligase activity of Nedd4 family proteins is finely regulated at several levels that span 
from intra-molecular interactions to adaptor protein interactions and post-translational 
modifications (Rotin and Kumar, 2009; Shearwin-Whyatt et al., 2006). 
As stated before, in resting conditions the C2 domain forms an intra-molecular 
interaction with the HECT domain (Figure 20). The C2:HECT interaction inhibits the E3 
ligase activity to possibly protect both the enzyme and the substrates from premature 
ubiquitination (Wiesner et al., 2007). Recent efforts from our and Wiesner lab resulted in 
the structural characterization of the Nedd4 and Smurf auto-inhibited conformation (Mari 
et al., 2014). NMR data and biochemical analyses on Smurf2 and Nedd4 showed that the 
C2 domain has the capacity to regulate E3 activity by maintaining the HECT domain in a 
low-activity state where its ability for transthiolation and noncovalent Ub binding are 
impaired (Mari et al., 2014) This in cis autoinhibition can be relieved by binding of the 
adaptor protein SMAD7 to the Smurf2 HECT domain (Ogunjimi et al., 2005), by an 
increase of Ca2+ intracellular content (Wang et al., 2010) or by post-translational 
modifications caused by upstream signaling in the case of Nedd4 (Persaud et al., 2014) 
(Figure 20). It has been proposed that the C2 domain interacts with Ca2+ and inositol 
1,4,5-trisphosphate (IP3) using the same surface involved in the HECT interaction 
(Escobedo et al., 2014). Our lab in collaboration with Rotin lab, has recently demonstrated 
the specific role of post-translational modifications for the dissociation of the auto-
inhibitor C2:HECT interaction in Nedd4 (Persaud et al., 2014). 
Upon EGF stimulation, EGFR is activated by dimerization and auto-trans-
phosphorylation of tyrosine residues in the kinase domain (Schlessinger, 2002). The 
phosphorylated form of EGFR recruits phospho-binding proteins as c-Src, promoting its 
activation and signaling transduction (Osherov and Levitzki, 1994). Our lab found that, 
once activated by the EGFR, c-Src phosphorylates Nedd4 in 5 different sites (Tyr43, Tyr111, 
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Tyr 332, Tyr585 and Tyr647). Two tyrosines, Tyr43 in the C2 domain and Tyr585 in the HECT 
domain, were particularly relevant as they are located near the regions involved in the C2-
HECT interaction. Phosphorylation of these Tyr induces the dissociation of the auto-
inhibition C2:HECT interaction, increasing the catalytic activity of Nedd4 (Persaud et al., 
2014) (Figure 20). Same sites and mechanism are in place in the case of the fibroblast 
growth factor receptor 1 (FGFR1) that is a substrate of Nedd4 (Persaud et al., 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Schematic representation of the regulation of intra-molecular inhibition C2:HECT 
domains (adapted from Mari, Structure, 2014). Here it is represented Nedd4-1. On the left, the C2 
domain binds and inhibits the catalytic activity of the HECT domain through the interaction with 
the UBD present in the HECT domain. Specific signals (i.e. increase of Ca2+ content-bottom panel) 
or post-translational modifications (i.e. specific phosphorylation on Tyr43 and Tyr585-right panel) 
could disrupt the C2:HECT interaction generating a fully activated Nedd4.   
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4. RABEX-5  
Rabex-5 (RABapitin associated EXchange factor for rab5) is a guanine nucleotide 
exchange factor (GEF) for Rab-5 that is an important regulator of endosomal trafficking 
(Figure 21A). The small GTPase Rab-5 regulates the transport of clathrin coated vesicles 
from the plasma membrane to the early endosomes (Mattera et al., 2006) and cycles 
between an active (GTP bound) state and inactive (GDP bound) state. Rab-5 activity is 
crucially regulated by enzymes as exchange factors (GEFs) and activating GTPase proteins 
(GAPs). 
Rabex-5 working as a GEF activates Rab-5 by stimulating GDP release and 
facilitating the GTP binding. Rabex-5 is present in the cytosol in complex with its activator 
Rabaptin-5 and subsequently is recruited to the plasma membrane of the endosome to exert 
its GEF activity (Haas et al., 2005). The Vps9-homology domain and the adjacent N-
terminal helical bundle (HB) composed the GEF catalytic core that is responsible for the 
GEF activity (Delprato et al., 2004). To increase this activity, accelerating the Rab-5 
activation (Lippe et al., 2001), Rabex-5 binds Rabaptin-5 through the coiled-coil (CC) 
domain and together they form a large multiprotein complex (Horiuchi et al., 1997) 
(Figure 21B).  
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Figure 21. Function and domain organization of Rabex-5. (A) (adapted from Raiborg, Trends 
Biochem Sci. 2006) Rabex-5 is a GEF of Rab-5 through the exchange of GDP with GTP. (B) 
(adapted from Mattera, EMBO J. 2008) Schematic representation of Rabex-5 domains. The helical 
bundle (HB) and the Vps9 domains are the GEF catalytic core, respectively in red and yellow. In 
light blue the coiled-coil (CC) domain involved in the binding of Rabaptin-5. In green the C-
terminal prolin rich domain (PR). Zinc finger and MIU domain are two UBDs, respectively 
depicted in pink and green.  	  
 
Rabex-5 plays an oncogene role in the formation and development of different malignant 
tumors; its up-regulation promotes tumor growth, migration and invasion of cancer cells. 
Recent studies demonstrated that Rabex-5 is overexpressed in several cancers like 
colorectal cancer (Nimmrich et al., 2000), breast cancer (Zhang et al., 2013), prostate 
cancer (Zhang et al., 2014) and gastric cancer (Wang et al., 2014).  
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4.1 UBDs of Rabex-5 
Our lab demonstrated that Rabex-5 binds Ub through two independent UBDs: 1) the MIU 
domain that recognizes the canonical hydrophobic surface of Ub centered on Ile44, Leu8, 
Val70 through Ile51, Leu57 and Ala58 on Rabex-5; 2) the A20 zinc finger (ZnF_A20) 
domain that interacts through Tyr25 and Tyr26 with Asp58 of Ub (Lee et al., 2006a; 
Mattera et al., 2006; Penengo et al., 2006). This second non-canonical interaction surface 
involves polar residues such as Arg54, Thr55, Ser57, Asp58, Tyr59 and Asn60 (Figure 
22).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Crystal structure of Rabex-5 in complex with Ub (adapted from Penengo, Cell, 
2006). Representation of the human Rabex-5 fragment (from 1 to 74 a.a.) in complex with Ub 
molecules. Rabex-51-74 is depicted in yellow and the two Ub molecules are in light and dark green. 
ZnF_A20 coordinates the Zn2+ ion represented as a sphere. Magnification of each interaction of Ub 
with Rabex-5 is shown in dashed box indicating different residues (depicted in red) are used. Ub 
interacts with the MIU domain through the Ile44 and with the ZnF_A20 using a non canonical 
Asp58 surface. 
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The MIU domain (48-74a.a.) is an amphipathic α-helix and possesses the same sequence 
as the well-described ubiquitin-interacting motif (UIM) found in many proteins but with 
the opposite orientation (Hicke et al., 2005). The interaction between the MIU domain and 
Ub has the dissociation constant (KD) of 28 µM (Penengo et al., 2006) that is lower respect 
the UIMs versus Ub (KD ~ 100-500 µM) (Hicke et al., 2005). 
 The presence of four cysteines (Cys19, Cys23, Cys35 e Cys38) at the N-terminus (2-
49a.a.) that interact with Zn2+ ion identifies in Rabex-5 a zinc finger module belonging to 
the ZnF_A20 family. This domain interacts with Ub on a different surface centered on 
Asp58 and the KD measured is around 12 µM (Lee et al., 2006b; Penengo et al., 2006).  
Each domain can interact with Ub independently and a single Ub molecule can 
interact with two Rabex-5 moieties (Penengo et al., 2006). Rabex-5 binds to the activated 
form of EGFR, which is known to be ubiquitinated, and ZnF_A20 or MIU domain 
mediates this binding (Penengo et al., 2006). It has been suggested that Rabex-5 UBDs are 
important for Rabex-5 localization at the plasma membrane and for their co-trafficking 
with Ub-cargoes (Penengo et al., 2006). Indeed, mutations on the UBDs that impaired the 
Ub binding strongly reduce Rabex-5 endosomal localization (Mattera and Bonifacino, 
2008). In addition, Rabex-5 undergoes coupled monoubiquitination driven by the MIU 
domain (Penengo et al., 2006).  
 
4.2 Rabex-5 as E3 ligase  
The GEF activity of Rabex-5 was extensively studied while little is known on the role of 
Rabex-5 as E3 ligase and the molecular mechanism that it used to perform substrate 
ubiquitination is still unclear. Rabex-5 has been proposed as E3 ligase based on its ability 
to self-ubiquitinate (Lee et al., 2006a). Having an A20 zinc finger domain (ZnF_A20) 
instead of a canonical RING, Rabex-5 can be considered as an atypical RING-E3. 
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Ras proteins were identified as possible substrates of the E3 ligase activity of 
Rabex-5. Ras proteins are small guanine nucleotide binding proteins involved in signal 
transduction regulating cellular growth, proliferation (Malumbres and Pellicer, 1998), 
survival (Cox and Der, 2003), differentiation and cell mobility. Being central hubs in these 
intracellular pathways they are the most common oncogenes in human cancer (Bos, 1989). 
These proteins can switch between active GTP-bound states and, upon GTP hydrolysis, in 
inactive GDP-bound states (Cox and Der, 2003). In the GTP-active state H-Ras can 
interact and activate a wide range of downstream effectors like ERK, PI3K and Raf 
(Malumbres and Pellicer, 1998). Studies performed by Dafna Bar-Sagi and co-workers 
have demonstrated that Rabex-5 is able to mono- and di-ubiquitinate both H-Ras and N-
Ras and that these modifications can promote their endosomal association leading to an 
attenuation of Ras-ERK signaling (Jura and Bar-Sagi, 2006; Xu et al., 2010). 
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MATERIALS AND METHODS 
1. Solutions  
1.1 TRIS-HCl (1 M) 
The solution was prepared by using TRIS base, dissolving 121.1g in 800 ml distilled H2O.  
The pH was adjusted to 7.4, 7.6 or 8.0 with HCl and ddH20 was added to bring volume to 
1 litre. 
 
1.2 10x TRIS EDTA (pH 7.4-8.0) 
100 mM Tris HCl (pH 7.4-8.0)  
10 mM EDTA (pH 8.0) 
 
1.3 50x TAE (Tris-Acetate-EDTA) 
242 g/L Tris base  
57.1 ml/L Acetic acid 0.5 M  
20 ml/L EDTA pH 8 
The pH was adjusted to 8.5 with HCl. 
 
1.4 TRIS-Buffered saline (TBS) 
137 mM NaCl  
2.7 mM KCl  
25 mM TRIS pH 7.4 
The pH was adjusted to 7.4 with HCl. 
 
1.5 1X SDS-PAGE Sample Buffer (Laemmli) 
2% SDS  
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50 mM TRIS pH 6.8  
10 % glycerol  
0.1 % saturated Bromophenol blue 
SDS-PAGE Sample Buffer was prepared as a 5X stock solution. 5 % (v/v) β- 
Mercaptoethanol (14M) or 100 mM DTT was added to the stock solution before use. The 
solution was stored at -20°C and protected from light. 
 
1.6 10X SDS-PAGE Running Buffer 
192 mM Glycine  
250 mM TRIS, pH 8.3  
1% SDS 
 
1.7 Buffer for preparation of Tris-Tricine gels (TRIS-Cl/ SDS) 
3 M TRIS-HCl 
0.3% SDS  
The pH was adjusted to 8.45 with HCl. The buffer was stored at 4°C. 
 
1.8 Running Buffers for Tris-Tricine gels 
1X Cathode buffer: 
0.1 M TRIS base  
0.1 M Tricine  
0.1% SDS 
5X Anode buffer: 
0.2 M TRIS-HCl, pH 8.9  
The pH was adjusted to 8.9 with HCl. The Cathode buffer was added in the upper chamber 
(-) of the gel apparatus and the Anode buffer in the lower chamber (+). 
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1.9 10X Western Transfer Buffer 
250 mM TRIS, pH 8.3  
192 mM Glycine  
20% v/v methanol or ethanol 
 
1.10 1x RIPA buffer 
50 mM Tris Hcl pH 7.6  
150 mM NaCl  
1% NP-40  
0.1% SDS 
0.5% Deoxycholic acid 
Phosphatases and protease inhibitors were added freshly to lysis and wash buffers: 
20 mM Na pyrophosphate pH 7.5  
50 mM NaF  
2 mM PMSF in ethanol  
10 mM Na vanadate in HEPES pH 7.5  
Protease Inhibitor Cocktail 1:500 (Calbiochem) 
 
1.11 1x YY buffer 
50 mM Na-HEPES pH 7.5  
150 mM NaCl  
1mM EDTA  
1mM EGTA  
10% glycerol  
1% triton-100 
 
	   58	  
1.12 1x ubiquitination buffer 
25 mM Tris–HCl pH 7.6  
5 mM MgCl2  
100 mM NaCl  
0.2 mM dithiothreitol  
2 mM ATP 
 
1.13 1x isopeptide buffer 
50 mM Tris–HCl pH 10.0  
5 mM MgCl2  
150 mM NaCl  
 
1.14 1x ITC buffer 
20mM Tris-HCl pH 8.0 
200 mM NaCl 
5% glycerol 
1mM DTT (freshly added) 
 
2. Reagents  
Polyubiquitin Lys63-linked chains were purchased from Enzo Life Sciences. Biotinylated 
Ub was purchased from BostonBiochem. Ub (from bovine red blood cells), ATP, TCEP 
and DTT were purchased from Sigma. Imperial Protein Stain and Instant blue were 
purchased from Thermo Scientific and Expedeon respectively. 
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2.1 Antibodies 
The following antibodies were used: mouse monoclonal anti-MIU and CUE domain 
respectively at N- and C-terminal part of Rabex-5 (generated in-house); mouse monoclonal 
anti-Ub ZTA10 (generated in-house); polyclonal anti-GST (generated in-house); 
streptavidin-HRP (Pierce); polyclonal anti-Ube2D (Santa Cruz). 
 
3. Cloning techniques 
3.1 Agarose gel electrophoresis 
DNA samples were loaded on 0.8%-2% agarose gels along with DNA markers. Gels were 
made in TAE buffer containing Gel Red (Biotium), according to the manufacturer’s 
instructions, and run at 90 V until desired separation was achieved. DNA bands were 
visualized under a UV lamp. 
 
3.2 Minipreps 
Clones picked from individual colonies were used to inoculate 2 ml LB (containing the 
appropriate antibiotic) and grown overnight at 37°C. Bacteria were pelleted for 5 minutes 
at 16,000 g. Minipreps were performed with the Wizard Plus SV Minipreps Kit (Promega) 
following the manufacturer’s instructions. The plasmids were eluted in 50 µl nuclease free 
H2O.  
 
3.3 Diagnostic DNA restriction 
0.5-2 µg DNA were digested for 2 hours at 37°C with 10-20 units of restriction enzyme 
(New England Biolabs). For digestion, the volume was brought to 20-50 µl with the 
appropriate buffer and distilled H2O. 
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3.4 Large Scale Plasmid Preparation 
Plasmid DNA was isolated from 200 ml of bacterial culture using the Qiagen Maxi-prep 
kit according to the manufacturer’s instructions. 
 
3.5 Transformation of competent cells 
50 µl of competent cells Top10 (Promega) (both for cloning and DNA preparation) or 
BL21-CodonPlus (Promega) (for GST or His-tagged proteins production), were thawed on 
ice prior to the addition of plasmid DNA. Cells were incubated with DNA on ice for 30 
minutes and then subjected to a heat shock for 45 seconds at 42°C. Cells were replaced on 
ice for 5 additional minutes. Then, 500 µl of SOC was added and the cells were left at 
37°C for another 60 minutes before plating them onto plates with the appropriate 
antibiotic. Plates were incubated overnight at 37°C. 
 
3.6 PCR (Polymerase Chain Reaction) 
Sense and an antisense oligo of 20-30 nucleotides each were generated, one annealing in 5’ 
(forward) and the other in 3’ (reverse) to the target sequence. The primers were designed 
of similar length and annealing temperature (calculated by running the primers on 
simulated PCR reactions, using the Ape programme). Primers were used in a PCR reaction 
together with the DNA template and the high fidelity Phusion DNA polymerase (BioLabs). 
Reaction mixture 
10 µl reaction buffer 5x  
50 ng DNA template  
0.5 µM primer forward  
0.5 µM primer reverse 
0.2 mM dNTPs mix  
0.01 U of Phusion enzyme   
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distilled H2O 
The PCR reaction (denaturation, annealing and extension) was repeated for various 
number of cycles (see table below). This was done on an automated cycler (GeneAmp 
PCR system 9700, Applied Biosystems. 
 
Cycling parameters:  
Step Temperature Time  Cycles 
1 98°C 30 seconds 1 
2 98°C 
40-44°C (calculated for each primer pair) 
72°C 
30 seconds 
30 seconds 
60 seconds 
5 
3 98°C 
50-55°C (calculated for each primer pair) 
72°C 
30 seconds 
30 seconds 
60 seconds 
25 
4 72°C 7 minutes 1 
5 4°C ∞ 1 
 
Construct Oligonucleotides 
Rabex-5 1-74 
For:ATCGGATCCACCATGAGCCTTAAGTCTGAACGCCGA 
Rev: CTTTGCCAGTCAGAGCTAACAAGGGCCCAATCCCT 
Rabex-5 1-49 
For:  ATCGGATCCACCATGAGCCTTAAGTCTGAACGCCGA 
Rev: CAAAGCCAGGCAGAAGTAGATTCAGGAGGACTG 
Rabex-5 48-
74 
For:  ATCGGATCCACCATGAGCCTTAAGTCTGAACGCCGA 
Rev:CTTGCCAGTCAGAGCTAACAAGGGCCCAATCCCT 
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3.7 Site directed mutagenesis 
Site directed mutagenesis was performed using the Quick Change Mutagenesis Kit 
(StrataGene), following the manufacturer’s instructions. Briefly, a sense and an antisense 
oligo, carrying the desired mutation in the middle of the sequence, were generated and 
used in a PCR reaction using the wild type construct (50 ng). The PCR was performed 
using the Pfu TURBO polymerase for 12-18 cycles. After amplification, 1 µl of DpnI 
restriction enzyme, which selectively cuts methylated DNA at the GATC sequence, was 
added to digest the wild-type parental DNA. After 1 hour of incubation at 37 ̊C, the PCR 
product was used to transform competent Escherichia coli cells. Single colonies were 
picked, plasmid DNA extracted (Miniprep) and sequenced for the presence of the desired 
mutation and the absence of other, unwanted, base changes. 
For the amplification step, 12-18 PCR cycles were performed with a denaturation step of 
30 seconds at 95°C followed by an annealing step of 1 minute at 55°C and an extension 
step at 68°C of 2 minutes/ kb of plasmid length. All the constructs were cloned in 
pGEX6P2 or pet14b vectors. 
In the table are shown the oligonucleotides used for the generation of each construct. 
 
Construct Oligonucleotides 
HECT C778S 
For: CTAGAGCTTCTTATGTCTGGACTGGGAGATGTTG 
Rev: CAACATCTCCCAGTCCAGACATAAGAAGCTCTAG 
HECT IDCNP 
For: AATCCAAACTCTGGAATCAACCCAGATCACCTCTC 
Rev: GAGAGGTGATCTGGGTTGATTCCAGAGTTTGGATT 
HECT C627A 
For: CCAAACTCTGGATTGGCTAACGAAGATCACCTC 
Rev: GAGGTGATCTTCGTTAGCCAATCCAGAGTTTGG 
HECT C627S 
For: CCAAACTCTGGATTGTCTAACGAAGATCACCTC 
Rev: GAGGTGATCTTCGTTAGACAATCCAGAGTTTGG 
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HECT DC627 
For: CCAAACTCTGGATTGAACGAAGATCACCTC 
Rev: GAGGTGATCTTCGTTCAATCCAGAGTTTGG 
HECT DC627NP 
For: AATCCAAACTCTGGATTGAACCCAGATCACCTCTC 
Rev: GAGAGGTGATCTGGGTTCAATCCAGAGTTTGGATT 
HECT F707A 
For: CATAGATGAAGAACTTGCTGGACAGACACATC 
Rev: GATGTGTCTGTCCAGCAAGTTCTTCATCTATG 
Ub G76C 
For: CTCCGTCTCAGAGGTTGCTAGGGATCCGGCTGC 
Rev: GCAGCCGGATCCCTAGCAACCTCTGAGACGGAG 
Ube2D3 C21S 
For: GACCCTCCAGCACAATCTTCTGCAGGTCCAGTTG 
Rev: CAACTGGACCTGCAGAAGATTGTGCTGGAGGGTC 
Ube2D3 
C107S/C111S 
For: GTTCTTTTATCCATTTCTTCACTGCTATCTGATCCAAACCCAG 
Rev:CTGGGTTTGGATCAGATAGCAGTGAAGAAATGGATAAAAGAAC 
Ube2D3 S22R 
For: GACCCTCCAGCACAATGTCGTGCAGGTCCAGTTGGG 
Rev: CCCAACTGGACCTGCACGACATTGTGCTGGAGGGTC 
Ube2D3 C85K 
For: CAGTAATGGCAGCATTAAGCTCGATATTCTAAGATCAC 
Rev: GTGATCTTAGAATATCGAGCTTAATGCTGCCATTACTG 
Ube2D3 C21S/S22R 
For: GACCCTCCAGCCACAATCTCGTGCAGGTCCAGTTGGG 
Rev: CCCAACTGGACCTGCACGAGATTGTGCTGGAGGGTC  
Ube2D3 C85S 
For: CAGTAATGGCAGCATTTCTCTCGATATTCTAAGATCAC 
Rev: GTGATCTTAGAATATCGAGAGAAATGCTGCCATTACTG 
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Rabex-5 A58G 
For: AGGACTGGGAGCTGGAGAGAGCGACTCCAGCG 
Rev: CGTGGAGTCGCTCCCAAGCTCCCAGTCCT 
Rabex-5 
Y25F 
For: AGAAAGGATGTGGTTTCTACG 
Rev: GCAGGGTTGCCGTAGAAACCACATCCTTTCT 
Rabex-5 Y/A 
For: TGCAAGAAAGGATGTGGTGCCGCCGGCAAACCCTGCCTGGCAG 
Rev: CTGCCAGGCAGGGTTGCCGGCGGCACCACATCCTTTCTTGCA 
  
4. Protein procedures 
4.1 SDS-PolyAcrylamide Gel Electrophoresis (SDS-PAGE) 
Gels for resolution of proteins were made from a 30%, 37,5:1 mix of acrylamide: 
bisacrylamide (Sigma). As polymerisation catalysts, 10% Ammonium PerSulphate (APS) 
and TEMED were used.  
 
Separating gel mix 
Gel % 6 8 10 15 
Acrylamide mix (ml) 2 2.7 3.3 5 
1.5M Tris HCl pH 8.8 (ml) 2.5 2.5 2.5 2.5 
Distilled H2O (ml) 5.3 4.6 4 2.3 
10% SDS (ml) 0.1 0.1 0.1 0.1 
10% APS (ml) 0.1 0.1 0.1 0.1 
TEMED (ml) 0.01 0.01 0.01 0.01 
TOTAL (ml) 10 10 10 10 
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Stacking gel mix 
Acrylamide mix (ml) 1.68 
1M Tris HCl pH 6.8 (ml) 1.36 
Distilled H2O (ml) 6.8 
10% SDS (ml) 0.1 
10% APS (ml) 0.1 
TEMED (ml)  0.01 
TOTAL (ml)  10 
 
To obtain a good resolution of small proteins like Ub, proteins were run on Tris-Tricine 
protein gels. For these gels a 30%, 29:1 mix of acrylamide: bisacrylamide (Sigma) was 
used.  
Separating gel mix (11%) 
Acrylamide mix (ml) 21.72 
Tris HCl/ SDS (ml) 20 
Distilled H2O (ml) 11.94 
Glycerol (ml) 6.34 
10% APS (ml) 0.1 
TEMED (ml)  0.03 
TOTAL (ml)  60 
 
Stacking gel mix (4%) 
Acrylamide mix (ml) 6.66 
Tris HCl/ SDS (ml) 12.4 
Distilled H2O (ml) 30.94 
10% APS (ml) 0.2 
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TEMED (ml)  0.12 
TOTAL (ml)  50 
 
4.2 Western Blot 
Desired amounts of proteins were loaded onto 1-1.5 mm SDS-PAGE gels for 
electrophoresis (Biorad). Proteins were transferred in western transfer tanks (Biorad) to 
nitrocellulose membranes (Schleicher and Schnell) in 1x Western Transfer buffer 
(supplemented with 20% methanol) at 30V overnight or 100V for 1 hour. Ponceau staining 
was used to roughly reveal the amount of protein transferred to the membranes. 
Membranes were blocked 1 hour (or overnight) in 5% milk in TBS supplemented with 
0.1% Tween (TBS-T). 
After blocking, membranes were incubated with the primary antibody, diluted in TBS-T 
5% milk for 1 hour at room temperature, followed by three washes of 5 minutes each in 
TBS-T and then incubated with the appropriate horseradish peroxidase-conjugated 
secondary antibody diluted in TBS-T for 30 minutes. After the incubation with the 
secondary antibody, the membranes were washed three times in TBS-T and the bound 
secondary antibody was revealed using the Enhanced ChemiLuminescence (ECL) method 
(Amersham). The images were acquired by using Chemidoc instrument and ImageLab 
software (Biorad). 
 
4.3 Anti-Ubiquitin WB 
After SDS-PAGE or tris–tricine gel, proteins were transferred on a PVDF (polyvinylidene 
fluoride) membrane (Immobilion P, Millipore), previously activated by incubation in 
100% MetOH for 1 minute at room temperature. Ponceau staining was avoided since it 
might interfere with antibody recognition. After transfer, membranes were subjected to a 
denaturing treatment in a dedicated solution (see Denaturing solution) for 30 minutes at 
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4°C. This treatment denatures Ub and facilitates the recognition of latent Ub epitopes by 
anti-Ub antibody resulting in intensification of the anti-Ub signal. After extensive washing 
in TBS-T buffer, filters were blocked overnight at 4°C in 5% BSA (dissolved in TBS-T). 
After blocking, membranes were incubated with antibodies against Ub, diluted in TBS-T 
5% BSA, for 1 hour at room temperature, followed by three washes of 10 minutes each in 
TBS-T and then incubated with the horseradish peroxidase-conjugated secondary antibody 
diluted in TBS-T 3% BSA for 30 minutes at room temperature. After incubation with the 
secondary antibody, the membranes were washed three times in TBS-T (5 minutes each) 
and the bound secondary antibody was revealed using the ECL method (Amersham). The 
images were acquired by using Chemidoc instrument and ImageLab software (Biorad). 
Denaturing solution 
6 M Guanidium Chloride  
20 mM TRIS, pH 7.4 
1 mM PMSF (freshly added) 
5 mM b-mercaptoethanol (freshly added)  
 
5. Protein production and purification  
5.1 GST-fusion proteins production 
BL21 cells were picked from individual colonies and transformed with the indicated GST-
fusion constructs, and used to inoculate 50 ml LB (containing 25 µg/ml ampicillin) and 
grown overnight at 37°C. The 50 ml overnight culture was diluted in 1 litre of LB and 
grown at 37°C until it reached approximately OD=0.6. Then, 0.5-1mM IPTG was added 
and the culture was grown at 18°C overnight. The cells were then pelleted at 4000 rpm for 
10 minutes at 4°C and pellets were resuspended in GST-lysis solution (20 ml/L of 
bacteria). Samples were sonicated 5 times for 20 seconds/each on ice and were pelleted at 
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14000 rpm for 30 minutes at 4°C. 1 ml of glutathione-sepharose beads (Amersham) (1:1 
slurry), previously washed 3 times with GST-lysis buffer, were added to the supernatants 
and samples were incubated 3-4 hours at 4°C on a rocking wheel. The beads were then 
washed 3 times in PBS containing 1% triton, and additional 2 times in PBS alone. The 
beads were finally resuspended in 1:1 volume of GST-maintenance solution and stored at –
80°C. 
 
GST-lysis solution 
50 mM Hepes pH 7.5  
200 mM NaCl  
1 mM EDTA  
0.1% NP40 
5% glycerol  
Protease Inhibitors (Calbiochem) 
 
GST-maintenance solution 
50 mM Tris pH 7.4  
100 mM NaCl  
1 mM EDTA  
10% glycerol  
1 mM DTT  
Protease Inhibitors (Calbiochem) 
 
5.2 Cleavage of GST-fusion proteins 
GST-fusion proteins were cleaved with PreScission Protease (GE). 1 unit of enzyme for 
100 µg of fusion protein was added to the beads in the presence of GST-maintenance 
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solution and either incubated over night at 4°C. After cleavage the supernatant containing 
the cleaved protein was collected and the beads were washed twice to allow the complete 
recovery of the cleaved protein. 
 
5.3 His-fusion proteins production 
BL21 cells picked from individual colonies and transformed with the His-constructs were 
used to inoculate 50 ml LB and grown overnight at 37°C. The 50 ml overnight culture was 
diluted in 1 litre of LB and was grown at 37°C until it reached approximately OD=0.6. 
Then, 1 mM IPTG was added and the culture was grown at 18°C overnight. Cells were 
then pelleted at 4000 rpm for 10 minutes at 4°C and pellets were resuspended in Buffer A. 
Samples were sonicated 5 times for 20 seconds/each on ice and were pelleted down at 
14000 rpm for 30 minutes at 4°C. 1 ml of Ni-NTA beads (QIAGEN), previously washed 3 
times with buffer A, was added to the supernatants and samples were incubated for 2 hours 
at 4°C, on a rocking wheel. The beads were then washed once with buffer A, once in the 
same solution plus 1 M NaCl, and once in the same solution plus 20 mM imidazole. His-
fusion proteins were eluted in two steps, first with buffer A plus 200 mM imidazole and 
second with buffer A plus 500 mM imidazole. Dialysis was then performed in GST-
maintenance buffer overnight, using Tris pH 6.8. 
 
Buffer A 
50 mM NaH2PO4 pH 7.8  
300mM NaCl  
10 % glycerol  
10 mM imidazole 
Protease inhibitors (Calbiochem) 
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5.4 Production of untagged Ub 
Ub G76C and Ub WT are expressed in BL21 (Amp). BL21 cells picked from individual 
colonies and transformed with the constructs were used to inoculate 50 ml LB and grown 
overnight at 37°C. The 50 ml overnight culture was diluted in 1 litre of LB and was grown 
at 37°C until it reached approximately OD=0.6. Then, 1 mM IPTG was added and the 
culture was grown at 18°C overnight. Cells were then pelleted at 4000 rpm for 10 minutes 
at 4°C and pellets were resuspended in a specific buffer:  
25mM ammonium acetate pH 7.0 
10% glycerol 
10mM β-mercaptoethanol 
protease inhibitors 
 
Samples were sonicated 5 times for 20 seconds/each on ice and were pelleted down at 
14000 rpm for 30 minutes at 4°C. The supernatant adjusted to pH 4.5-5.0 with 
concentrated acetic acid because acid-precipitable proteins were removed by centrifugation 
(15000 rpm for 30 min) and the supernatant containing the ubiquitin monomers was passed 
through a 0.45 mm PES filter. 
To change the buffer, dialysis (o.n. in tubes with 3.5 Kd MWCO) was performed against: 
 20 mM Tris HCl pH 8 
 200 mM NaCl 
 5% glycerol 
 1mM EDTA 
            1mM DTT 
 
Eventually Ub can be concentrated after dialysis using concentrator (centricon of 3.0 kDa 
of cut-off) and purified by a Superdex 75 column. 
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5.5 Protein purification 
After cleavage from the GST tag (for GST-fusion proteins) or elution from Ni-NTA beads 
(for His-fusion proteins) proteins were purified using either size exclusion chromatography 
or ion exchange chromatography. Prior to run on a Superdex 200 or 75 size exclusion 
column, the samples were concentrated using Vivaspin (of different dimension and 
different molecular weight cut off according to the protein of interest) and centrifuged at 
4000 rpm at 4°C. The concentrated sample was run onto a Superdex size exclusion column 
of different sizes according to the total amount of protein using a specific gel filtration 
buffer.  
 
Gel filtration buffer 
20 mM Tris pH 8.0  
200 mM NaCl  
1 mM EDTA  
1 mM DTT  
5% glycerol 
 
The desired protein was eluted in a clear, well isolated peak according to its size and 
shape. Purity of the peak was assayed by SDS-PAGE gel and Coomassie staining. The 
desired fractions were collected, pooled and concentrated using Vivaspin tubes.  
Other proteins were purified using ion exchange chromatography (Resource S or Q) 
depending on its isoelectric point. Samples were diluted with the purification buffer 
without NaCl to reduce the concentration to 30 mM of NaCl in order to allow the binding 
of the proteins to the ion exchange column. The samples were applied on the column pre-
equilibrated with the buffer without salt and eluted using a gradient (20 column volume) 
from 30 mM to 500 mM NaCl in the same buffer. Fractions were analysed by SDS-PAGE 
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or Tris-tricine gel and the desired fractions were pooled and concentrated using Vivaspin 
tubes. The final concentration of the samples was obtained as the ratio between the 
measured absorbance at 280 nm and the theoretical molar extinction coefficient at 280 nm, 
according to Lambert–Beer’s law. 
 
6. Pull-down experiments  
For pull-down experiments, 2µM of GST proteins were incubated with 250 ng of K63 
chains or 2 mM of mix composed by 1/3 Ub-loaded E2 and 2/3 E2 for 2 hours at 4°C in 
YY buffer. After four washes of the GST proteins with YY buffer, specifically bound 
proteins were resolved on tris-tricine gel and detection was obtained by immunoblotting 
using specific antibodies. 
 
7. Pull-down Experiments with In vitro translated E2s 
In vitro translated E2 was obtained by adding 1 µg of circular plasmid DNA, containing a 
T7 promoter, coding for E2 protein to an aliquot of the TNT Quick master mix (Promega) 
and 20µCi of [35S]-methionine. 50 µl reaction was then incubated for 90 minutes at 30°C 
and the radioactive protein was analysed by SDS-PAGE. 
For pull down experiments, 4 µM GST-Rabex-5 WT or mutants immobilized onto GSH 
beads were incubated with 8 µl of in vitro translated E2 for 2 h at 4°C in a buffer 
containing 50 mM Hepes pH 7.5, 150 mM NaCl, 10% glycerol and 1% Triton X-100. 
Three washes with YY buffer were made. Specifically bound proteins were resolved on 
Tris-Tricine-PAGE and transferred on nitrocellulose membrane. Ponceau staining of the 
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membrane was performed to show the loading of GST‐fusion protein. Films were exposed 
and developed after 24h of incubation.  
 
8. In vitro Ubiquitination assay 
Ubiquitination assays were performed at 37°C using purified enzymes. In particular, auto-
ubiquitination reactions contained 20 nM E1, 500 nM His6‐tagged Ube2D3, 500 nM GST-
Rabex-5 WT or mutants, 2.5 µM of ubiquitin in ubiquitination buffer (25 mM Tris–HCl, 
pH 7.6, 5 mM MgCl2, 100 mM NaCl, 0.2 µM dithiothreitol, 2 mM ATP). GST-tagged 
Rabex-5 was used immobilized on glutathione beads. For substrate ubiquitination assay 20 
nM E1, 500 nM Ube2D3, 500 nM Rabex-5 produced as GST fusion protein, cleaved with 
PreScission protease and purified, 5µM of Ub-biotinylated and 500 nM of substrate (GST-
Ras1-166 or GST-H-Ras) were added to the reaction mixture. At the indicated time points 
samples were centrifuged to separate the beads (“pellet”), containing the ubiquitinated E3s 
or the ubiquitinated substrate, from the supernatant, containing unbound enzymes. The 
pellet was washed four times in RIPA buffer (50 mM Tris HCl pH 7.6, 150 mM NaCl, 1% 
NP-40, 0.1% SDS, 0.5% Deoxycholic acid) before loading on SDS–PAGE. Detection was 
performed by immunoblotting, using specific antibody. For Ub-biotinylated the detection 
was performed using HRP-streptavidin. A coomassie‐stained membrane was used to show 
the loading of GST‐fusion protein after immunoblotting 
 
9. In vitro Transthiolation assay 
Different new E1 concentrations were simultaneously tested comparing with 100ng of E1 
in used. The reaction was performed with 100ng of E1 in presence of 1mg of Ub-
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biotenylated and 2 mM ATP in in vitro Ub-buffer (25 mM Tris–HCl, pH 7.6, 5 mM 
MgCl2, 100 mM NaCl, 0.2 µM dithiothreitol) at 37°C for 30 minutes. The reaction was 
stopped by addition of laemmli without DTT in order to detect the amount of E1~Ub. 
Samples were loaded on a SDS-PAGE gel and detection was made using HRP-
streptavidin. 
 
10. Directed yeast two-hybrid screen 
10.1) Yeast growth conditions and strain 
Yeast cells were grown in rich medium (YPD; 1% yeast extract, 2% peptone, 2% glucose) 
or synthetic minimal medium (0,67% yeast nitrogen base without amino acids) with 
glucose 2% (SD), galactose 2% (SGal) or raffinose 2% (SRaf) as carbon source and amino 
acids as required. Yeast strain used for the screen is AH109 (Clontech). 
Yeast strain Reporter gene Transformation markers 
AH109 HIS3, ADE2, lacZ, MEL1 Trp1, Leu2 
 
10.2) Constructs and plasmids for yeast two hybrid screening 
DNA encoding for Rabex-5 (1-74) domain was obtained by PCR amplification and 
subcloned into pGBKT7- bait vector (Clontech) and the construct was sequence verified. 
The E2s DNA cloned into pACT2-prey vector (Clontech) were kindly provided by Rachel 
Klevit(Christensen et al., 2007).  
pGBKT7 contains TRP1 nutritional gene, whereas pACT2 contains LEU2 nutritional gene 
to allow yeast growth on limiting synthetic media. 
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10.3) High-efficiency LiAc transformation 
AH109 cells were inoculated in an appropriate volume of YPD complete medium to obtain 
5x106 cells/ml culture. After o.n. growth at 28-30°C cells were centrifuged at 4000 rpm for 
3 minutes at room temperature and pellets were resuspended in 2 ml of LiAc/TE solution 
(LiAc 0,1 M/TE 1x) and incubated for 40 minutes-1h at 28-30°C. Competent cells were 
then centrifuge at 4000 rpm for 3 minutes at room temperature and pellets were 
resuspended in 400µl of LiAc/TE solution, and incubated (100µl of cells per 
transformation) for 40 minutes at room temperature with plasmid DNA to be transformed 
(100 ng), along with excess carrier DNA (100µg). 1 ml solution of 40% Polyethylene 
glycol (PEG) 6000 in LiAc/TE is then added and the mixture of DNA and yeast cells and 
incubated for additional 40minutes-1hour. After the incubations, the cells were heat 
shocked for 30 minutes at 42°C, to allowed the DNA to enter the cells. The cells are then 
plated on the appropriate medium to select for transformants containing the introduced 
plasmid(s).  
 
10.4) TCA yeast protein extraction 
Yeast protein extraction was performed with Tricloroacetic acid (TCA). This method is 
very efficient to avoid proteolytic phenomena when cells are broken. 
Cells from an exponentially growing colture were collected and centrifuged for 5 minutes 
at 4000 rpm. Then cells were washed with 1ml of TCA 20%, vortexed, transferred to 2 ml 
microfuge tubes and centrifuged for 2 minutes at 14000 rpm. The pellet was resuspended 
in 100 µl of TCA 20% and an equal volume of acid-washed glass beads (Sigma) was 
added, leaving a layer of supernatant over the beads. The samples were then vortexed 
continuously for 4 minutes in order to break the cells. Lysed cells were transferred to a 
fresh tube, and the beads were washed twice with 100 µl of TCA 5%. In this way, each 
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tube contains 300 µl of liquid with 10% TCA final concentration. Samples were 
centrifuged at 4000 rpm for 10 minutes. The pellet was resuspended in 50 µl Laemmli 
buffer 1x (mix colour should be yellow). To neutralize the acid pH 25 µl of Tris Base 1M 
were added to each sample (mix colour should turn blue). Then the protein extract was 
boiled at 95°C for 3 minutes and centrifuged again at maximum speed. Finally, the 
supernatant, containing the final protein extract, was collected in a new tube and extracts 
were stored at -20°C. 
 
11. Disulfide bond reaction 
The formation of the disulfide bond was conducted as described in reference (Serniwka 
and Shaw, 2009) with a dialysis treatment in disulfide-bond buffer (100 mM Na2HPO4− 
NaH2PO4, pH 7.5, 200 mM NaCl, 5% glycerol and 25 µM CuCl2) at room temperature. 
Disulfide bond formation was monitored by nonreducing SDS-PAGE until Ub G76C 
monomer depletion. HECT~Ub complex was obtained by mixing together 100µM of 
HECT C778S/IΔC627NP with 100µM of UbG76C and subsequently the complex was 
purified through anionic exchange column (Resource Q) in the following buffer: 20mM 
Tris-HCl pH 8.0, 5% glycerol, 10mM of CuCl2 using a NaCl gradient from 2 mM to 500 
mM. The Ube2D3~Ub complex was obtained mixing together 100µM of E2 
(C21S/C107S/C111S) mutant with 500µM of UbG76C in a molar ratio of 1:5. Purification 
step performed on an anionic exchange column (HiTrap S) using a NaCl gradient form 
30mM to 500mM and fraction’s composition was analyzed by loading on a non-reducing 
SDS-PAGE gel. With this column we were able to purify the E2 species from Ub2 and Ub 
alone due to the difference of the isoelectric points. Fractions were collected and 
concentrated with centricon of 3kDa of cut-off.   
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12. Isopeptide bond reaction 
The enzymatic reaction was performed by incubating 200µM of Ube2D3 S22R/C85K with 
200µM of His6-tagged ubiquitin and 1µM of E1 at 37°C for 26h in a buffer containing 
3mM ATP, 5mM MgCl2, 50mM Tris-HCl pH 10.0, 150mM NaCl. The E2-Ub conjugate 
was purified by Ni2+-affinity chromatography and the E2-Ub was eluted from beads using 
200mM imidazole. The last purification step was done by size exclusion chromatography, 
using a Superdex 75. Fraction’s composition was analyzed by loading on a reducing SDS-
PAGE gel and the most pure fractions were collected and concentrated with concentricon 
of 3kDa of cut-off. 
 
13. Disulfide bond stability assay 
The kinetic experiments were performed by incubating 60µM of purified E2~Ub (see 
Material and Methods paragraph 11) in the presence of 5µM of Rabex-51-74 WT or mutants 
in ubiquitination buffer (25mM Tris-HCl pH 7.6, 5 mM MgCl2, 100 mM NaCl) at 37°C. 
E2~Ub disulfide disruption was monitored by quenching the reaction at different time 
points with Laemmli buffer without reducing agent (i.e. DTT) and analyzing the presence 
of free-Ub by immunoblot with anti-Ub (ZTA10, generated in house, dilution 1:5).   
 
14. Isothermal Titration Calorimetry 
ITC measurements were performed on a MicroCal VP-ITC (MicroCal, Inc.) instrument at 
24°C. All proteins were extensively dialyzed against ITC buffer (20mM tris HCl pH 8.0, 
200mM NaCl, 5% glycerol and 1mM DTT). Rabex-51-74 WT at a concentration of 0.74-
0.91mM was injected into 2ml of solution containing 35µM of Ube2D3-Ub or Ub alone in 
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injection of 4µl. Experimental heats were corrected by subtracting the blank measurements 
and analyzed using the Origin software package. Binding constants and other 
thermodynamic parameters were calculated by fitting the integrated titration data assuming 
a single binding site. 
 
15. Crystallization trays  
The crystallization screening experiments were performed with a Honeybee Cartesian 
nano-dispenser robot by sitting-drop vapor diffusion method at 20°C and 4°C, allowing us 
to screen at the same time 96 different conditions using commercially available kits 
(Hampton, Qiagen). To screen for initial crystallization conditions, 100nl of protein 
solution, at specific concentration, was mixed with 100nl reservoir solution and 
equilibrated against 150ml of reservoir solution. Different commercial crystallization 
screens were tested such as the Morpheus, Midas, JCSG+, PACT, Pro-complex, Index. 
 
16. Small Angle X-ray Scattering (SAXS) 
SAXS data were collected at the BM29 beamline of the European Synchrotron Radiation 
Facility (Grenoble). Data were collected for HisUb-loaded UbcH5c S22R/C85K through 
the isopeptide bond, Rabex-51-74 A58G and the complex formed in a ratio 1:1 at 250mM in 
a final volume of 90ml. Rabex-51-74 A58G and the complex were run on a size exclusion 
chromatography (Superdex 75) using a SAXS compatible buffer (20mM Tris-HCl pH 8.0, 
200mM NaCl, 5% glycerol and adding fresh TCEP). Next, they are analyzed by X-Ray 
scattering. On the contrary the E2-Ub was directly analyzed by SAXS due to it is 
homogeneous.  
	   79	  
17. In vitro ubiquitination assay using protein microarray (Life Sensor) 
17.1 Array Hybridization 
Protein microrrays were removed from -80°C storage and placed at room temperature (RT) 
for 15 minutes in a sealed, dessicated container before opening, to avoid formation of 
condensate. The arrays were rehydrated in a solution of 1M urea, 0.5M ethanolamine, pH 
7.5, 25% glycerol, 20mM glutathione, and 1mM DTT for 30 min at RT. The arrays were 
washed twice in PBST (PBS containing 0.1% Tween-20) and then blocked for 1 hour at 
RT in PBST containing 20mM reduced glutathione, 1mM DTT, 5% BSA, and 25% 
glycerol. Each array was ubiquitylated with TAMRA-labeled ubiquitin (Ub-TMR), 
ubiquitin activating enzyme (UBE1), 100nM UBE2D3, and His-MBP-Rabex-5 full length 
for 120 minutes RT. The ubiquitylation buffer also contained 20mM Hepes, pH 7.4, 
150mM NaCl, 0.5mM DTT, 1mM ATP, 2mM MgCl2, and an ATP regeneration system 
consisting of creatine phosphate, creatine phosphokinase, and inorganic pyrophosphatase. 
A control array was treated with the same reaction mixture minus the E3. Arrays were 
washed with three changes PBST, four changes 0.2 micron-filtered water, and then 
centrifugally dried (1000 RPM for 5 minutes at RT). The arrays were scanned using a 
GenePix 4100A Microarray Scanner (Molecular Devices, Inc.) using the 532nm channel. 
17.2 Data Analysis 
Microarray images were gridded and quantitated using GenePix Pro (v7) software. Median 
intensities (features and local backgrounds) were utilized and median feature intensities 
minus background were calculated (F-B). Negative F-B values were assigned a value of 
one relative fluorescence unit for further calculations. F-B values for all both arrays, 
control (null), Rabex5-treated, were log(base 2) transformed and subjected to Quantile 
Normalization (Bolstad, Irizarry et al. 2003; Reimers 2010) to normalize intensity (IN) 
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between arrays and remove technical sources of error (print-tip and location). Control IN 
values were subtracted from experimental IN values to yield the final estimate of 
magnitude change (MN). Duplicate features (representing identical proteins) were used to 
calculate the average (avg MN) and standard deviation. Note that although calculation of 
standard deviation technically requires three data points, Excel will report a value from 
two, useful for estimating reproducibility. T-test (paired, 2 tailed) was used to assess the 
probability that the experimental IN value was different from the control IN value. A 
threshold of 95% confidence (p < 0.05) was employed to filter data.  
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RESULTS 
Characterization of E3 ligase activity of HECTNedd4  
Nedd4 is a well-characterized E3 ligase able to catalyze the formation of Lys63-linked 
chains through a sequential addition mechanism. By solving the structure of the HECT 
domain in complex with free Ub we have structurally characterized the UBD, present in 
the N-lobe, which interacts with Ub in a non-covalently manner (Maspero et al., 2011). We 
have shown that this surface plays a critical role in the enzyme processivity to promote 
substrate polyubiquitination (Maspero et al., 2011) (Figure 19). Yet, the mechanism used 
by Nedd4 to achieve linkage specificity remains poorly understood. 
We aimed at to understanding the detailed molecular mechanism of how 
HECTNedd4 domain transfers the donor Ub (UbD) from the catalytic cysteine to the growing 
chain on the substrate. Our goal was to solve the structure of a catalytic intermediate 
formed by the UbD-charged HECTNedd4 domain and the acceptor Ub molecule non-
covalently bound to the UBD. 
1. Catalytic intermediate of the HECTNedd4 domain 
To crystallize the catalytic intermediate (HECT~UbD:Ub) we needed an HECT~Ub 
complex stable in crystallization conditions and easy to produce in a large amount. In the 
case of naturally occurring thioester bond, we envisioned two major caveats: i) the low 
yield of the enzymatic production of the HECT~Ub intermediate, ii) the short life of the 
thioester HECT~Ub bond that is prone to rapid transfer UbD from the catalytic cysteine to 
any acceptor lysine (even of the enzyme itself).  
To overcome these problems we replaced the thioester bond with a stable disulfide 
bond that we chemically generated between the catalytic cysteine (C867) of the HECT 
domain and a modified form of the UbD (Figure 23A). NMR studies have shown that the 
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disulfide bond nicely mimics the native thioester bond, most likely thanks to the flexibility 
of Gly76 in the thioester, able to compensate for the extra bond length distance present in 
the S-S bridge (Serniwka and Shaw, 2009). The Ub protein does not possess any Cys. 
Thus, to mimic the thioester bond we replaced the last Gly (G76) of the Ub moiety with a 
Cys residue generating the UbG76C mutant.  
The chemical reaction needed to generate the disulfide bond is, in principle, not 
able to distinguish between the catalytic cysteine and the other cysteines present in the 
HECT domain. Thus, we mutagenized the two additional non-catalytic Cys of the HECT 
domain, C627 and C778, which are positioned in the UBD of the N-lobe and in close 
proximity to the flexible linker, respectively.  
Once mutated to Ser we verified whether the Ub binding ability of the generated 
mutants was altered. A pull-down assay was performed incubating 2µM of GST-HECT 
mutants with 250ng of K63-linked Ub chains for 2h (Figure 23B). We used GST-HECT 
wild type as positive control for the binding while as negative control either GST alone or 
the GST-HECT F707A mutant, previously demonstrated to be impaired in the Ub binding 
(Maspero et al., 2011). Results showed that single point mutation of C778 residue did not 
affect Ub binding ability (Figure 23B) whereas the mutation of C627 residue caused a 
severe impairment in Ub binding. This is possibly due to its position in the middle of the 
UBD.  
We thus decided to replace C627 and its surrounding residues with the amino acids 
sequence of Nedd4 yeast counterpart, Rsp5, which naturally does not possess Cys residue 
in this region (Figure 23C) but has the same structural folding of the HECTNedd4 (Figure 
23D). Therefore we mutagenized the HECT C778S in the context of a few amino acids 
substitution (IΔC627NP, details in the materials and methods) generating the double mutant 
HECT IΔC627NP/C778S that was subsequently tested in pull-down assay with K63-linked 
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Ub-chains. Results demonstrated that the IΔC627NP mutation was able to restore the Ub 
binding ability of the HECT domain lacking the two non-catalytic cysteines (Figure 23E). 
Figure 23. Generation of the HECT mutant for the disulfide bond. (A) Schematic drawing of 
the naturally occurring thioester bond between the catalytic cysteine (Cys867) of the HECTNedd4 
domain and the C-terminal of Ub. To mimic the short-lived thioester bond we replaced it with a 
stable disulfide bond chemically produced between the Cys867 of the HECT domain and the 
cysteine of Ub (G76C) mutant. (B) Different HECT mutants were tested for their ability to bind Ub 
by GST pull-down assay. The indicated GST-fusion proteins were incubated for 2h at 4°C in YY 
buffer with synthetic K63-polyUb chains and analyzed by immunoblotting (IB) anti-Ub as 
indicated. Coomassie staining shows comparable loading of GST proteins. (C) Sequence 
alignment, color-coded according to ClustalX, of the region surrounding the Cys627 of the HECT 
domains of human Nedd4 and yeast Rsp5, performed with Muscle program. Region mutated in the 
HECTNedd4 to produce the stable disulfide bridge with Ub is indicated with a red box and the 
Cys627 is highlighted by a black triangle. (D) Cartoon representation of the region surrounding the 
Cys627 of the HECTNedd4 WT (in purple, PDB:2XBB) superposed to HECTRsp5 (in green, 
PDB:3OLM) showing the difference in the secondary structure of the region of interest. (E) As in 
(B), different HECT mutants were tested for their ability to bind Ub using synthetic K63-polyUb 
chains by GST pull-down assay. GST and GST-HECT F707A were negative control, GST-HECT 
WT was a positive control. 
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 Next, the HECT C778S/IΔC627NP mutant was produced in bacteria as GST-tagged 
protein. We removed the GST tag by Prescission protease cleavage (Figure 24A) and 
purified the HECT by size exclusion chromatography (Superdex 200 column) (Figure 
24B). The untagged ubiquitin G76C mutant was produced and purified through an acid 
precipitation (Figure 24C) (for details see Materials and Methods). Then it was purified by 
a size exclusion chromatography (Superdex 75 column) in which the UbG76C was eluted 
from 70 to 90ml of elution volume (Figure 24D). Proteins and nucleic acids composed 
other peaks as contaminants. 
	  
Figure 24. HECT C778S/IΔC627NP and UbG76C production and purification. (A) Example of 
HECT C778S/IΔC627NP cleavage from glutathione beads incubating with Prescission protease. 
First and second lanes were beads before and after cleavage, respectively. In the third line there 
was the HECT sample needed to be purified. (B) Elution profile of cleaved HECT 
C778S/IΔC627NP on a size exclusion column (Superdex 200). Fractions depicted were loaded on a 
reducing SDS-PAGE gel and Coomassie staining was performed. (C) Example of UbG76C 
production. Lane 1 and 2 were bacteria lysates pre and post-induction with IPTG. Lane 3 was 
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bacteria lysate post-sonication. Lane 4 and 5 were respectively pre and post-acid precipitation. (D) 
Chromatogram from size exclusion chromatography (Superdex 75 column). Lower panel’s 
fractions from the peak loaded on a reducing SDS-PAGE gel.   
 
 
 Once we obtained the purified proteins, we set up the disulfide bond reaction with a 
dialysis treatment in disulfide bond buffer supplemented with 25µM of CuCl2 (Merkley et 
al., 2005). The reaction was performed mixing together the two proteins at 1:1 molar ratio 
with a final concentration of 100µM/each. The disulfide bond formation was stopped by 
adding laemmli without DTT and was monitored by non-reducing SDS-PAGE. After 48h 
the free UbG76C was exhausted and large amount of HECT~Ub was obtained (Figure 
25A). 
 For successful crystallization trials, homogeneous, highly pure and concentrated 
sample is required. Since it is a chemical reaction, we obtained not only the heterodimer 
HECT~Ub but also HECT~HECT and Ub~Ub homodimers as well as single, not-modified 
proteins. To purify the HECT~Ub from the mixture, we performed an anionic exchange 
column (Resource Q), taking advantage of a sizeable difference in isoelectric points of the 
different species. Fractions were monitored by a non-reducing SDS-PAGE followed by a 
Coomassie staining. In these conditions we were able to separate the HECT~Ub from other 
proteins, and in particular from the HECT domain alone. Pure fractions comprised between 
140-160 ml of elution volume were collected (Figure 25B).  
 To obtain the complex for crystallization, we mixed together the purified HECT~Ub 
with free Ub wild type in a 1:2 molar ratio in order to saturate the UBD in the N-lobe. The 
complex was subsequently concentrated until 37 mg/ml using Centricon column 
(Millipore) with a cut-off of 3kDa.  
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Figure 25. Preparation of HECTNedd4~UbD complex. (A) Disulfide bond reaction between HECT 
C778S/IΔCNP and Ub G76C, in specific dialysis buffer supplemented with CuCl2, monitored by 
non-reducing SDS-PAGE and Coomassie staining. At 48h the reaction was stopped due to Ub 
monomer depletion. (B) Elution profile of anionic exchange column, based on a NaCl gradient, 
showing the separation of HECT C778S/IΔCNP~Ub from HECT C778S/IΔCNP dimer, monomer 
and Ub dimer. Lower panel, Coomassie staining shows fractions composition from the peak 
containing HECT C778S/IΔCNP~Ub, loaded on non-reducing SDS-PAGE.  
 
2. Crystal structure of the catalytic intermediate (HECTNedd4~UbD:Ub) 
We tested several crystallization conditions with a number of commercially available 
nanovolume crystallization screening trays, performed at the High Throughput 
Crystallization Laboratory (HTX Lab) of the EMBL Grenoble outstation. Crystals were 
then reproduced in house, in collaboration with the Crystallization Unit at the IFOM-IEO 
campus, using a Honeybee liquid Cartesian robot by sitting drops vapor diffusion method, 
allowing us to monitor with an automated imaging system (CF400, Bruker) the 96-well 
plates.  
 Diffracting crystals were obtained at 4 °C in 2.4–2.6 M sodium	  malonate, pH 5.7–
6.2 (Figure 26A). Crystals were harvested from the 96-well plate and directly vitrified in 
liquid nitrogen and data were collected at the European Synchrotron Radiation Facility 
(Grenoble). Data collection, data processing, model building and refinement was carried 
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out by the head of the crystallization facility, Sebastiano Pasqualato, who previously 
solved the HECT:Ub structure (Maspero et al., 2011). The crystal structure of the complex 
(HECTNedd4~UbD:Ub) was determined at 2.51Å resolution (Table 2).  
 
Table 2: Data collection and refinement statistics 
 
 
 As expected, loading of the UbD onto HECTNedd4 catalytic cysteine is compatible 
with non-covalently Ub binding. The N-lobe adopts the same conformation in the presence 
 
 
HECT Nedd4 ~UbD–Ub HECT Nedd4  A889F
Data collection
Space group R32:h P3121
Cell dimensions
 a, b, c (Å) 196.54, 196.54, 98.77 100.55, 100.55, 96.45
 _, `, a (°) 90, 90, 120 90, 90, 120
Resolution (Å) 56.74–2.51 (2.57–2.51) a 44.58–3.00 (3.10–3.00) a
Rmerge 8.8 (88.5) 6.8 (69.7)
I / m I 16.6 (2.9) 28.4 (3.9)
Completeness (%) 100.0 (100.0) 99.3 (99.1)
Redundancy 7.4 (7.5) 13.0 (12.4)
Re!nement
Resolution (Å) 56.74–2.51 44.58–3.00
No. re!ections 22,567 11,550
Rwork / R free 18.4 / 22.9 24.6 / 29.5
No. atoms
 Protein 4,381 3,124
 Water 112 3
B  factors
  Nedd4 HECT domain 52.8 136.4
 UbD 50.4
 Ub 82.3
 Water 46.1 93.9
r.m.s. deviations
 Bond lengths (Å) 0.008 0.003
 Bond angles (°) 1.12 0.78
aValues in parentheses are for highest-resolution shell.
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or absence of UbD (root-mean-square deviation -rmsd- of 0.8 Å over 258 Cα) with free Ub 
kept in the binding site crafted by the N-lobe subdomains (Maspero et al., 2011).  
 Previous structures of various HECT domains have already shown the extreme 
flexibility between the N- and C-lobes (Figure 14). This was the first structure of an Ub-
loaded HECT E3 ligase primed for catalysis and showed an “inverted T” shape 
conformation with the C-lobe sited at the middle of the N-lobe. 
 The overall HECT domain structure remarkably resembles that of Nedd4-like HECT 
domain (HECTNedd4L) crystallized in complex with Ube2D2~Ub (Kamadurai et al., 2009), 
(Figure 26B, superposition with a rmsd of 1.1 Å over 369 Cα). This is the first time that 
two C-lobes from different HECTs show the same orientation. Strikingly, the UbD in the 
HECTNedd4~UbD:Ub structure sits in the same position as the Ub loaded on the E2 in 
HECTNedd4L: Ube2D2~Ub structure (Kamadurai et al., 2009).  
 As the interaction pattern between the C-lobe and UbD is unaltered with respect to 
what described by Schulman and coworkers we conclude that we have trapped the 
following step in the E3-mediated ubiquitination reaction, in which UbD has been handed 
over to the C-lobe, and is ready to be transferred to the substrate.  
 Differently from the bulk of conserved contacts between UbD and the C-lobe (Figure 
26B), the last three residues of UbD display a dramatic re-arrangement with respect to the 
HECTNedd4-Like:Ube2D2~Ub structure (Figure 26C). The UbD tail zips onto β-strand β9, 
upstream of the catalytic Cys867, and organizes a hydrogen bond pattern that results in β-
sheet augmentation, a common motif in protein-protein interactions. These residues are 
thus locked in an extended conformation that causes the “stretch” of the Ub tail. 
 This re-arrangement of the UbD tail orients the thioester bond, held on the HECT 
domain, resulting in an optimal conformation for nucleophilic attack by the incoming 
lysine residue of the substrate (Dou et al., 2012; Plechanovova et al., 2012).  
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Figure 26. Structure of the Ub-loaded HECT in complex with Ub. (A) Image of diffracting 
crystals composed by HECTNedd4~UbD:Ub obtained at 4 °C in 2.4–2.6 M sodium malonate, pH 5.7–
6.2. (B) Cartoon representation of the superposition of HECTNedd4~UbD:Ub with 
HECTNedd4L:Ube2D2~Ub (PDB:3jw0). Ube2D2 is not shown to allow a better view of the HECT 
and Ub superposition. N- and C-lobe of HECTNedd4 are in light blue and in dark green respectively; 
UbD is in orange, non-covalently-bound Ub is in yellow. In the case of HECTNedd4L N-, C-lobe and 
loaded Ub are in dark blue, light green and in brown, respectively. (C) Close-up of the Ub tail in 
the crystal structure of HECTNedd4~UbD:Ub. When bound to the catalytic cysteine of HECTNedd4, the 
ubiquitin tail zips onto β-strand β9, upstream the catalytic Cys867, and organizes a hydrogen bond 
pattern that results in a β-sheet augmentation. 
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Characterization of Rabex-5 as E3 ligase 
Rabex-5 is able to bind Ub through two independent UBDs, MIU domain and ZnF_A20 
domain (Figure 22) (Lee et al., 2006b; Penengo et al., 2006). In addition, it has been 
demonstrated that Rabex-5 may exert an E3 ligase activity through its ZnF_A20 domain 
(Lee et al., 2006b). Due to the presence of A20 zinc finger domain (ZnF_A20) instead of a 
canonical RING domain, Rabex-5 can be defined as an atypical RING-E3 ligase. How 
Rabex-5 acts as E3 ligase is poorly understood and biochemical and structural information 
are lacking. Our aim was to validate the E3 ligase activity of Rabex-5 and to eventually 
characterize the molecular mechanism adopted by Rabex-5 to perform this activity.  	  
3. Rabex-51-74 has an E2 binding domain 
It is becoming clear that, at least for RING-type E3 enzymes, different combinations of 
E2/E3 enzymes catalyze the formation of different types of ubiquitin chains associated 
with distinct biological functions (Wickliffe et al., 2011; Williamson et al., 2009). 
 To determine which E2s can interact with Rabex-5, we carried out in the lab a yeast-
two-hybrid screen (Y2H) using a library of E2s (Christensen et al., 2007) with Rabex-51-74 
(containing both the ZnF_A20 and the MIU domains) as a bait (Figure 27A). This 
fragment has been previously shown to be sufficient for auto-ubiquitination (Lee et al., 
2006b). Two families of E2s, Ube2D and Ube2E, were found to be positive for Rabex-51-74 
interaction (Figure 27A-B). We therefore selected them for further validation.  
 First, we validated the Y2H by a pull-down assay, using in vitro translated Ube2D3 
and Ube2L3 as negative control. Pull-down experiment was performed incubating 4µM of 
GST- Rabex-51-74 with 8µl of in vitro translated ([35S]-methionine) E2s for 2h at 4°C. After 
washes with YY buffer, samples were loaded either on a reducing (100 mM DTT) SDS-
PAGE gel (Figure 27C-left panel) or on a non-reducing SDS-PAGE gel (Figure 27C-
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right panel) and detection of the binding was done by autoradiography.  
 As shown in Figure 27C, in both conditions the positive hit Ube2D3 showed a clear 
binding to GST-Rabex-51-74 while Ube2L3 was negative. This assay confirmed the Y2H 
result, demonstrating a specific recognition of the E2 moiety by Rabex-51-74. Based on 
these results, we used and referred to Ube2D3 as the specific E2 of Rabex-5. Caveat of this 
experiment is that the loading with Ub of the E2s, detected in the input in absence of DTT 
(Figure 27C-right panel), is less efficient in the case of Ube2L3 respect Ube2D3. 
	  
Figure 27. Interaction between Rabex-5 and specific E2s. (A) Schematic representation of the 
plated transformants. Rabex-51-74 was expressed in fusion with GAL4 DNA binding (Kim et al., 
2007) protein and its interaction with different E2 proteins fused with GAL4 activation domain 
(AD) was tested by yeast two-hybrid assay. Triplicate of yeast transformants were grown on SD 
medium lacking indicated amino acids. Protein interaction was assessed from growth on SD -Trp -
Leu -His medium (middle panel). The presence of both the fusion proteins was assessed from 
growth on SD -Trp -Leu (top panel) and yeast strain viability was assessed from growth of 
complete medium (bottom panel). (B) Panel of the different E2 screened showing their main 
features. Four E2s are highlighted in red as positive interactors of Rabex-51-74. (C) Pull-down assay 
performed with GST-Rabex-51-74 and in vitro translated E2s (35S-methionine), Ube2D3 and 
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Ube2L3, respectively a positive and negative hit in Y2H. On the left washes of pull-down 
experiments were made in buffer containing 100mM DTT and on the right all the experiment is 
performed in absence of reducing agent to score the loaded statues of the E2s. Detection was made 
by autoradiography. 
 
4. The interaction between Rabex-5 and Ube2D3 is mediated by ubiquitin 
To better characterize whether the E2:Rabex-5 interaction is Ub-dependent or independent, 
we performed the same pull-down experiment with in vitro translated Ube2D3(C85S) 
mutant. We mutagenized the catalytic cysteine (C85) of Ube2D3 to a less-reactive serine 
to obtain a stable in vitro translated Ub-loaded-E2 through oxyester bond (Plechanovova et 
al., 2011). Using this mutant we can visualize and distinguish in the input not only the E2 
alone but also the Ub-loaded-E2 (Figure 28A-first line). We then performed a pull-down 
assay using 4µM of GST-Rabex-51-74 wild type with 8µl of in vitro translated Ube2D3 
C85S for 2h at 4°C. As shown in Figure 28A, Rabex-5 clearly demonstrated a preference 
for the Ub-loaded Ube2D3 even if the stoichiometry of the E2 species in the input was 
unbalanced towards the E2 alone. With this assay we proved that Ub plays a critical role in 
the binding to activated E2. 
 Next, we intend to determine which UBD of Rabex-5 is involved in the binding. To 
this end, we tested GST-Rabex-51-74 constructs with specific mutations that abrogate the 
binding with ubiquitin: Y25F for the ZnF_A20 domain and A58G for the MIU domain 
(Penengo et al., 2006). Our analysis suggested that both UBDs participate to the binding to 
Ub-loaded E2 as only the double mutant showed a clear impairment (Figure 28A).   
 The same experiment was repeated with GST-Rabex-5 full-length protein and also in 
this case we found a preferential binding for the Ub loaded form of the E2 (Figure 28B). 
As shown in Figure 28B Rabex-5 full-length and Rabex-51-74 bind Ub loaded E2 in 
comparable manner, suggesting that no additional domains are required.   
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Figure 28. Interaction between Rabex-5 and Ube2D3 is mediated by Ub. (A) Pull-down assay 
performed with GST as negative control, GST-Rabex-51-74 WT and UBDs mutants (Y25F for the 
ZnF_A20 domain and A58G for the MIU domain) with in vitro translated Ube2D3 C85S. Ube2D3 
C85S formed a non-reducible oxyester bond with Ub (input line). Washes were made with buffer 
containing 100mM DTT and detection was made by autoradiography. (B) Same as in (A), using 
GST-Rabex-51-74, GST-Rabex-5 full-length and GST-Rabex-51-74 Y/A (double mutants in Y25F 
and A58G) 
 
 We also performed a pull-down experiment with the isolated UBDs. To skip ([35S]-
methionine labeling of the E2, we used a Ube2D3 modified with an isopeptide bond 
between the E2 and Ub. This strategy has been recently proved to be successful to mimic 
the thioester bond E2-Ub in the crystallization of the E2-Ub:RNF4 complex (Plechanovova 
et al., 2012). This product was obtained as described later (paragraph 5.2). The isolated 
UBDs of Rabex-5, Rabex-51-49 (ZnF_A20 domain) and Rabex-548-74 (MIU domain), either 
wild type or harboring single point mutation were produced as GST proteins. To mimic 
competition, as for the previous experiments, we mixed the E2-Ub and E2 alone in a 1:3 
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molar ratio. Pull-down assay was performed incubating 2µM of GST-proteins with 2µM of 
the E2 mix for 2h at 4°C. After washes with YY buffer, samples were loaded on a reducing 
SDS-PAGE gel. Detection was performed using anti-Ube2D antibody. 
 Also in this case, results were not conclusive regarding the relative importance of the 
two UBDs. We confirmed selective binding to the E2-Ub also for GST-Rabex-51-49 and 
GST-Rabex-548-74 and, we found that single point mutants on the UBD were able to impair 
E2-Ub binding (Figure 29). 
 
 
 
 
 
 
 
 
 
 
Figure 29. Interaction between Rabex-5 fragments and Ube2D3. Pull-down assay performed 
with GST, GST-Rabex-5 UBDs fragments and mutants (Y25F for the ZnF_A20 domain and A58G 
for the MIU domain) with a mix composed by a 3:1 molar ratio of Ube2D3 C85K and the Ub 
modified E2 (E2-Ub). Washes were made with buffer containing 100mM DTT and analyzed by IB 
as indicated.     
 
 Finally, we measured the binding affinity between Rabex-51-74 wild type and Ub-
loaded Ube2D3 performing the isothermal titration calorimetry (ITC). This technique 
allows the measurement of the affinity constant (the reciprocal of the dissociation constant 
KD) between two proteins in solution. For the ITC experiment, Rabex-51-74 was produced 
as GST protein, cleaved from GST tag by Prescission protease treatment and purified by 
size exclusion chromatography (Superdex 75 column) using an ITC compatible buffer 
(20mM Tris-HCl pH 8.0, 200mM NaCl, 5% glycerol and 1mM DTT). The ITC 
measurements were performed titrating 740µM of Rabex-51-74 into 2ml of solution 
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containing 35µM of the Ube2D3-Ub (isopeptide bond) protein. Experimental heats were 
corrected by subtracting the blank measurements and analyzed using the Origin software 
package. Binding constants and other thermodynamic parameters were calculated by fitting 
the integrated titration data assuming a single binding site. The measured KD is 2.67 ± 0.06 
µM (Figure 30, left panel).  
 Not surprisingly, direct binding with the E2 alone was impossible to measure. To 
evaluate the contribution of the E2 binding, we repeated the ITC measurement between 
Rabex-51-74 and Ub. Untagged Ub was produced by acid precipitation method and purified 
by size exclusion chromatography (Superdex 75 column) using the ITC buffer. 35µM Ub 
was titrated with 912µM Rabex-51-74. In this case we determined a KD of 5.9 ± 0.2 µM 
(Figure 30, right panel). Comparing the two KD , we can assume that Rabex-51-74 has an 
E2 binding domain, which minimally contributes to the binding affinity. Thus, the initial 
interaction seems to be mediated by binding to Ub. The minimal E2 binding may facilitate 
the correct positioning of the E2 on Rabex-5. We are currently investigating which is the 
binding affinity for each GST-Rabex-5 fragments. 
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Figure 30. Isothermal Titration Calorimetry Assays. Representative ITC curves are shown and 
the average KD with standard deviation for each data set is reported under each panel. Data were 
acquired and analyzed using the Origin software package. For each titration, the heat released upon 
E2-Ub:Rabex-51-74 WT or Ub:Rabex-51-74 WT association in the course of the ITC experiment, y 
axis, is displayed as a function of time, x axis (top quadrant). The integrated heats for each 
injection are plotted against the E2-Ub:Rabex-51-74 WT or Ub:Rabex-51-74 WT molar ratio together 
with the fitted curve (bottom quadrant). 
 
5. Structure of the complex Rabex-51-74:Ube2D3~Ub 
To understand the molecular mechanism exerted by Rabex-5 in the ubiquitination process, 
we set to crystallize a complex composed of our positive hit Ube2D3 loaded with Ub and 
Rabex-51-74. The latter product is soluble, easy to produce and purify (Penengo et al., 
2006). The thioester-linked E2~Ub is a short-lived bond and highly unstable in 
crystallization conditions. To overcome this problem we tried different strategies. 
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5.1. Disulfide bond 
 
As first strategy, we used the same approach that we successfully undertook to produce a 
stable Ub-loaded HECT (Figure 23). We replaced the thioester bond with a stable 
disulfide bond chemically produced between the catalytic Cys85 of the Ube2D3 and the 
one we introduced in Ub (G76C) (Figure 31A). To favor the catalytic Cys85 of Ube2D3 
during the disulfide bond formation, we mutagenized all surface exposed Cys present in 
the E2 to Ser. We generated the E2 mutant containing the following mutations 
C21S/C107S/C111S by site directed mutagenesis. To verify whether this mutant maintains 
the tridimensional structure we carried out a pull-down assay using 4µM of GST-Rabex-51-
74 and in vitro translated Ube2D3 C21S/C107S/C111S (C/S) mutant in absence of reducing 
agent (DTT). As positive control of the reaction we used the previously described Ube2D3 
C85S. As shown in Figure 31B the Ube2D3 C/S mutant formed a thioester adduct very 
efficiently. In addition, similar to the E2 C85S~Ub, the Ube2D3 C/S~Ub was able to 
specifically interact with GST-Rabex-51-74 wild type. Thus, we confirmed that the triple 
mutations do not alter the structural conformation and function of the E2.  
 We then proceeded with the generation of a large scale Ube2D3 C/S~Ub. Ube2D3 
C21S/C107S/C111S was produced and purified using a size exclusion column (Superdex 
75). The reaction was performed mixing together 100µM of E2 (C21S/C107S/C111S) 
mutant and 500µM of UbG76C against a disulfide bond buffer supplemented with 25µM 
CuCl2 at room temperature. The disulfide bond formation was stopped by adding laemmli 
without DTT and was monitored by non-reducing SDS-PAGE. After 72h the free UbG76C 
was exhausted (Figure 31C).  
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Figure 31. Disulfide bond formation between E2 and Ub. (A) Schematic drawing of the 
naturally occurring thioester bond between the catalytic cysteine (C85) of the E2 enzyme and the 
C-terminal of Ub. To mimic the short-lived thioester bond, we replaced it with a stable disulfide 
bond, chemically produced between the Cys85 of E2 and the cysteine of Ub (G76C) mutant. (B) 
Pull-down assay performed with GST-Rabex-51-74 WT and in vitro translated Ube2D3 C85S 
(positive control) and Ube2D3 C21S/C107S/C111S mutant (indicated as E2 C/S). Washes were 
made in non-reducing condition and detection was made by autoradiography. (C) Disulfide bond 
reaction between E2 (C21S/C107S/C111S) mutant and UbG76C, in specific dialysis buffer 
supplemented of CuCl2, monitored by non-reducing SDS-PAGE and Coomassie staining. After 72h 
the reaction was stopped because the monomeric Ub was exhausted.  
 
 
 We then purified the E2~Ub from the other side products of the reaction, by a two 
steps purification protocol. The first anionic exchange column (HiTrap S) allowed us to 
separate E2 species from Ub2 and Ub alone due to the difference of the isoelectric points 
(Figure 32A). Fractions from F6 to H1 (Figure 32A) were collected, concentrated and 
loaded on a size exclusion column (Superdex 75) to purify the E2~Ub from the other E2 
species. We analyzed the composition of single fractions of the peak by a non-reducing 
SDS-PAGE gel (Figure 32B). Unfortunately, separation was suboptimal as the molecular 
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weights of the various species were too similar.  
 
 
 
Figure 32. Purification of the disulfide E2~Ub complex. (A) Elution profile of the disulfide bond 
E2~Ub complex on an anionic exchange column (HiTrapS) using a NaCl gradient. Fractions 
depicted with a black line were loaded on a non-reducing SDS-PAGE and Coomassie staining was 
performed. (B) Chromatogram of the E2~Ub sample purified on a size exclusion column 
(Superdex 75). Lower panel shows fractions from the peak loaded on a non-reducing SDS-PAGE. 
  
As alternative strategy, we decided to take advantage of the ability of Rabex-51-74 
to bind selectively the E2~Ub. First, we ran an analytical size exclusion chromatography. 
A Superdex 75 column was loaded with the two separated proteins, Rabex-51-74 or E2~Ub 
mixture at 100µM concentration (Figure 33). 
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Figure 33. E2~Ub purification strategy.	  Analytical size exclusion analysis of the E2~Ub mixture, 
obtained from previous purifications, and Rabex-51-74 WT. Elution profile of the E2~Ub mixture is 
represented as a red line, Rabex-51-74 WT alone as a blue line, the two complexes obtained mixing 
together the E2~Ub mixture:Rabex-51-74 WT in a ratio 1:1 and 1:2 are respectively green and 
orange. The E2~Ub curve showed a peak shift upon addition of different concentration of Rabex-5. 
Fractions from 9 to 15 ml (indicated with a black line in the graph) of each run were analyzed by 
Tris-tricine PAGE and Coomassie staining. Lower panel represented a magnification of the upper 
panel (depicted by the black line and asterisk) to show the presence of an additional band, not 
present in the input and corresponding to free Ub, upon Rabex-5 incubation with E2~Ub sample.  	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In blue is represented the elution profile of Rabex-51-74 alone, while the red line 
represented the one of the E2~Ub mixture. Fractions of the two runs were loaded on a non-
reducing SDS-PAGE gel. Rabex-51-74 alone is eluted at the expected molecular weight and 
the species of the E2~Ub were co-eluted as in Figure 32B. 
Then, 100µM of the E2~Ub mixture was incubated with Rabex-51-74 in a 1:1 molar 
ratio and subsequently ran on the size exclusion column. The elution profile (Figure 33, 
green line) showed the appearance of an additional peak at higher molecular weight 
corresponding to the formation of Rabex-51-74:E2~Ub complex. Analysis of the fractions 
confirmed the appearance of the complex (third panel, Figure 33). Importantly, both the 
E2 homodimer and the E2 alone did not change their elution profile in presence of Rabex-5 
confirming that Rabex-51-74 binds specifically the Ub-loaded form of the E2. Increasing the 
concentration of Rabex-51-74 to a 2:1 molar ratio (Figure 33, orange line) caused a further 
increase in the intensity of the complex formation.  
 Close inspection of the gel, revealed the appearance of a faint band at the same 
molecular weight of free Ub (magnification-bottom panel Figure 33). Since no free Ub 
was present in the input, we hypothesized that Rabex-51-74 was able to disrupt the disulfide 
bond on the E2. 
 While this can be seen as a possible proof of its E3 ligase activity, it prevents further 
use of the complex for crystallization purpose as the complex is not stable in presence of 
Rabex-51-74. 
 
 
5.2. Isopeptide bond 
To generate a stable complex for crystallization trials, we therefore decided to generate a 
more stable isopeptide bond between Ube2D3 and Ub, according to a recently published 
protocol (Plechanovova et al., 2012) (Figure 34A). To this purpose, we created a mutant 
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Ube2D3 in which we mutagenized the catalytic Cys85 into a Lys as well as Ser22 into 
Arg. The newly generated Lys85 in the E2 (C85K) is in an optimal position to perform the 
nucleophylic attack on the catalytic Cys of the Ub-loaded E1 (Figure 34B). Mutation 
S22R destroys a non-covalent interaction with Ub, present in the backside of the E2 and 
previously shown to be necessary for the enzyme’s processivity (Brzovic et al., 2006). This 
mutation increases the yield of E2-Ub product in the enzymatic reaction (Plechanovova et 
al., 2012).  
 We set up an enzymatic reaction with E1, the E2 S22R/C85K mutant and free N-
terminal His-tagged-Ub. To obtain a reasonable amount of E2-Ub, we produced the single 
components in large amount and we purified them through chromatographic passages: an 
anionic exchange (HiTrap S column) and a size exclusion (Superdex 200 column) for the 
E1 enzyme and a single size exclusion (Superdex 75 column) for His-Ub and Ube2D3 
S22R/C85K. The isopeptide bond formation was generated mixing together 200µM 
Ube2D3 S22R/C85K, 200µM His-tagged Ub and 1µM E1 at 37°C in a buffer containing 
3mM ATP, 5mM MgCl2, 50mM Tris-HCl pH 10.0 and 150mM NaCl. After 26h the 
reaction was stopped because the His-Ub was almost exhausted (Figure 34C). 
To purify the E2-HisUb from the enzymatic mixture we performed a first 
purification step using nickel beads, which bind both E2-HisUb and His-Ub (Fraction 7 
and 8 Figure 34D). Those two proteins were subsequently purified through a size 
exclusion column (Superdex 75), taking advantage of their molecular weight difference 
(Figure 34E). 
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Figure 34. Isopeptide bond formation between E2 and Ub. (A) Schematic drawing of the 
naturally occurring thioester bond between the catalytic cysteine (Cys85) of the E2 and Ub. To 
mimic the short-lived thioester bond with a more stable bond we enzymatically produced an 
isopeptide bond between the lysine of E2 mutant (C85K) and Ub. (B) Cartoon representation of a 
nucleophilic attack of K85 of E2 towards an Ub∼loaded E1, allowing the formation of E2-Ub. (C) 
Isopeptide bond reaction was monitored by a reducing SDS-PAGE and Coomassie staining. After 
26h the reaction was almost completed due to formation of the largest amount of our target E2-Ub. 
(D) Purification of E2-HisUb by incubation with nickel beads for 2h at 4°C. Beads were washed 
with 1M NaCl (Fraction 4) and 20mM imidazole (Fraction 5) before elution with 200mM 
(Fractions 7) and 500mM (Fraction 8). Fractions were loaded on a reducing SDS-PAGE and 
Coomassie staining was performed. (E) Elution profile of purified E2-HisUb (Fraction 7 of D) on a 
size exclusion column (Superdex 75). Indicated fractions were analyzed by reducing SDS-PAGE 
and Coomassie staining. Fraction depicted with a red box was analyzed by Mass-Spectrometry. 
 
Before proceeding with the following steps, we analyzed by mass spectrometry (MS) the 
major band of the E2-HisUb purified peak (depicted with a red box in Figure 34E). 
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MS data confirmed that the band is exclusively made of E2-Ub with Ub attached on 
residue Lys 85 (Figure 35).  
 
 
 
 
 
 
 
 
Figure 35. Mass-spectrometry of isopeptide E2-Ub. MS/MS spectrum of the Ube2D3 C85K 
peptide with the diglycine-modified lysine residue. Peptide sequence was shown with the 
annotation of the identified matched b ions in red and the y ions in blue. 
 
We also noticed other bands appearing above the one of interest that were further 
analyzed by MS (Figure 34). Results demonstrated that additional natural lysines were 
modified by the Gly-Gly peptide, sign of ubiquitination: Lys8, Lys133 and Lys144. Thus, 
even if at low stoichiometry, additional lysines may be directly modified by the E1. To 
reduce this side effect of the reaction, we generated a triple K8R/K133R/K144R mutant by 
site directed mutagenesis. Unfortunately, this E2 variant was not soluble and impossible to 
purify (data not shown). This behavior prevented further experiments with this mutant.  
Since the multi-Ub E2-HisUb represented a minimal percentage of the total E2-
HisUb obtained, we decided to proceed with the Ube2D3 S22R/C85K-Ub being selective 
with the fractions collection upon purification. As shown in Figure 34E, we collected 
fractions from D10 to D2, and we concentrated our sample to 6mg/ml. This sample was 
used for pull-down experiments and ITC analysis shown before (Figure 29-30) and for 
crystallization purpose as described below.  
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5.3. Rabex-51-74:Ube2D3-Ub complex and crystallization trays 
	  
Purified Ube2D3 S22R/C85K-Ub, was mixed with Rabex-51-74 wild type in a 1:2 molar 
ratio and the mix was concentrated until a final concentration of 60µM. 
 We evaluated the complex by size exclusion column (Superdex 75) and aliquots of 
fractions were run in a reducing SDS-PAGE (Figure 36). As shown in the chromatogram 
of Figure 36 (red line), the complex Rabex-51-74 wild type:Ube2D3-Ub was eluted at 
higher molecular weight than the nominal one. This was possibly due to the fact that the 
two UBDs of Rabex-51-74 may engage multiple interactions with modified E2-Ub 
generating a not homogeneous complex. Being the two surface of interaction different, Ub 
could act as a bridge between two molecules of Rabex-51-74 wild type, and these molecules 
could in turn bind other Ubs, thus creating long ‘chains’ of not necessarily identical Rabex-
5:E2-Ub units. To overcome this problem we decided to include in the crystallization 
screening, Rabex-51-74 A58G mutant (MIU-impaired mutant) that apparently shows a wild 
type catalytic activity. Our previous data (shown in paragraph 6) seems in fact to confirm 
that the ZnF_A20 domain is the domain responsible for the E3 ligase activity of Rabex-5 
(Lee et al., 2006b; Xu et al., 2010).  
 Rabex-51-74 A58G was produced as GST tagged protein, cleaved from the GST tag 
with Prescission protease, and purified using a size exclusion column (Superdex 75). We 
analyzed its behavior alone (Figure 36-blu line) or in complex with E2-Ub in a ratio 1:2 at 
final concentration of 60µM (Figure 36-green line). Compare to the complex made with 
Rabex-51-74 wild type, the complex of Rabex-51-74 A58G:Ube2D3-Ub eluted at the 
expected molecular weight, indication of  a more homogenous and monodisperse sample. 
 Unfortunately, in both cases, we scored several peaks, including the one of Ube2D3-
Ub that ran immediately after the peak of the complex. To have a more homogeneous 
sample we were quite stringent in choosing the fractions. For E2-Ub:Rabex-51-74 wild type 
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complex we collected fractions from E4 to E7 while for E2-Ub:Rabex-51-74 A58G complex 
we collected fractions from E7 to E9 (Figure 36). Then, complexes were concentrated and 
tested in several crystallizations trays. For E2-Ub:Rabex-51-74 wild type complex we tested 
two different concentrations, 13mg/ml and 30mg/ml, while E2-Ub:Rabex-51-74 A58G 
complex was tested at 20mg/ml. Trays were set-up at two different temperatures (20°C and 
4°C), using commercial screens: PACT, JCSG+ and Procomplex from Qiagen, 
Stura/Macrosol, Morpheus and Structure screen 1⁄2 from Molecular Dimension, Crystal 
screen 1⁄2 and Index from Hampton. Unfortunately, no reproducible crystals were 
obtained.  
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Figure 36. Rabex-51-74:Ube2D3-Ub complex. Size exclusion column of the E2-Ub:Rabex-51-74 
complex. Elution profile of E2-Ub:Rabex-51-74 WT complex is depicted in red, E2-Ub:Rabex-51-
74A58G complex is depicted in green and Rabex-51-74A58G alone in blue. The curves of the 
complexes showed peak shifts respect to Rabex-51-74 alone. Fractions from 1.4 to 2.1 ml were 
monitored in the lower panels by reducing SDS-PAGE and Coomassie staining.  
 
 
5.4. SAXS 
 
Since all our structural efforts failed, we decided to use Small Angle X-ray Scattering 
(SAXS) to get an idea of the tridimensional arrangement of the Rabex-51-74:Ube2D3-Ub 
complex. In collaboration with Sebastiano Pasqualato at IEO (Milan), Adam Round and 
Martha Brennich of the BM29 beamline at the European Synchrotron Radiation Facility 
(Grenoble), we performed SAXS analysis obtaining technically good spectra.  
 We described results obtained with Rabex-51-74A58G and not with Rabex-51-74 wild 
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type, even if we tested both, due to the unsuccessful results obtained with the wild type 
protein. Even if we previously ran Rabex-51-74 wild type:Ube2D3-Ub complex on a size 
exclusion chromatography (Superdex 75 column) the complex formed aggregates at high 
molecular weight, as shown in Figure 36, with a low intensity of scattering. Therefore, 
elaboration of data from the spectrum was not possible. 
 First, we subjected to X-Ray scattering the two single proteins, Rabex-51-74A58G and 
the isopeptide Ube2D3 S22R/C85K-Ub sample. We decided to test Rabex-51-74A58G 
mutant as it maintained the catalytic domain intact (see below, chapter 6.2) and behaved as 
homogeneous sample. 
 We ran Rabex-51-74A58G sample on a size exclusion chromatography (Superdex 75) 
to isolate the scattering of the monodisperse sample from that of aggregated or 
oligomerized one. The isopeptide Ube2D3 S22R/C85K-Ub sample was directly tested by 
X-Ray scattering without size exclusion chromatography, because the sample was 
sufficiently homogeneous and monodisperse (data not shown). The obtained spectra were 
analyzed using as model the crystal structures of Rabex-51-74 (PDB:2C7N) (Penengo et al., 
2006) and of various E2~Ub. Indeed, the E2~Ub can assume various conformations 
(Pruneda et al., 2011) therefore we chose crystal structure of E2-Ub alone (PDB:3UGB 
(Page et al., 2012), PDB:3A33 (Sakata et al., 2010), PDB:1FXT (Hamilton et al., 2001)) or 
in complex with RING-E3 ligase (PDB:4AP4) (Plechanovova et al., 2012) or HECT-E3 
ligase (PDB:3JW0) (Kamadurai et al., 2009).  
 As shown in Figure 37A, theoretical scattering (the curve depicted in orange) 
calculated from the crystal structure of Rabex-51-74 A58G perfectly fits the experimental 
data. This data confirmed the correct tridimensional arrangement of our sample. In the case 
of E2~Ub, each theoretical scattering was generated from the structures indicated in 
Figure 37B. Our experimental scattering fits well with curves generated from PBD 3UGB 
and 3JW0 that are obtained from crystal structure of E2-Ub alone or in complex with the 
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HECT domain of Nedd4-2. On the contrary, theoretical curves obtained using 4AP4 (E2-
Ub in complex with the RING protein-RNF4), does not fit well, suggesting that in solution 
our E2-Ub sample adopts a conformation different from the active ‘folded back’ 
conformation assumed in the complex with RNF4 (Plechanovova et al., 2012). 
 Next, we analyzed the complex E2-Ub:Rabex-51-74 A58G obtained mixing together 
the two proteins to have a final concentration of 250µM. We performed the size exclusion 
chromatography (Superdex 75) and then we analyzed by SAXS the eluted sample. X-ray 
scattering did not allow the unambiguous ab-initio positioning of the E2 molecule, due to 
the very low scattering provided by the small E2. We thus decided to analyze the complex 
based on models that we generated from crystal structures, to see if one of their theoretical 
curves might fit the experimental data. We based our models on all the E2-Ub tested 
before, positioning the Ub in the ZnF_A20 domain as in the previous crystallized complex 
Rabex-51-74:Ub (Penengo et al., 2006). As shown in Figure 37C the experimental data did 
not fit with any theoretical models, suggesting that the complex can assume a different 
conformation respect from what we proposed. Unfortunately, we cannot resolve the 
tridimensional arrangement of our complex Rabex-51-74 A58G:E2-Ub from the 
experimental data due to the low intensity of scattering and high degree of flexibility of the 
complex.  
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 Figure 37. SAXS analysis. A) Dots representing the SAXS profile of Rabex-51-74 A58G that we 
fitted with the curve calculated with the crystal structure of Rabex-51-74 in complex with 
Ub(Penengo et al., 2006) (PDB:2C7N). B) Dots represented the SAXS profile of Ub-loaded 
Ube2D3 S22R/C85K through the isopeptide bond. All curves are obtained from different E2 
loaded with Ub crystallized alone or in complex with an E3. C) Dots are the analysis of the 
complex Rabex-51-74 A58G:E2-Ub by SAXS. In this case curves are obtained by modeling the 
different E2-Ub structures on Rabex-51-74 (PDB:2C7N) considering the mutation A58G.  
 
 
 
6. Characterization of E3 ligase activity of Rabex-5  
	  
6.1 Rabex-5 can alter the stability of E2~Ub disulfide bond 
During the preparation of Rabex-51-74:Ube2D3~Ub complex for crystallography we 
realized that the disulfide bond of E2~Ub was not stable in the presence of Rabex-51-74. We 
hypothesized that this was due to the E3 ligase activity of Rabex-5. 
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 To prove our hypothesis further, we performed a disulfide bond stability assay in 
which 60 µM of the E2~Ub mixture was incubated with 5µM of Rabex-51-74 wild type in a 
time course reaction at 37°C. As a source of E2~Ub we used an E2~Ub mixture, 
containing both E2~E2 dimer as well as E2~Ub, previously obtained from in the anionic 
exchange column (Figure 32A). Reaction was stopped by addition of laemmli buffer 
without DTT and loaded on a non-reducing SDS-PAGE. The detection was performed by 
immunoblot anti-Ub (Figure 38A). To control the stability of the E2~Ub alone in the 
reaction conditions, the E2~Ub was incubated for 2h at 37°C in the same buffer without 
DTT, alone or in the presence of 5µM of GST. No free Ub was detected, demonstrating 
that the E2~Ub is stable in these conditions. Incubation of E2~Ub with 5µM Rabex-51-74 
wild type induced disruption of disulfide bond detected by increased amount of free Ub. 
The same effect is visible upon addiction of 1µM of HECTNedd4, a well-characterized E3 
ligase. We thus, consider this phenotype as a validation of E3 ligase activity of Rabex-5 
(Figure 38A). 
 To understand which domain is responsible for the Ub detachment, we performed the 
same assay, adding to the E2~Ub either 5µM of Rabex-51-74 wild type or single mutants in 
one of the two UBDs of Rabex-5 (Rabex-51-74Y25F and Rabex-51-74A58G). As negative 
control, we used GST alone while, as positive control, the GST-HECTNedd4 domain. 
E2~Ub was also incubated with DTT to break entirely the disulfide bond  (Figure 38B). 
Through the detection of free Ub, we confirmed that the incubation of Rabex-51-74 wild 
type with E2~Ub induced disruption of disulfide bond. A detectable amount of free Ub 
was observed also when the E2~Ub is incubated with Rabex-51-74 A58G. However no free 
Ub was scored in the case of Rabex-51-74 Y25F (Figure 38B).  
 Thus, also with this assay, we can ascribe to the ZnF_A20 domain the ligase activity 
of Rabex-5, as previously suggested by other groups (Lee et al., 2006a; Xu et al., 2010). 
 The disulfide bond disruption could be an unspecific effect of the presence of the 
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thiol (-SH) group of Cys residue in the proteins. However we scored a different behavior 
between Rabex-51-74 A58G and Rabex-51-74 Y25F to disrupt the disulfide bond. We 
proposed this effect as prove of the E3 ligase activity of Rabex-5. 
 
 
 
 
 
 
 
 
 
 
 
Figure 38. E2~Ub disulfide bond stability in the presence of Rabex-5. (A) Incubation of 
purified E2~Ub in presence of Rabex-51-74 WT, at 37°C for the indicated time. As control E2~Ub 
alone was incubated in a buffer without DTT or together with GST or GST-HECT. At different 
time point, reaction was blocked by addition of laemmli buffer without DTT. Detection of free Ub 
was performed with IB anti-Ub. (B) E2~Ub was incubated in the presence of Rabex-51-74 either 
WT or mutants in the ZnF_A20 domain (Y25F) and the MIU domain (A58G) at 37°C for 2h. GST 
alone, HECTNedd4 and E2~Ub in presence or absence of DTT in the buffer were added as control 
reaction. Free Ub was detected by IB anti-Ub. 
 
6.2. Self-ubiquitination of Rabex-5 
We then performed a classical in vitro auto-ubiquitination assay. We tested either GST-
Rabex-51-74 wild type or full-length protein in order to verify if the N-terminal fragment is 
sufficient to drive catalysis. The assay was performed using 500 nM GST-proteins in 
presence of 20 nM E1, 500 nM Ube2D3 and 2.5 µM Ub in ubiquitination buffer. At the 
indicated time points the reaction was stopped by addition of laemmli with DTT and the 
	   113	  
detection was performed by anti-Ub. 
 As shown in Figure 39A, GST-Rabex-51-74 and GST-Rabex-5 full-length were both 
able to sustain self-ubiquitination but apparently with different kinetics; full length Rabex-
5 seems to be faster than Rabex-51-74 (Figure 39A). In both cases, only few Ub molecules  
(possibly one in case of Rabex-51-74) were attached to the E3s. We also performed in vitro 
auto-ubiquitination assay in the previous conditions, using GST-Rabex-51-74 wild type and 
single mutants in the two UBDs (Rabex-51-74Y25F and Rabex-51-74A58G). The reaction 
was stopped at the indicated time points adding laemmli with DTT. The Ub modification 
was detected by anti-Ub (Figure 39B). 
 We confirmed that GST-Rabex-51-74 wild type is able to ubiquitinate itself and we 
showed that this activity is reduced when the ZnF_A20 domain is mutated at residue Y25. 
Instead, the A58G mutation on the MIU domain of GST-Rabex-51-74 did not affect its 
activity. Only when both UBDs are mutagenized the enzyme was completely dead (Figure 
39B). We also performed the in vitro auto-ubiquitination reaction using single UBDs, 
GST-Rabex-51-49 and GST-Rabex-548-74. In this case again, only constructs containing an 
intact ZnF_A20 domain were able to sustain ubiquitination reaction as well as the GST-
Rabex-51-74 (Figure 39C).  
 From the sum of these assays we can confirm literature’s data concluding that the 
ZnF_A20 is the main responsible for the ligase activity shown by Rabex-5.  
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Figure 39. E3 ligase activity of Rabex-5. (A) In vitro auto-ubiquitination assay carried out with 
GST-Rabex-51-74 (MW 34kDa) and GST-Rabex-5 full length (MW 84kDa) in presence of E1 and 
the specific E2 (Ube2D3). Reactions were performed at 37°C and at different time points beads 
were collected and washed with RIPA buffer three times. Ubiquitinated form of Rabex-5 was 
detected with IB anti-Ub and sample loading by direct ponceau staining of the membrane. (B) In 
vitro auto-ubiquitination assay performed with GST-Rabex-51-74 WT and mutants. Reactions were 
performed at 37°C and at different time points beads were collected and washed with RIPA buffer 
three times. Modified and unmodified form of Rabex-5 were detected by IB anti-Ub and anti-GST, 
respectively. (C) In vitro auto-ubiquitination assay carried out with GST-Rabex-5 fragments of 
single UBDs (1-49 contains the ZnF_A20 domain and 48-74 contains the MIU domain). GST-
Rabex-51-74 and GST alone were included as control in the reaction. Reactions were performed at 
37°C and at different time points beads were collected and washed with RIPA buffer three times. 
Ubiquitination was detected by IB anti-Ub.  
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7. Substrates Identification   
Once we demonstrated that Rabex-5 has the ability to self-ubiquitinate, we analyzed its 
catalytic activity towards possible substrate candidates.  
 
7.1. H-Ras is not a real Rabex-5 substrate  
We focused our attention on H-Ras, which is the unique substrate of Rabex-5 so far 
identified. Xu and colleagues demonstrated that H-Ras become mono- and di-ubiquitinated 
by Rabex-51-76 and that mutation in ZnF_A20 impaired the catalytic activity of the enzyme 
(Xu et al., 2010).  
 Initial experiments were made using Ras1-166 fragment, which lacks the hypervariable 
C-terminal part that confers biochemical diversity between the three isoforms of Ras (H-
Ras, K-Ras and N-Ras). The construct was kindly provided by Dr. Campbell (Baker et al., 
2013). We produced and purified GST-Ras1-166. 
 We performed an in vitro substrate ubiquitination assay using 500 nM GST-Ras1-166 
as substrate and 500 nM Rabex-51-74 as E3 ligase at 37°C for the indicated time points 
(Figure 40A). As negative control of the reaction we performed the same reaction without 
the E2 or without the E3. During the time course we scored an increase in GST-Ras1-166 
monoubiquitination but at the same level as in the absence of Rabex-51-74 (Figure 40A).  
 We hypothesized that the C-terminal part of Ras could have a critical role in Rabex-5 
recognition and consequently may determine a different mode of substrate ubiquitination. 
We tested several conditions both in vivo and in vitro, using H-Ras full-length and both 
Rabex-51-74 or full-length, always with negative results (data not shown). We thus decided 
to use the same settings of the published protocol (Xu et al., 2010) performing the reaction 
with 20 nM E1, 500 nM Ube2D3, 3 µM Rabex-51-74 cleaved and purified, 2,5 µM GST-H-
Ras and 5µM Ub-biotinylated. The reaction was stopped adding laemmli with DTT at the 
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indicated time points (Figure 40B). A parallel sample was performed in the absence of 
Rabex-51-74. Negative control was the same reaction using GST alone as substrate. Using 
biotinylated-Ub, the detection was performed using HRP-streptavidin. As shown in Figure 
40B we scored increasing level of monoubiquitination of GST-H-Ras during the time 
course. Unfortunately, once again we detected Ras monoubiquitination also in the absence 
of Rabex-5 as E3 ligase. We concluded that Ube2D3 is sufficient to trigger the Ub 
modification of Ras. This is not surprising as when particularly high concentration of 
enzymes is used, the E2 alone is able to ubiquitinate a substrate (Hoeller et al., 2007). 
 Unfortunately, we never scored an effect of Rabex-5 on Ras, not even an anticipated 
kinetics, thus we concluded that H-Ras is not a Rabex-5 target protein.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40. In vitro Ras ubiquitination. (A) In vitro substrate ubiquitination assay carried out 
using E1, Ube2D3 as E2, Rabex-51-74 as E3 ligase, GST-Ras (1-166, lacking the hypervariable 
region) as substrate. Reactions were performed at 37°C and different time points were collected. 
Beads were then washed with RIPA buffer three times. Ubiquitination was detected by IB anti-Ub 
and sample loading by IB anti-GST. (B) In vitro substrate ubiquitination assay carried out using 
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E1, Ube2D3, Rabex-51-74, GST-H-Ras as substrate and biotinylated-Ub. Reactions were performed 
at 37°C and different time points were collected. Beads were then washed with RIPA buffer three 
times. GST alone was used as negative control. Ubiquitination was detected with HRP-conjugated 
streptavidin and sample loading by ponceau. 
 
7.2. Substrate identification using protein microarray  
To characterize possible substrates of Rabex-5 E3 ligase with an unbiased approach, we 
performed an in vitro ubiquitination assay using protein microarray as candidate substrates 
(Persaud et al., 2009). Life Sensors performed for us the in vitro ubiquitination assay on 
microarray as well as the substrate profiling. For this assay we decided to use the CDI 
microarray in which there were spotted 20.000 human proteins produced in yeast. The 
reaction was performed on the array using a mixture composed by the E1, the E2 candidate 
(Ube2D3), the E3 candidate and fluorescent-Ub. Ubiquitinated substrates were identified 
by the detection of fluorescent-Ub that remains covalently attached to the proteins after 
washing. The control array was treated with the same ubiquitylation machinery without the 
E3. 
 
7.2.1 Production and purification of His-MBP-Rabex-5 full-length  
We decided to use Rabex-5 full-length protein instead of the minimal region Rabex-51-74 in 
order to allow a correct recognition of the substrates by the E3 ligase. Ideally for the 
screening we should avoid GST-tagged protein, thus we subcloned Rabex-5 in pET43a 
vector that carries two different tags at the N-terminus: His and MBP. His-MBP Rabex-5 
was purified from bacterial lysate using nickel beads and subsequently eluted from the 
beads using 200mM of imidazole. Each fraction of the washes and elutions were loaded on 
a reducing SDS-PAGE gel (Figure 41A). Fraction 7 was collected and extensively 
dialyzed to eliminate imidazole, then loaded on a cationic exchange column (HiTrap Q) 
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(Figure 41B). We analyzed the composition of the single fractions on a gel. We also 
performed an immunodetection with an anti-CUE antibody that specifically recognize the 
C-terminus of Rabex-5 full length (Figure 41B-lower panel). Fractions from 18 to 21 ml 
were collected and further purified on a size exclusion column (Superdex 200) to separate 
Rabex-5 full length from the degradation products. We collected fractions from 11,5 ml to 
13,5 ml (Figure 41C). The sample was loaded on a SDS-PAGE gel and the band at 
100kDa was analyzed by mass spectrometry (data not shown). The MS data confirmed that 
the band is made exclusively by His-MBP-Rabex-5.  
 Prior to send the target protein to the Life Sensor Company, we analyzed its activity 
by in vitro self-ubiquitination assay. The reaction was performed with 20 nM E1, 500 nM 
His-Ube2D3, 500 nM His-MBP-Rabex-5 full length and 2.5 µM of Ub-biotinylated in 
ubiquitination buffer for 2h at 37°C (Figure 41D). As positive control, we used GST-
Rabex-5 full length. Detection of ubiquitination was done by HRP-streptavidin while 
detection of the level of Rabex-5 was performed with an anti-MIU antibody. His-MBP-
Rabex-5 full length was active and able to perform self-monoubiquitination in the same 
way as the GST-Rabex-5 full length (Figure 41D). 
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Figure 41. His-MBP-Rabex-5 f.l. production and purification. (A) Example of His-MBP-
Rabex-5 f.l. production. Fraction 1 and 2 were bacteria lysates pre and post-induction with IPTG. 
His-MBP-Rabex-5 was purified from bacterial lysate (fraction 3) by incubation with nickel beads 
(fraction 4-supernatant post-beads) for 2h at 4°C. Specifically bound proteins were washed with 
20mM imidazole (fraction 5) and 35mM imidazole (fraction 6) before elution with 200mM 
(fractions 7) and 500mM (Fraction 8). Fractions were loaded on a reducing SDS-PAGE and 
Coomassie staining was performed. (B) Elution profile of purified His-MBP-Rabex-5 f.l. (Fraction 
7 of A) on a cationic exchange column (HiTrapQ) using a NaCl gradient. Fractions depicted with a 
black line were loaded on a reducing SDS-PAGE gel and Coomassie staining was performed. 
Fractions containing bands corresponding to the molecular weight of the target protein were 
analyzed by IB anti-CUE, a specific antibody against the CUE domain present at C- terminus of 
Rabex-5 f.l. (C) Chromatogram from size exclusion chromatography (Superdex 200 column). 
Lower panel showed fractions from the two peaks loaded on a reducing SDS-PAGE gel. (D) In 
vitro auto-ubiquitination assay performed with His-MBP-Rabex-5 f.l. using E1, Ube2D3 and 
biotinylated-Ub. GST-Rabex-5 f.l. was used as positive control. Reactions were performed at 37°C 
for 2h and beads were then washed with RIPA buffer three times. Modified Rabex-5 was detected 
with HRP-conjugated streptavidin and sample loading was assessed by IB anti-MIU. 
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7.2.2 Identification of possible substrates  
Of roughly 20,000 human proteins on the microarray, 1007 features showed a significant 
difference (p<0.05) in ubiquitination between the Rabex-5-treated and the control arrays. 
Of these, 629 showed increased ubiquitination. In Table 3 we reported the top 67 “hits”, 
which were filtered first by MN value, which is the magnitude change estimated from the 
normalized intensity of experimental values subtracting the control value, and then by F-B 
value, calculated by median feature intensities minus background, using an arbitrary cut-
off of F-B ≥50RFU. These were also the features that showed the highest fluorescent 
intensities on the experimental arrays (by visual inspection). This list represents the most 
statistically stringent and conservative estimate for Rabex-5 substrates. Interestingly, the 
large number of positive hits on the Rabex-5 treated arrays showed low signal intensities 
that we interpreted as most likely indicating mono- or di-ubiquitination events. This well 
fits with our previous results. This effect is also visible in Figure 42, which shows block 
15 from both the control (A) and Rabex-5 treated arrays (B).  
 
 
Figure 42. Representative sub-arrays from control and Rabex-5-treated arrays. The four 
bright features at the bottom of each sub-array were controls labeled with a fluorescent dye. 
 
Based on the knowledge that Rabex-5 is involved in the regulation of Rab-5 
GTPases and aspects of the endocytic pathway, on the list of the top 67 hits (Table 3), we 
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have highlighted six hits that appear to function in Rho GTPase pathways (light red) and 
five that may be involved in secretion/endocytic pathways (light green). These proteins 
will be the first to validate in the nearest future.  
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Table 3. Potential Rabex-5 substrates  
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ID = GenBank accession number; MN = duplicate-summarized, normalized, log2 transformed 
fluorescence intensity from the protein, values obtained from the experimental array minus those 
obtained from the negative control array; SD = standard deviation of the difference above (standard 
deviation of two numbers subtracted was the square root of the sum of squares of the standard 
deviations associated with each of the two numbers); pVal = p value from 2-tailed, paired T-test 
for significance of change. 
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DISCUSSION 
E3 ubiquitin ligases are key regulatory enzymes of the ubiquitination pathway as they are 
responsible for substrate specificity. This thesis aimed at deciphering the molecular 
mechanisms through which two different E3 ligases, Nedd4 and Rabex-5, exert their 
activity. 
Nedd4 is the prototype for HECT-E3 ligase while Rabex-5, containing an A20 zinc finger 
domain (ZnF_A20) instead of a canonical RING, could be defined as an atypical RING-E3 
ligase. 
 
1. Dissecting the mechanism of catalysis of Nedd4 
Nedd4 belongs to the family of E3 enzymes known as HECT. Homologous to E6-AP C 
terminus (HECT) E3 ligases recognize and directly catalyze ligation of Ub to their 
substrates. The HECT domain is the catalytic portion of these E3 enzymes and is necessary 
and sufficient to promote ubiquitination. This region is composed of two lobes, the N-lobe 
and the C-lobe, that are connected by a flexible linker. Intriguingly, previous structural 
studies suggested that these lobes might adopt a variety of positions with respect to each 
other (Figure 14). This flexibility is absolutely required for catalysis (Kamadurai et al., 
2013; Verdecia et al., 2003). 
Nedd4 and other HECT E3s function through a two-step mechanism. First, ubiquitin is 
transferred from the catalytic cysteine of an E2 enzyme to that on the E3 HECT domain. 
This produces a transient HECT~ubiquitin intermediate that is linked by a thioester bond. 
Next, ubiquitin is transferred from the HECT E3 cysteine to either a substrate protein, or to 
a specific lysine on the surface of ubiquitin to generate a chain. This process is often 
compared to a relay, where ubiquitin is the baton transferred between athletes (e.g. E2, E3, 
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substrate, and eventually ubiquitin linked to substrate). Chains are thought to be generated 
by a sequential addition mechanism (Kim and Huibregtse, 2009) (Figure 19). Molecular 
details of this process remain unknown. 
In particular, no one has ever been able to "see" the transient intermediate with 
ubiquitin linked at a HECT E3 catalytic cysteine, because such complexes are extremely 
unstable. We overcame this challenge by using an alternative, more stable bond to link the 
active site of the Nedd4 HECT and ubiquitin. The crystal structure of the complex 
(HECTNedd4~UbD:UbA) was determined at 2.51Å resolution (Table 2 and Figure 26).  Our 
structure was the first capturing the elusive HECT~ubiquitin intermediate, after transfer of 
ubiquitin from E2 (Maspero et al., 2013). 
 
1.1 Molecular validation of the sequential addition model 
The HECTNedd4~Ub transitory intermediate provides a structural basis for the proposed 
sequential addition mechanism. The Ub of the HECTNedd4~Ub interacts with the C-lobe of 
the HECT in the same position as in the crystal structure of Nedd4-like HECT domain in 
complex with Ub-loaded Ube2D2 (Kamadurai et al., 2009). The relative orientation 
between the N- and C-lobe and between the C-lobe and UbD is also maintained (Figure 
26B). To our knowledge this is the first time that two C-lobes from different HECT 
structures show the same orientation. Based on that, we can conclude that our structure 
represents the step that immediately follows the transfer of the thioester bond from the E2 
to the E3, in which UbD has been handed over to the C-lobe, and is ready to be transferred 
to the substrate. 
One of the key features that we found is that, after the transfer of UbD from the E2 
to the E3, the non-covalent interaction between the C-lobe and the UbD is conserved 
(Kamadurai et al., 2009). Thus, due to steric hindrance, a second Ub-loaded E2 enzyme is 
unable to access the C-lobe Ub binding site until the E3 transfers its transiently bound Ub 
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to the substrate or to the growing Ub chain. Only after this has occurred, another cycle of 
transthiolation reaction between the E2~Ub and the E3 can take place. This discovery 
strongly supports the sequential addition model proposed for some HECT ligases in which 
single Ub moiety are added at one time (Kim and Huibregtse, 2009; Maspero et al., 2011).  
 
1.2 Implications for the UbD C-terminal tail-locking 
Differently from most of the conserved contacts between UbD and the C-lobe, the last three 
residues of UbD display a dramatic rearrangement with respect to the 
HECTNedd4L:Ube2D2~Ub structure. The UbD, transferred from the E2, acquired an extra 
surface of interaction with the C-lobe. Clearly visible in our structure, the Ub C-terminal 
tail, generally flexible, is locked in an extended conformation due to the hydrogen bond 
pattern that generates a β-sheet augmentation, common motif in protein-protein interaction 
(Figure 26C and Figure 37A). 
 This stretched conformation shows the catalytic bond suitably positioned for attack 
by the substrate protein's lysine. A similar UbD tail stretch conformation was recently 
observed in other E3s structures such as the one of RNF4:Ube2D1~Ub (Plechanovova et 
al., 2012) and of BIRC7:Ube2D2~Ub complex (Dou et al., 2012) (Figure 43B-C). The 
authors demonstrated that the Ub tail held on the E2, is in an optimal conformation for 
nucleophilic attack by the incoming lysine residue of the substrate. In addition, the same 
tail stretch was displayed by SUMO~RanGAP1-Ubc9-Nup358 complex even if the SUMO 
modifier is just transferred to the substrate (Reverter and Lima, 2005) (Figure 43D). 
Therefore, we propose that docking the flexible C-terminal tail of Ub in an extended 
conformation might be a common, evolutionary-conserved, mechanism adopted by both 
E2s and E3s to prime the UbD for catalytic transfer to the substrate.  
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Figure 43. The tail stretch of UbD primed for catalysis (adapted from Maspero E., Nat. Struct. 
Mol. Biol. 2013). Extended conformation of the UbD tail (orange) or SUMO C-terminal tail 
(yellow) when formed the complex HECTNedd4~Ub(Maspero et al., 2013) (A), or in the complex 
RNF4-Ube2D1~Ub(Plechanovova et al., 2012) (B), BIRC7-Ube2D2-Ub(Dou et al., 2012) (C) and 
SUMO~RanGAP1-Ubc9-Nup358 complex(Reverter and Lima, 2005) (D). 
 
1.3 Role of the UBD in the N-lobe 
Our data elucidated some aspects of the molecular mechanism by which the HECT domain 
of the E3 ligase Nedd4 exerts its catalytic activity. However, several important questions 
remained. As predicted (Maspero et al., 2011), loading of the UbD onto HECTNedd4 
catalytic cysteine is compatible with free Ub bound to the Ub binding region embedded in 
the N-lobe of the HECT. Previously, we have characterized this UBD present in Nedd4, by 
solving the structure of the HECT domain in complex with free Ub (Maspero et al., 2011). 
We have postulated that this site is important to keep the acceptor Ub from the growing 
chain in close proximity to the catalytic cysteine favoring enzyme processivity. In a 
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parallel study, Huibregtse and colleagues reached the same conclusion about the role of the 
UBD in Rsp5 (Kim et al., 2011).  
Once we solved the structure of the Ub-loaded E3 in complex with Ub, the position 
of the non-covalently bound Ub molecule in the crystal structure did not provide any clue 
on how ubiquitination should work, as Lys63 of the “acceptor” Ub (UbA) is far away from 
the HECT catalytic cysteine. Thus, we concluded that the free Ub bound to the UBD is not 
the UbA. One possibility is that the Ub bound to UBD is instead the last before the UbA of 
the chain. To solve this issue we intend to determine the crystal structure of the Ub-loaded 
E3 in complex with Ub Lys63 dimer or trimer.  
Another intriguing possibility is that the non-covalently bound Ub may work as an 
allosteric activator of the HECT, as it was recently found for the Ub bound to the “back 
side” of the E2 enzyme (Buetow et al., 2015). Using RNF38 as model system, Huang and 
colleagues found that the free Ub bound the UBD in the back side of the E2 has a primary 
role to stabilize a catalytic favorable conformation of the RING E3:Ube2D2-Ub 
interaction. This catalytic favorable conformation facilitates the Ub transfer including 
initial Ub transfer to a substrate lysine (Buetow et al., 2015). It could be possible that the 
binding of Ub in the UBD of the HECT domain may induces a similar allosteric activation, 
promoting enzyme processivity, even if our initial observation using KO ubiquitin (data 
not shown) seems to disprove this idea. 
 
1.4 Nedd4 polyubiquitination: chain elongation is different from the first Ub 
addition?  
After our study, Schulman and co-workers have captured the moment in which Rsp5, the 
HECT enzyme essential in yeast, transfers ubiquitin to a lysine residue within a target 
protein called Sna3 (Kamadurai et al., 2013). The authors took a chemical approach to 
substitute the substrate lysine acceptor with a bifurcated crosslinker conjugated to a 
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modified Ub Cys75 and the HECT catalytic Cys. The structure suggests that both specific 
orientation between the N- and the C-lobes of the HECT domain and unique active site 
conformation are required for the selection of the target Lys and ligation. Importantly, 
Kamadurai et al. revealed that a dramatic re-arrangement of the C-lobe of the HECT 
domain is required to transfer the Ub to the lysine of the substrate. They described a C-lobe 
swiveling of ~130° to place the thioester in proximity to a substrate lysine (Figure 
44)(Kamadurai et al., 2013).  
 
 
 
 
 
 
 
Figure 44. Substrate ubiquitination performed by HECTRsp5 domain (adapted from 
Kamadurai, eLIFE, 2013). Schematic view of the E2-to-E3 transfer of Ub (on the left) and the next 
step of the transfer of Ub from the catalytic cysteine of the HECTRsp5 domain to the lysine of the 
substrate (on the right). These steps required a dramatic re-arrangement of the C-lobe. 
 
This re-arrangement fits well with the previous studies showing the importance of 
the flexible linker between the N- and the C-lobe (Kamadurai et al., 2013; Kamadurai et 
al., 2009; Verdecia et al., 2003), and with the various crystal structures that show 
variability in the reciprocal orientation of the two subdomains (Figure 14). This structure, 
though, does not help in rationalizing the role of the UBD.  
The sum of our and Schulman’s lab data led us to propose an intriguing model. 
First Nedd4 faces E2 to receive ubiquitin. After ubiquitin transfer to the Nedd4 HECT 
domain, a new beta sheet stabilizes the intermediate. Then, the Nedd4 HECT E3 turns 
around to face the substrate and deliver the ubiquitin to the first lysine. After the first 
Ub transfer from HECT E3 to SubstrateUb transfer from E2 to HECT E3
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ubiquitin has been attached, the HECT might continue to receive Ub from the E2 and to 
polymerize ubiquitin chains, without the C-lobe rotation and stabilizing the interaction 
with the growing chain thanks to the UBD. This hypothesis is based on the observation 
that a point mutation in the UBD of the HECT domain, which abrogates the Ub interaction, 
impairs the polyubiquitination of the substrate without altering the addition of the first Ub 
moiety (Maspero et al., 2011). It is also supported by computational docking data we are 
generating in collaboration with Anna Tramontano in Rome. In essence, we propose that 
monoubiquitination and polyubiquitination mediated by Nedd4 occurs via two distinct 
mechanisms that have different requirements. For monoubiquitination we need the 
swinging of the C-lobe but not the UBD while for chain elongation the UBD is required 
while the C-lobe rotation is not.  
To provide a clear picture about the role of the UBD, other structural studies with 
Nedd4 in complex with ubiquitinated substrate or Ub chains are required. To trap the 
catalytic step we will use the same approach as in HECT~UbD:Ub complex in which the 
HECT domain is loaded with UbD (active state) through a non reducible covalent bond. It 
will be interesting to see if HECT E3s can also be ‘caught in the act’ of assembling a 
chain, as this could reveal how multiple interactions contributed by several domains of the 
enzyme establish catalytic efficiency and specificity. 
 
2. Characterization of Rabex-5 as E3 ligase 
 
Our lab demonstrated that Rabex-5 binds Ub through its two UBDs, MIU domain and the 
ZnF_A20 domain, determining its coupled monoubiquitination and allowing interaction in 
vivo with the ubiquitinated form of EGFR (Penengo et al., 2006). Rabex-5 was also 
proposed to be an E3 ligase thanks to its ability to ubiquitinate itself via the ZnF_A20 
domain (Lee et al., 2006a) and its substrate H-Ras (Xu et al., 2010). Still unclear is how 
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Rabex-5 exerts its E3 ligase activity. This thesis intended to clarify some aspects of the E3 
ligase activity of Rabex-5. 
 
2.1 Efforts to solve the structure of Rabex-5 with its specific E2 
In most of the studied cases the E2-E3 interaction is selective. Few E2s are expected to 
function with a given E3 and each E2-E3 pairs may be selective for putative substrates and 
for their type of Ub modification (Christensen et al., 2007). So the first step in the Rabex-5 
characterization as E3 ligase was the identification of possible E2 partners.  
 In order to define the E2s, we set up a yeast-two-hybrid screening between Rabex-51-
74 and a complete library of human E2s and we demonstrated that Rabex-51-74 interacts 
specifically only with a subset of them (Figure 27). These E2s are members of the Ube2D 
and Ube2E families.  
 The E2-E3 interaction is usually transient and of modest affinity, and indeed we 
found that the binding between Rabex-51-74 and the specific E2 was significant only when 
the E2 is in its active state, loaded with Ub (Figure 28A). Using either single point 
mutants in the UBDs on Rabex-51-74 as well as isolated UBDs (ZnF_A20 and MIU 
domains) we are unable to define which was the UBD required for the interaction as both 
seem to be necessary (Figure 28A-29). In addition, Rabex-5 full length binds the E2-Ub in 
a comparable manner respect to the Rabex-51-74 fragment suggesting that no additional 
domains are required (Figure 28B).  
 ITC analysis confirmed our biochemical data, proving that the contribution of the E2 
in binding Rabex-51-74 is very limited and that the interaction between the two proteins is 
mainly mediated by the Ub carried by the E2 and the UBDs of Rabex-5 (Figure 30). Thus, 
we propose that the initial binding occurs through this interaction that drives the correct 
positioning of the E2, possibly allowing activation of the E2. As the two UBDs of Rabex-5 
are able to interact with Ub using different surface (Penengo et al., 2006) we hypothesize a 
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possible different role of the two in substrate ubiquitination.  
 To characterize Rabex-5 as E3 ligase it is crucial to obtain the structure of the Rabex-
51-74:E2-Ub complex. We tried different strategies to obtain a stable Rabex-51-74:Ube2D3-
Ub complex, enough pure and homogeneous for crystallization purpose and for SAXS 
analysis. 
 Our first attempt was the generation of a disulfide bond between the catalytic 
cysteine of the E2 and Ub (G76C) mutant. This approach was unsuccessful due to the 
instability of the disulfide E2~Ub in presence of Rabex-51-74. Indeed, we considered the 
ability of Rabex-5 to break down the disulfide bond, releasing free Ub a clear sign of its E3 
activity (Figure 33, further discussed below). To mimic an E2 loaded with Ub, we decided 
to create an isopeptide bond between the C-terminal of Ub and the artificially created Lys 
of the E2 C85K mutant. Mixing together the isopeptide E2-Ub with Rabex-51-74 and 
purified the complex on a size exclusion chromatography (Superdex 75 column), we 
obtained a suitable sample that we used both in crystallization trays and in SAXS analysis. 
In this context, we generated complexes using either Rabex-51-74 wild type or Rabex-51-74 
A58G. This MIU mutant generates a more homogenous sample, maintaining the catalytic 
activity of the ZnF_A20 domain (Figure 36).  
 Unfortunately, in none of the conditions tested we obtained reproducible crystals. 
One possible reason for this failure is that the samples were not enough pure or 
homogeneous. Indeed, the isopeptide bond is formed via an in vitro reaction and analyzing 
our samples we found that the ubiquitination occurs at our target Lys 85 (Figure 35) but 
also at the natural Lys (K8, K133 and K144) present in the E2 determining the presence of 
these different species impossible to eliminate with purification procedures (Figure 34). A 
second possible explanation could arise from the constructs we used. To improve the rate 
of isopeptide reaction we used an E2 mutated in the backside (S22R, (Plechanovova et al., 
2012)) while to avoid aggregation we used a MIU mutant (A58G, (Penengo et al., 2006)). 
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As previously discussed, a recent paper underlined the importance of the interaction 
between the backside E2 and the allosteric activator free Ub (Buetow et al., 2015). A 
future effort will be to repeat the crystallization trays with E2-Ub:Rabex-51-74 wild type 
complex in presence of free Ub.   
 SAXS analysis was also disappointing and we did not obtain any information about 
the tridimensional arrangement of the complex. We initially tested Rabex-51-74 wild type 
(data not shown) but the presence of high aggregation in size exclusion chromatography 
and low scattering intensity precluded data elaboration. With the Rabex-51-74 A58G:E2-Ub 
complex we obtained technically good spectra but we failed to obtain an unambiguous ab-
initio positioning of the E2 molecule due to its small size and consequent low scattering 
intensity. 
 To overcome this problem we generated models of Rabex-51-74:E2-Ub interaction 
based on the crystal structure of Rabex-51-74 wild type (Penengo et al., 2006) and different 
crystal structures of E2-Ub alone (Hamilton et al., 2001; Page et al., 2012; Sakata et al., 
2010) and in complex with a RING-E3 ligase (Plechanovova et al., 2012) or with an 
HECT-E3 ligase (Kamadurai et al., 2009). Unfortunately, all models generated did not fit 
with the experimental data suggesting that the complex assume a different conformation 
that we are unable to determine in these conditions (Figure 37). 
 
2.2 Ligase activity of Rabex-5 
	  
It has been reported that Rabex-5 possessess an E3 ligase activity thanks to its ability to 
ubiquitinate itself (Lee et al., 2006a) and its substrate H-Ras (Xu et al., 2010). Using in 
vitro ubiquitination assay, Lee et al. demonstrated that Rabex-5 undergoes 
polyubiquitination that is impaired once the ZnF_A20 domain is mutated in specific 
tyrosine residues (Y25 and Y26) critical for Ub binding (Lee et al., 2006b; Penengo et al., 
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2006). Two parallel studies proved, by in vivo experiments, that Rabex-5 undergoes to 
monoubiquitination and for this process the MIU domain is required (Mattera et al., 2006; 
Penengo et al., 2006). Later, H-Ras was found as a possible substrate of the E3 ligase 
activity of Rabex-5 by in vivo and in vitro assays. H-Ras becomes mono- and di-
ubiquitinated in presence of Rabex-5 wild type while the ubiquitination is impaired when 
the ZnF_A20 domain mutant (Y25/Y26A) is used (Xu et al., 2010). This modification can 
promote endosomal association leading to attenuation of Ras-ERK signaling (Jura and Bar-
Sagi, 2006; Xu et al., 2010). 
 
2.2.1 Ability to perform self-ubiquitination 
	  
To clarify whether Rabex-5 as E3 ligase is able to perform self-ubiquitination by adding 
one or multiple Ub moieties, we set up an in vitro self-ubiquitination assays in which we 
scored monoubiquitination of Rabex-51-74 and of the full-length protein. Interestingly, full-
length kinetics seems to be faster than the Rabex-51-74 kinetics, a difference that we intend 
to investigate further (Figure 39A). 
 Taking advantage of point mutants on Rabex-51-74 as well as of the isolated UBD 
domains, we confirmed the important role of the ZnF_A20 domain in self-ubiquitination 
(Figure 39B-C). We also proved the E3 ligase activity of Rabex-5 using a second assay 
that measure the disruption of the disulfide bond of the E2~Ub in the presence of Rabex-5 
fragments. Incubation of the E2~Ub with Rabex-51-74 wild type increases free Ub over the 
time while we did not score the same effect when we used the Rabex-51-74 mutated in the 
ZnF_A20 (Figure 38). The disulfide bond disruption could be ascribed as an unspecific 
effect due to the presence of a Cys residue in the protein. However mutation on the 
putative ZnF_A20 domain responsible for the E3 ligase activity is impaired in the disulfide 
bond disruption. Based on this result we proposed that the scored effect is a specific 
	   135	  
behavior of Rabex-5 related to the E3 ligase activity. 
We speculate that Rabex-5 may act as an E3 ligase via the evolutionary conserved 
mechanism we discussed for Nedd4 (Figure 43) that primes the UbD linked to the active 
site for catalysis. Unfortunately, in the absence of the Rabex-5:E2-Ub structure we did not 
have the possibility to prove/disprove our hypothesis so far.  
 
2.2.2 Substrate ubiquitination 
	  
An important validation for the putative role of Rabex-5 as E3 ligase is the identification of 
substrates proteins. Except for H-Ras (Xu et al., 2010), no other substrates of Rabex-5 are 
identified to date. As a first approach, we tested H-Ras protein using different in vivo and 
in vitro conditions and evaluating both Rabex-5 full length and Rabex-51-74. We were able 
to score H-Ras monoubiquitination only in an in vitro assay but this was evident also in the 
absence of Rabex-5 (Figure 40). As not even a difference in reaction kinetics was visible 
between the two conditions, we concluded that Rabex-5 is not an E3 for H-Ras. Positive 
results are possibly due to the high concentration of E2 used that can force the reaction to 
proceed in the absence of an E3 (Hoeller et al., 2007).  
We then decided to search for new Rabex-5 substrates with an unbiased approach 
using a protein microarray and a fluorescence-Ub-based assay provided by LifeSensor. To 
be sure about the specificity of the Rabex-5 ligase activity we ran the assay also in the 
absence of the Rabex-5 but in the presence of the E2.  
From all 20,000 human proteins tested, 1007 hits showed a significant difference in 
fluorescence respect to the negative control. Interestingly, all positive hits showed low 
fluorescence intensity suggesting that they could be only mono or di-ubiquitinated. This 
result fits well with our in vitro data. At first glance, 629 out of 1007 were considered 
positive hits as they showed an increase of intensity in ubiquitination, but most of them are 
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borderlines. Starting from these 629 possible substrates we selected the top 67 hits based 
on their highest fluorescent intensities (Table 3). We are going to validate these possible 
substrates starting from proteins that are involved in the endocytic pathway.  
 
In conclusion, we have elucidated some aspects of how Rabex-5 may act as E3 
ligase but much more needs to be done. At this point we can only speculate about how 
Rabex-5 exerts its activity and about the role of self-ubiquitination. An important question 
that remains to be answered is the role of the two different UBDs in Rabex-5. While the 
ZnF_A20 domain is apparently required, similar to the RING, to promote catalysis, we still 
do not have clues on the function of the MIU. 
It could be possible that the MIU in Rabex-5 works in a way similar to the UBD 
present in the N-lobe of Nedd4, maintaining the binding of ubiquitinated substrates and 
promoting their polyubiquitination by the ZnF_A20 domain. Alternatively, the binding of 
the MIU with free Ub may allosteric activate Rabex-5 (Buetow et al., 2015). We tend to 
exclude that the MIU may bind the Ub bound to the backside of the E2 as both domains 
requires the same hydrophobic patch centered on Ile44. It worth mentioning that the MIU 
domain may also trigger coupled monoubiquitination (Penengo et al., 2006), similar to 
what occurs in several UIM-containing endocytic proteins (Woelk et al., 2006). 
From the functional point of view, the MIU together with the ZnF_A20 domain are 
critical for the interaction with the ubiquitinated form of EGFR (Penengo et al., 2006) and 
are required for Rabex-5 recruitment to the endosomes (Mattera and Bonifacino, 2008). 
Once Rabex-5 is associated with the endosome it exerts its GEF activity to Rab-5 
promoting homo- and heterotypic endosomes fusion (Mattera and Bonifacino, 2008). 
Bonifacino‘s lab also provided evidence that MIU-dependent coupled monoubiquitination 
may lead to Rabex-5 dissociation from the endosome. The authors proposed a model 
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whereby the UBDs interact with the Ub moiety covalently attached to Rabex-5 (Mattera 
and Bonifacino, 2008)(Figure 45). Also this hypothesis remains to be tested. 
 
 
Figure 45. Proposed model of the role of UBDs or 
Rabex-5 and its monoubiquitination (adapted from 
Mattera and Bonifacino, Embo J, 2008). Rabex-5 is 
recruited to the endosome by the interaction between 
the two UBDs, ZnF_A20 (Z) and MIU (M) domains, 
and the ubiquitinated cargoes. At the endosome 
Rabex-5 activates Rab-5 via its GEF activity, 
determining endosome fusion. Dissociation from 
endosome with consequent Rabex-5 release in the 
cytosol occurs thanks to its monoubiquitination that 
causes an intra molecular interaction.   
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Substrate ubiquitination occurs through an E1-E2-E3 Ub conjugation 
cascade. The E3 ligases play a crucial part in the whole pathway, as 
they determine the specificity of the reaction. Members of the HECT-
type ligases receive Ub from the E2 through a thioester conjugate 
before catalyzing Ub transfer to their substrates1. The human genome 
encodes 28 HECT E3s, and a large number of them are involved in the 
genesis of several human diseases2. They are divided into subgroups 
according to the presence of interaction domains, although this clas-
sification probably does not reflect the natural evolution of these 
enzymes3. The Nedd4 family is a monophyletic group represented 
by nine members in humans and characterized by a C2 domain and 
three to four WW domains responsible for substrate recognition4.
Structural studies on HECT domains revealed their architecture. 
The HECT is a bilobed domain consisting of an N-terminal N lobe that 
interacts with the E2 and a C-terminal C lobe that contains the catalytic 
cysteine and is free to rotate around the flexible hinge that tethers it to the 
N lobe5. Recent studies have demonstrated the existence and relevance of 
two Ub-interaction surfaces within the HECT domain. The first, present 
in the C lobe, is essential for E2-to-E3 Ub transfer6; the second, in the 
N lobe, is critical for enzyme processivity7,8. Notably, the ability to build 
up different Ub chains appears to be an intrinsic feature of the HECT 
domain8–10. The Nedd4 family of HECTs seems to use a sequential addi-
tion mechanism by which Ub molecules are added one at a time from the 
catalytic cysteine to the distal lysine of the growing chain8,9. However, 
most of the mechanistic details of HECT catalysis remain elusive, owing 
to the lack of structures of key catalytic intermediates.
To gain insight into the ubiquitination reaction catalyzed by HECT 
E3 ligases, we set out to determine the crystal structure of the Ub-
loaded HECT domain of Nedd4 in complex with Ub noncovalently 
bound in the Ub-binding domain (UBD) present in the N lobe of 
HECTNedd4 (ref. 8).
RESULTS
Structure	of	the	HECTNedd4~UbD–Ub	complex
Because a thioester-linked HECT~Ub is highly unstable, we generated 
a stable complex by bridging the HECTNedd4 with a modified form of Ub 
donor (UbD), G76C, by a disulfide bond (Supplementary Fig. 1a–d). 
We solved the crystal structure of the complex (HECTNedd4~UbD–Ub) 
at 2.51-Å resolution by molecular replacement (Table 1 and Fig. 1a). 
As predicted8, loading of the UbD onto the HECTNedd4 catalytic 
cysteine is compatible with noncovalent Ub binding in the N lobe. 
Furthermore, the N lobe adopts the same conformation in the pres-
ence and absence of UbD (r.m.s. deviation of 0.8 Å over 258 Cα), with 
free Ub kept in the binding site crafted by the N-lobe subdomains 
(Supplementary Fig. 1e–g). The N- and C-lobe organization mark-
edly resembles that of the Nedd4-like HECT domain (HECTNedd4L) 
crystallized in complex with UbcH5B~Ub6 (Fig. 1b, superposition 
with an r.m.s. deviation of 1.1 Å over 369 Cα), with the highly con-
served N-lobe Tyr616 completely buried at the interface between the 
two lobes (Fig. 1c and Supplementary Fig. 2).
Notably, the UbD in the HECTNedd4~UbD–Ub structure sits in the 
same position as does the Ub loaded on the E2 in the HECTNedd4L–
UbcH5B~Ub structure6 (Fig. 1b). The main interaction surface 
is contributed by hydrophobic residues Leu71, Leu73, Ile36 and 
Pro37 of UbD and Leu861, Met888 and Ala889 of the C lobe, and 
it is surrounded by hydrogen bonds between Gln40 and the Leu861 
main chain and between Asn892 and Leu8 and the Thr9 main 
chain, as well as by salt bridges between Asp39 and Lys860 (Fig. 1d 
and Supplementary Fig. 3). As the relative orientation between the 
two HECT lobes and between the C lobe and UbD in our structure 
is unchanged with respect to that described in another study6, we 
conclude that our structure represents the step that immediately 
follows the transfer of the thioester bond from the E2 to the E3, 
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Structure of a ubiquitin-loaded HECT ligase reveals the 
molecular basis for catalytic priming
Elena Maspero1, Eleonora Valentini1, Sara Mari1, Valentina Cecatiello2, Paolo Soffientini1,  
Sebastiano Pasqualato2 & Simona Polo1,3
Homologous	to	E6-AP	C	terminus	(HECT)	E3	ligases	recognize	and	directly	catalyze	ligation	of	ubiquitin	(Ub)	to	their	substrates.	
Molecular	details	of	this	process	remain	unknown.	We	report	the	first	structure,	to	our	knowledge,	of	a	Ub-loaded	E3,	the	human	
neural	precursor	cell–expressed	developmentally	downregulated	protein	4	(Nedd4).	The	HECTNedd4~Ub	transitory	intermediate	
provides	a	structural	basis	for	the	proposed	sequential	addition	mechanism.	The	donor	Ub,	transferred	from	the	E2,	is	bound	to	
the	Nedd4	C	lobe	with	its	C-terminal	tail	locked	in	an	extended	conformation,	primed	for	catalysis.	We	provide	evidence	that	the	
Nedd4-family	members	are	Lys63-specific	enzymes	whose	catalysis	is	mediated	by	an	essential	C-terminal	acidic	residue.
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in which the UbD has been handed over to the C lobe and is ready 
to be transferred to the substrate.
Implications	for	the	UbD	C-terminal	tail-locking
Differently from the aforementioned set of conserved contacts 
between UbD and the C lobe, the last three residues of UbD display 
a pronounced rearrangement with respect to the HECTNedd4L–
UbcH5B~Ub structure, which locks the Ub tail in an extended 
conformation (Fig. 2a,b). The UbD tail zips onto C-lobe β-strand 
β9, just upstream of the catalytic Cys867, and organizes a hydrogen 
bond pattern that results in β-sheet augmentation, a common motif in 
protein-protein interactions11. Furthermore, Arg74, which is involved 
in a single hydrogen bond with residue Ser91 of UbcH5B in the E2-
loaded conformation6, folds back onto the C lobe and contributes two 
hydrogen bonds with the main chain carboxylic groups of Gln825 
and Phe826 (Fig. 2a). We reasoned that these additional tail interac-
tions may disfavor the reversibility of the thioester transfer, so that 
the thioester bond could not be handed back from the E3 to the E2. 
Owing to the involvement of backbone carbonyls, mutational analysis 
is precluded, but we note that R74A-mutated UbD was inefficiently 
released from the E2 in a pulse-chase assay12.
A similar stretched conformation of UbD was recently observed 
in the RNF4–UbcH5A~Ub and BIRC7–UbcH5B~Ub structures13,14, 
wherein the Ub tail was shown to orient the thioester bond, held 
on the E2 in an optimal conformation for nucleophilic attack by the 
incoming lysine residue of the substrate (Fig. 2c,d). Notably, the Ub-
tail stretching has been reported also in the SUMO~RanGAP1–Ubc9–
Nup358 complex15, although in this case the crystal structure trapped 
the reaction product, with the protein modifier already transferred 
to the substrate (Fig. 2e). In the context of the HECTNedd4, the rigid 
configuration assumed by the C-terminal tail of UbD may ensure two 
important functions: it confers the directionality of the transthiolation 
reaction and, analogously to RNF4 and BIRC7, it facilitates acceptor 
recognition and optimizes the attack by the substrate lysine through 
the alignment of the thioester bond. Locking the flexible C-terminal 
tail of Ub in an extended conformation may be a common mechanism 
adopted by both E2s and E3s to prime the UbD for catalytic transfer 
to the substrate, though further structural studies are required to 
confirm this hypothesis.
Essential	role	of	the	Nedd4	C-terminal	residue	for	catalysis
Close inspection of the sequence alignment of the HECT C-terminal 
tail revealed the presence of an invariable acidic residue as the last 
amino acid within the Nedd4 family (Supplementary Fig. 4a), 
suggesting that this might be a catalytic residue important in posi-
tioning and/or activation of the incoming lysine of the Ub accep-
tor (UbA). Indeed, mutations or even deletion of this single aspartic 
acid in Nedd4 supported this idea because it resulted in wild-type 
levels of transthiolation but completely undetectable ubiquitination 
(Fig. 3a,b). We obtained similar results assessing other Nedd4 fam-
ily members: deletion of the last residue in Nedd4-like, Itch, Smurf2, 
WWP2 and Rsp5 abrogated substrate catalysis (Fig. 3c).
To test whether the C-terminal acidic residue could be in prox-
imity to the catalytic site, we replaced it with a lysine. Consistently 
with previous mutational analysis, this single substitution abrogated 
Ub-chain formation (Fig. 3d). Notably, this terminal lysine was able 
to attack the thioesther bond, as demonstrated by the stoichiometric 
amount of Ub-modified HECT present in the reaction (Fig. 3d). MS 
analysis confirmed that the ubiquitinated peptide was the C-terminal 
one containing the diglycine-modified Lys900 (Fig. 3e). In contrast, 
no Ub modification of Lys900 was visible when we used the C867S 
catalytically impaired mutant, which proves that Lys900 did not attack 
the thioester-linked E2~Ub (Fig. 3d). Thus, upon correct positioning 
of the substrate or UbA the catalytic core is formed with the terminal 
acidic residue of Nedd4 located at the active site of catalysis. Once 
there, this acid residue may perform its still-undefined function, 
either contributing to the active catalytic site or helping to position 
the UbA. Further structures are needed to uncover its specific role.
Nedd4-family	members	are	Lys63-specific	E3	ligases
Our structure did not provide clues on the UbA position. Clearly, the 
Ub bound in the UBD present in the N lobe of HECTNedd4 does not rep-
resent the UbA carrying the attacking lysine (Supplementary Fig. 1e). 
Nedd4 is a Lys63-specific E3 ligase8,9, and the UBD is not essential 
for chain specificity. Indeed, mutants in the critical residues required 
for Ub binding were defective in chain elongation but still retained 
Lys63 specificity8. Data from a previous study9 have demonstrated that 
chain type specificity is an inherent property of the HECT domain 
itself and that the determinants of chain type specificity are located 
within the last 60 amino acids of the C lobe (Supplementary Fig. 4b). 
We extended this knowledge, performing absolute-quantification 
(AQUA) experiments on various HECTs of the Nedd4 family. Our data 
demonstrated that, with wild-type Ub as a source of Ub, all Nedd4-
family members showed a clear preference for Lys63 linkage in vitro 
(Fig. 4a,b), although we failed to define a specific Lys63 sequence 
pattern by using a sequence conservation analysis (S. Polo and 
K. Hofmann, personal communication). Thus, we concluded that the 
Nedd4-family members are Lys63 specific and are characterized by a 
conserved and essential residue as the last amino acid.
Notably, other HECTs not belonging to the Nedd4 family do not 
have an acidic residue as the final amino acid (Supplementary Fig. 4a). 
Table 1 Data collection and refinement statistics
HECTNedd4~UbD–Ub HECTNedd4 A889F
Data collection
Space group R32:h P3121
Cell dimensions
 a, b, c (Å) 196.54, 196.54, 98.77 100.55, 100.55, 96.45
 α, β, γ (°) 90, 90, 120 90, 90, 120
Resolution (Å) 56.74–2.51 (2.57–2.51)a 44.58–3.00 (3.10–3.00)a
Rmerge 8.8 (88.5) 6.8 (69.7)
I / σ I 16.6 (2.9) 28.4 (3.9)
Completeness (%) 100.0 (100.0) 99.3 (99.1)
Redundancy 7.4 (7.5) 13.0 (12.4)
Refinement
Resolution (Å) 56.74–2.51 44.58–3.00
No. reflections 22,567 11,550
Rwork / Rfree 18.4 / 22.9 24.6 / 29.5
No. atoms
 Protein 4,381 3,124
 Water 112 3
B factors
  Nedd4 HECT domain 52.8 136.4
 UbD 50.4
 Ub 82.3
 Water 46.1 93.9
r.m.s. deviations
 Bond lengths (Å) 0.008 0.003
 Bond angles (°) 1.12 0.78
aValues in parentheses are for highest-resolution shell.
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Previous data indicated that E6AP preferentially synthesizes Lys48 
chains9,10. Deletion of the last amino acid of E6AP did not affect its 
activity16, which suggests a different catalytic mechanism. To gain 
insight into this difference, we substituted the last four residues after 
Nedd4 Phe896 with the three residues of E6AP. This short substitution 
showed reduced chain-formation kinetics (Fig. 4c), and the mutant 
was able to partially modify the type of the chains produced, as visual-
ized by Lys63- and Lys48-specific antibodies (Fig. 4d). On the basis 
of these results, we concluded that the last three or four amino acids 
present in the C-terminal tail of the HECT ligases might participate, 
together with the determinants present in the C lobe9, in determining 
chain specificity.
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N and C lobes, respectively; orange, UbD; yellow, noncovalently bound Ub. Right, same representation, rotated as indicated. (b) Cartoon representation 
of the superposition, done through their HECTs, of HECTNedd4~UbD–Ub with HECTNedd4L–UbcH5B~Ub (PDB 3JW0). UbcH5B is not shown, to permit 
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Ala889	is	critical	for	Nedd4	C-terminal	tail-positioning
To test the functional importance of the UbD position for substrate 
ubiquitination, we examined various HECT mutants that elicit moder-
ate catalytic effects in transthiolation reactions6. Ala889, which is con-
served in all HECT ligases (Supplementary Fig. 4a), showed a notable 
behavior. Ala889 is buried largely within the C-lobe hydrophobic core, 
surrounded by Phe826, Leu861 and Pro862. Leu73 from UbD conceals 
the residual 5-Å2 surface exposed to solvent (Fig. 1c). Mutations of 
Ala889 to other hydrophobic residues are unlikely to have a marked 
effect on the UbD position. Consistent with this, the transthiolation 
reaction occurred equally for the A889V, A889I and A889F variants. 
However, A889V and A889I mutants showed substantial impairment 
in chain elongation kinetics, whereas the A889F was a ‘dead’ mutant 
incapable of using Ub as a pseudosubstrate (Fig. 5a,b).
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Ala889 sits in helix α14, just upstream of the C-terminal tail of 
the HECT. One possibility is that Ala889 is not required per se but 
rather functions to position the C-terminal tail during catalysis. To 
investigate this possibility, we solved the structure of the Nedd4 HECT 
domain carrying the A889F mutation (Table 1). The organization 
of the N and C lobes is different from those previously observed for 
HECTNedd4 and closely resembles that adopted by the HECT domain 
of WWP1 (ref. 5 and Supplementary Fig. 5a). Mutation of Ala889 
to phenylalanine does not induce any rearrangement in the structure 
of the C lobe, which superposes with that of HECTNedd4~UbD–Ub 
with an r.m.s. deviation of 0.6 Å over 111 Cα. The bulky side chain 
of Phe889 fills a hydrophobic pocket usually occupied by the Phe826 
side chain, which is extruded from the C-lobe core and turned toward 
the C terminus (Fig. 5c and Supplementary Fig. 5b). This side chain 
extrusion, compatible with UbD loading, pushes the C-terminal tail 
far from the C-lobe core, owing to steric hindrance between the 
newly located Phe826 and Thr893 (Fig. 5c). Mutational analysis of 
Phe826 is precluded because this residue was previously shown to be 
critical for E2-to-E3 transthiolation6. Of note, substitution of Asp900 
with lysine in the context of the A889F mutant did not result in 
Lys900-modified peptide as in the case of the wild-type HECT 
(Fig. 5d). On the basis of these results, we concluded that the incor-
rect positioning of the C-terminal tail is the primary cause of the 
catalytic defect of the A889F mutant.
DISCUSSION
The structure of the HECTNedd4~UbD–Ub complex offers the first 
glimpse, to our knowledge, of a Ub-loaded HECT primed for catalysis 
and, together with the biochemical data presented here, provides a 
framework for deciphering Lys63 specificity.
A key feature of the structure is the conserved noncovalent bind-
ing of the UbD to the HECT C lobe that is preserved after the transfer 
of the thioester bond from the E2 to the E3 (this study and ref. 6). 
This finding supports the notion that formation of a Ub chain requires 
cycling of the E3 between E2 and the substrate and is fully consist-
ent with the sequential addition mechanism previously hypothesized 
for some HECT ligases: owing to steric hindrance, a Ub-loaded E2 
enzyme is unable to access the C-lobe Ub-binding site until the E3 
transfers its UbD to the substrate. Although molecular details may 
vary, Lys63 chain specificity together with sequence and structural 
conservation suggests that this catalytic mechanism may be general 
among the Nedd4 HECT–family members. This would not be neces-
sarily true for other types of HECT ligases, such as E6AP, which is able 
to build a Lys48-linked chain on its HECT cysteine residue10 and was 
recently suggested to carry two E2-binding sites17. These two features 
are indeed more compatible with the indexation or the seesaw models 
previously hypothesized5,18.
An unresolved mystery of HECT catalysis is the role exerted by 
the conserved and essential phenylalanine residue16 located most 
commonly at position –4 with respect to the C terminus of HECT 
(Phe896, position –5 in Nedd4; Supplementary Fig. 4a). We have 
been able to build this phenylalanine residue into the electron-
 density map (Fig. 1d). However, its location appears to be stabilized 
by interaction with a symmetry-related molecule, and it is probably 
not the one assumed during catalysis. We speculate that Phe896 will 
be positioned to exert its critical function only upon correct posi-
tioning of the substrate or the Ub acceptor. Its correct location will 
not necessarily be on the C lobe but possibly on an interface created 
by the correct orientation of the N and the C lobes. In the absence 
of the substrate, this binding site is not formed, as suggested by the 
fact that this residue has never been found ordered in HECT struc-
tures solved so far. This binding cleft should be conserved, because 
the phenylalanine residue is required in all the HECTs tested but 
has remained elusive because it is likely to be shaped only when the 
N and C lobes are organized with the substrate or the UbA in the 
catalytic position.
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We were able to identify a second residue within the Nedd4 family, 
the acidic residue present at the extreme C terminus, exclusively 
required for the ligation step and not for the E3 thioester formation. 
On the basis of our mutational analysis (Fig. 3) we propose a specula-
tive model about the possible catalytic mechanism adopted by Nedd4- 
family members. Upon correct positioning of the substrate or of the Ub 
acceptor in a growing chain, the catalytic core will be formed thanks 
to Phe896, which works as a pivot to guide the terminal residue of 
Nedd4 toward the active site of catalysis. However, the role of the −4 
phenylalanine remains elusive. A definitive understanding of the ubi-
quitination process will require additional high-resolution structures of 
catalytic complexes of HECT and substrates and/or Ub chains.
METHODS
Methods and any associated references are available in the online 
version of the paper.
Accession codes. Coordinates for HECTNedd4~UbD–Ub complex and 
HECTNedd4 A889F have been deposited at the Protein Data Bank 
under accession codes 4BBN and 4BE8, respectively.
Note: Supplementary information is available in the online version of the paper.
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ONLINE	METHODS
Reagents and constructs. Antibodies and their suppliers were: mouse mono-
clonal anti-Ub (ZTA10, generated in house, dilution 1:5); rabbit monoclonal 
anti-Lys48 and anti-Lys63 antibodies (clone Apu2 and Apu3, Millipore, dilu-
tion 1:1,000); streptavidin HRP and Imperial Protein Stain (Thermo Scientific). 
Biotinylated Ub was from Enzo Life Sciences. Bovine Ub was from Sigma-Aldrich. 
Nedd4 HECT–based constructs were engineered by site-directed mutagenesis. 
All other constructs were previously described8,19. All constructs were sequence-
verified. Details are available upon request.
Protein expression and purification. GST fusion proteins were expressed in E. coli 
BL21 (DE3) at 18 °C for 16 h after induction with 500 µM IPTG at an OD600 of 
0.5. Cell pellets were resuspended in lysis buffer (50 mM Na-HEPES, pH 7.5, 
200 mM NaCl, 1 mM EDTA, 0.1% NP40, 5% glycerol and Protease Inhibitor Cocktail 
set III (Calbiochem)). Sonicated lysates were cleared by centrifugation at 20,000 r.p.m. 
for 45 min. Supernatants were incubated with 1 ml of glutathione-Sepharose beads 
(GE Healthcare) per liter of bacterial culture. After 4 h at 4 °C, beads were washed 
with PBS and equilibrated in cleavage buffer (50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 
1 mM EDTA, 1 mM DTT and 5% glycerol). To cleave off GST, 10 units of PreScission 
protease (GE Healthcare) per mg of substrate were incubated for 16 h at 4 °C.
Untagged Ub G76C mutant was expressed in BL21 (DE3) E. coli at 18 °C for 
16 h after induction with 1 mM IPTG at an OD600 of 0.5. Cell pellets were resus-
pended in lysis buffer (25 mM ammonium acetate, 10 mM β-mercaptoethanol, 
10% glycerol and protease inhibitors, pH 7.0) and lysed by sonication. Cell debris 
was removed by centrifugation, and the supernatant was adjusted to pH 4.5–5.0 
with concentrated acetic acid. Precipitated proteins were removed by centrifu-
gation, and the supernatant containing the Ub monomers was passed through 
a 0.45-mm PES filter. After dialysis, Ub was purified onto a Superdex 75 size- 
exclusion chromatography column equilibrated with 20 mM Tris-HCl, pH 8.0, 
200 mM NaCl, 1 mM EDTA, 2 mM DTT and 5% glycerol. Bovine Ub was purified 
onto a Superdex 75 size-exclusion chromatography column equilibrated with 20 mM 
Tris-HCl, pH 8.0, 200 mM NaCl, 1 mM EDTA, 1 mM DTT and 5% glycerol.
HECTNedd4~UbD production. Cleaved HECTNedd4 was concentrated in Vivaspin 
concentrators (MW cutoff 30 kDa, Sartorius Stedim Biotech) and loaded onto 
a Superdex 200 size-exclusion chromatography column (GE Healthcare) equili-
brated with 20 mM Tris-HCl, pH 8.0, 200 mM NaCl, 1 mM EDTA, 1 mM DTT 
and 5% glycerol. Fractions containing HECTNedd4 were collected, concentrated at 
0.1 mM and incubated with 0.1 mM Ub G76C in the presence of 2 mM TCEP at 
room temperature for 30 min to fully reduce the cysteines. Formation of disulfide 
bonds was conducted essentially as described in ref. 20 with a dialysis treatment 
in disulfide-bond buffer (100 mM Na2HPO4– NaH2PO4, pH 7.5, 200 mM NaCl, 
5% glycerol and 25 µM CuCl2) at room temperature. Disulfide-bond formation 
was monitored by nonreducing SDS-PAGE until Ub G76C monomer depletion 
(48 h). The HECTNedd4~Ub complex was purified through a Resource Q anion-
exchange column (GE Healthcare). Fractions containing pure HECTNedd4~Ub 
complex were confirmed by nonreducing SDS-PAGE, collected and concentrated 
(Supplementary Fig. 1). HECTNedd4~Ub and bovine Ub were mixed at a ratio of 
1:2 and concentrated at 0.5 mM for subsequent crystallization studies.
Crystallization and structure determination. For the HECTNedd4~UbD–Ub 
complex, nanovolume crystallization screening experiments were performed 
at the High Throughput Crystallization Laboratory (HTX Lab) of the EMBL 
Grenoble outstation as described21. Crystals were reproduced in house in sitting 
drops in 96-well plates set up with a Honeybee Cartesian robot, with 37 mg/ml 
protein complex. Diffracting crystals were obtained at 4 °C in 2.4–2.6 M sodium 
malonate, pH 5.7–6.2. Crystals were harvested from the 96-well plate and directly 
vitrified in liquid nitrogen. Data were collected at the European Synchrotron 
Radiation Facility (Grenoble) on beamline ID14-4 at 0.9393 Å and 100 K. For 
HECTNedd4 A889F, initial hits were obtained by screening for crystallization con-
ditions in sitting drops in 96-well plates set up in house with a Honeybee Cartesian 
robot. Diffracting crystals were grown at 20 °C in hanging drops in 24-well plates 
with 1.15 M potassium sodium tartrate, 100 mM Tris-HCl, pH 9.0, using protein 
at 10 mg/ml. Crystals were cryocooled in mother liquor supplemented with 10% 
ethylene glycol, and data collection was performed at beamline X06DA (PXIII) 
of the Swiss Light Source at the Paul Scherrer Institut, at 1.0000 Å and 100 K. 
All data were processed with XDS/XSCALE22 within the automated data reduction 
system xia2 (ref. 23) or the automated go.com procedure available in house at 
beamline X06DA. The structures were solved by molecular replacement with 
Phaser24 within the CCP4 suite25, using Ub, N lobe and C lobe from PDB entry 
2XBB. The models were improved by iterative cycles of manual building in Coot26 
and refinement with phenix.refine27 and Refmac28. For HECTNedd4~UbD–Ub, 
97.9% of residues are in the favored regions of the Ramachandran plot, and no 
residues are in the disallowed regions. For HECTNedd4 A889F, 97.0% of residues 
are in the favored regions and no residues are in disallowed regions.
Ubiquitination assays. All assays were performed in ubiquitination buffer (25 mM 
Tris-HCl, pH 7.6, 5 mM MgCl2, 100 mM NaCl, 0.2 µM DTT and 2 mM ATP) with 
the HECT domain cleaved and purified as previously described and Ube2D3 as the 
E2 enzyme. Ube2D3 was produced as a His6 fusion protein and purified by using 
Ni-NTA agarose beads (Qiagen, manufacturer’s protocol) and size-exclusion chro-
matography. Bovine Ub (Sigma) was purified by size-exclusion chromatography.
For the transthiolation assay, the pulse-chase was performed in two steps. First, 
Ube2D3 (5 µM) was loaded with biotinylated Ub (10 µM) with E1 enzyme (100 nM) 
in ubiquitination buffer for 15 min at 37 °C and then quenched on ice by a two-fold 
dilution with 0.5 M EDTA. Then the loaded E2 was mixed with E3 HECTNedd4 in 
ubiquitination buffer to the following final concentrations: E2, 1.4 µM; Ub, 2.8 µM; 
E3, 1 µM. Thioester formation on the HECTNedd4 was monitored by quenching 
the reaction at different time points with Laemmli buffer without reducing agent. 
All mutants were assayed side by side with wild-type controls.
For the Ub chain formation assay, reaction mixtures (50 µl) containing puri-
fied enzymes (20 nM E1, 250 nM purified His6-tagged Ube2D3 and 500 nM 
HECTNedd4) and 1.25 µM of Ub in ubiquitination buffer were incubated at 37 °C 
and stopped at the different time points by addition of 4× Laemmli buffer with 
reducing agent (100 mM DTT).
For Ub AQUA analysis, reaction mixtures (20 µl) containing purified enzymes 
(50 nM E1, 1.5 µM purified His6-tagged Ube2D3 and 2.2 µM HECT) and 
12.5 µM of Ub in ubiquitination buffer were incubated at 37 °C for 1 h and 
stopped by addition of 4× Laemmli buffer with reducing agent (100 mM DTT).
Mass spectrometry and quantitative analysis. Proteins were resolved by SDS-
PAGE on a gradient gel (4–12% TGX Precast Gel, Bio-Rad) and stained with 
colloidal blue (Colloidal Blue Staining Kit, Invitrogen). Gel bands corresponding 
to Ub-modified HECT were digested with trypsin. Briefly, samples were subjected 
to reduction in 10 mM DTT for 1 h at 56 °C. Digestion was carried out by satu-
rating the gel with 12.5 ng/µl sequencing-grade modified trypsin (Promega) in 
50 mM ammonium bicarbonate overnight. Peptide mixtures were acidified with 
trifluoroacetic acid (TFA, final concentration 3%), extracted from gel slices with 
30% acetonitrile (ACN)/ 3% TFA and concentrated to 100 µl in a vacuum concen-
trator. Peptides were loaded onto homemade C18-stage tips, dried and dissolved 
in 5% formic acid (FA) before analysis on the Agilent 1100 LC system (Agilent) 
coupled to Ultra LTQ-FT (Thermo Fisher Scientific). MS data were analyzed for 
protein identification and presence of diglycine signature by using Mascot con-
sidering the following parameters: Gly-Gly (K) +114.043 Da, Leu-Arg-Gly-Gly 
(K) +383.228 Da, peptide tolerance 10 p.p.m., MS/MS tolerance 0.5 Da.
For AQUA analysis, samples were directly dissolved with a solution of refer-
ence peptides for Lys6, Lys11, Lys27, Lys29, Lys33, Lys48 and Lys63 polyubiquitin 
branched chains (Cell Signaling Technology) in 5% formic acid. Samples were ana-
lyzed by using a range of reference-peptide concentrations spanning from 1 pico-
mole to 100 femtomoles, injecting three technical replicates per concentration. All 
spectra were acquired in data-dependent mode. Ion chromatograms for reference 
and sample peptide-pair precursor ions were manually extracted with Xcalibur 
v1.4 (ThermoElectron). Chromatographic coelution of reference and endogenous 
peptide pairs and accurate peak integration were manually confirmed.
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Structure of the HECT:ubiquitin complex and its role
in ubiquitin chain elongation
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Several mechanisms have been proposed for the synthesis of
substrate-linked ubiquitin chains. HECT ligases directly catalyse
protein ubiquitination and have been found to non-covalently
interact with ubiquitin. We report crystal structures of the Nedd4
HECT domain, alone and in complex with ubiquitin, which show
a new binding mode involving two surfaces on ubiquitin and both
subdomains of the HECT N-lobe. The structures suggest a model
for HECT-to-substrate ubiquitin transfer, in which the growing
chain on the substrate is kept close to the catalytic cysteine to
promote processivity. Mutational analysis highlights differences
between the processes of substrate polyubiquitination and
self-ubiquitination.
Keywords: catalysis; E3 ligase; polyubiquitination; structure;
ubiquitin
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INTRODUCTION
The ubiquitination process is carried out by an enzymatic cascade
that includes an activating enzyme (E1), a conjugating enzyme
(E2) and a ligase (E3; Dye & Schulman, 2007). The transfer of the
ubiquitin moiety from the thioester-linked E3 (in HECT-type
ligases) to the acceptor lysine on the substrate is the last step of this
process. Subsequent chain elongation requires the modification of
specific lysine residues in consecutive ubiquitin moieties. With
few exceptions (Petroski & Deshaies, 2005; Jin et al, 2008), little
is known about the mechanisms of ubiquitin-chain assembly,
although various models have been proposed (Hochstrasser, 2006).
The Nedd4 family of HECT domain E3 ligases is a well-
characterized class of enzymes that present a conserved modular
organization with an amino-terminal C2 domain that is crucial for
membrane localization, between two and four WW domains that
recognize substrates and adaptor proteins and a carboxy-terminal
catalytic HECT domain. In humans, there are nine members of
this family that are implicated in a range of biological processes
such as endocytosis, protein transport, viral budding, signalling,
cellular growth and proliferation (Rotin & Kumar, 2009). This
class of E3 enzymes seems to use a sequential addition
mechanism, by which ubiquitin molecules are added one
at a time from the catalytic cysteine to the distal lysine of the
growing chain (Kim & Huibregtse, 2009). A key question is how
E3 enzymes deal with the shifting position of the acceptor site
during chain elongation.
Two groups have recently identified a surface implicated in
non-covalent ubiquitin binding on the HECT-type E3 ligases Rsp5
and Smurf2 (French et al, 2009; Ogunjimi et al, 2010). This
surface was proposed to have a role in regulating polyubiquitina-
tion, although opposite mechanisms were suggested by the
groups, with the surface being required to either restrict the
length of polyubiquitin chains synthesized by the HECT domain
(French et al, 2009) or to promote polyubiquitination (Ogunjimi
et al, 2010). In this study, we show the crystal structure of the
HECT domain of Nedd4 alone and in complex with ubiquitin, and
we present molecular insights into the mechanism by which
Nedd4 catalyses polyubiquitination.
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RESULTS AND DISCUSSION
Structure of HECTNedd4 and HECTNedd4:ubiquitin
We characterized the interaction of the isolated HECT domain of
Nedd4 (HECTNedd4) with ubiquitin in detail. The ubiquitin-binding
ability resides in the N-lobe, does not show preference for Lys 63-
or Lys 48-polyubiquitin chains and requires the canonical
hydrophobic patch on ubiquitin, centred on Ile 44 (supplementary
Fig S1 online). We extended this analysis to the other mammalian
Nedd4 family members and found that only a subset of these
HECT domains binds to ubiquitin, namely Nedd4, Nedd4-like and
Smurf2 (Fig 1A).
To understand how ubiquitin binds to the HECT, we determined
the crystal structure of the HECTNedd4 in isolation (at 2.5 A˚) and
in complex with ubiquitin (at 2.7 A˚) by molecular replacement
(supplementary Table S1 online and supplementary Fig S2 online).
In both structures, HECTNedd4 displays the typical HECT fold
(Huang et al, 1999; Verdecia et al, 2003; Ogunjimi et al, 2005)
composed of two lobes connected by a flexible hinge (Fig 1B,C).
The N-lobe, an elongated array of helices and b-hairpins, consists
of two moieties, known as the large and small subdomains (Fig 1B).
The small subdomain, which hosts the E2-binding site, comprises
helices a6–a8 and b-sheets b5–b6 (Huang et al, 1999; Kamadurai
et al, 2009). The large subdomain of the N-lobe is present below
the C-lobe, an a/b sandwich domain that carries the catalytic
cysteine. The orientation of the C-lobe differs in the two HECTNedd4
structures, and both orientations are distinct from those of
previously reported HECT domain structures (supplementary
Fig S3 online). This highlights the freedom of movement of the
C-lobe, which is key for the catalytic function of HECT domains
(Verdecia et al, 2003; Kamadurai et al, 2009).
Non-covalent ubiquitin binding to HECTNedd4 conceals a
solvent-accessible interaction surface area on ubiquitin of
approximately 900 A˚2, the largest surface identified so far for
ubiquitin-binding domains (supplementary Table S2 online).
Ubiquitin makes contact with Glu 554 and neighbouring residues
of helix a1; Tyr 604, Tyr 605 and Tyr 610 from the region
comprising helix a30 and strand b3; Asn 628 and Glu 629 from
helix a40 and the ensuing loop; and Phe 707 and neighbouring
residues of the b5–b6 beta hairpin. These residues are distributed
in both the small and the large subdomains of the N-lobe
(Figs 1E,2A). In the absence of ubiquitin, the relative orientation of
the small and large subdomains is not fixed and varies for different
structures (Huang et al, 1999; Verdecia et al, 2003; Ogunjimi
et al, 2005). Ubiquitin binding might therefore be expected
to stabilize a specific reciprocal orientation of the N-lobe
subdomains. Indeed, superposition of the large subdomains
of HECTNedd4 and HECTNedd4:ubiquitin (root mean square
deviation of 0.6 A˚ over 181 Ca) clearly indicates a relative
movement of the b5–b6 hairpin of the small subdomain in the
HECTNedd4:ubiquitin structure by approximately 5 A˚ towards the
large subdomain of the N-lobe (Fig 1D).
As predicted by the defective behaviour of the I44A ubiquitin
mutant (supplementary Fig S1C online), the interaction surface on
ubiquitin involves the canonical Ile 44 hydrophobic patch, which
also includes Gly 47, Leu 8 and Val 70 (Fig 2A). However, the
surface of interaction is not limited to this patch, but extends to a
‘second hydrophobic patch’, including the residues Ile 36/Leu 71/
Leu 73, the role of which has recently been discussed in the
context of the E2-to-HECT ubiquitin transfer (Kamadurai et al,
2009; Fig 2A; supplementary Fig S4 online). The Asn 628, Tyr 634
and Glu 554 side chains on Nedd4 form hydrogen bonds with the
main chain nitrogen atoms of ubiquitin-Leu 73, Arg 74 and Gly 75,
whereas the ubiquitin-Leu 73 side chain is stacked between
Tyr 634 and Tyr 605 of Nedd4.
We generated Nedd4 mutants that substantiate the functional
importance of both interacting patches on ubiquitin. Mutation
of Tyr 605 to Ala (Y605A) or Phe 707 to Ala (F707A) almost
abolished HECTNedd4 binding to Lys 63 ubiquitin (Fig 2B). Phe 707
to Tyr (F707Y), Asn 628 to Ala (N628A) or Glu 629 to Ala (E629A)
mutations had milder effects, preserving the association with
higher molecular weight Lys 63 ubiquitin to varying degrees
(Fig 2B). We confirmed these results by measuring the interaction
between the HECT domains and monomeric and dimeric
ubiquitin by fluorescence polarization and surface plasmon
resonance (SPR) assay (Fig 2C; supplementary Fig S1D–F online).
Both ubiquitin ligands interact with the HECT with rapid kinetics
(fast Kon and Koff rate constants, data not shown). Wild-type
HECTNedd4 displays a moderate affinity (KD approximately 11 mM)
in the range of those reported for ubiquitin-binding domains
(supplementary Table S2 online), whereas Y605A and F707A
mutations show from 20- to 30-fold decreases in binding (Fig 2C;
supplementary Fig S1F online).
Role of ubiquitin binding in Nedd4 activity
Next, we analysed the catalytic activity of Nedd4 HECT mutants.
In principle, the ubiquitin-binding surface might have a role at
three stages of the E3 catalysis: binding to the E2, transthiolation
process from E2 to E3 or substrate ubiquitination. We tested all of
these possibilities using the isolated HECT, which retains the
ability to ubiquitinate itself as well as substrates, albeit with
reduced efficiency (not shown).
Pull-down and SPR assays showed that mutants have no
significant impairment in binding with either the apo or the
ubiquitin thioester-linked form of E2 enzyme Ube2D3 (Fig 3A and
data not shown). Indeed, the E2 binding is built on an adjacent but
non-overlapping surface on the large subdomain of the N-lobe
(Huang et al, 1999; Fig 4C). We then tested the importance of
the ubiquitin-binding surface in the E2-to-HECT transthiolation
process by using a pulse-chase protocol (Fig 3B). Again, no
appreciable transthiolation defects were observed for the mutants,
supporting the notion that the ubiquitin-binding surface is not
involved in the upstream steps of the enzymatic cascade. Of note,
the thioester HECTBubiquitin bond is unstable and the ubiquitin
moiety is immediately transferred to the lysine/s of the HECT, as
demonstrated by the appearance of higher molecular-weight
proteins that are resistant to dithiothreitol treatment (Fig 3B,
lower panels).
These results led us to propose that the ubiquitin-binding
surface on the HECT might act to bind a ubiquitin moiety that is
already conjugated to a substrate, thus promoting polyubiquitina-
tion. Indeed, when we assayed F707A and Y605A in an in vitro
ubiquitination reaction, we found that mutations in the ubiquitin-
binding surface strongly impaired free-chain formation and
ubiquitination of all the substrates tested (Fig 3C; supplementary
Fig S5 online). The mutant enzymes were efficient in the first cycle
of substrate ubiquitination and in ubiquitin dimer formation, using
free ubiquitin as a pseudosubstrate (Fig 3C; supplementary Fig S5
online). This was confirmed by using a ubiquitin Lys 0 mutant and
Structure of the HECTNedd4:ubiquitin complex
E. Maspero et al
&2011 EUROPEAN MOLECULAR BIOLOGY ORGANIZATION EMBO reports VOL 12 | NO 4 | 2011
scientificreport
343
Ubiquitin
N-lobe HECTNedd4/Ub
N-lobe HECTNedd4
C
N-lobe
large subdomain
α6
α7
α7′
α1
α10
α9
α4′α4
α3′
α2
α1′α3
α8
β5
β4 β3β2
β1
β6
C-lobe
N-lobe N
C
N-lobe
small subdomain
C-lobe
N
C
N
C
N-lobe
Ubiquitin
A B
D
IT
CHSm
ur
f2
Ne
dd
4-
lik
e
W
W
P2
W
W
P1
Ne
dd
4
GS
T
IB:
Coomassie
Ub
20
kDa
15
30
60
10
E6
AP
40
Ub2
Ub4
Ub3
Ub5
Ub6-n
Ub
Inp
ut
E
C-lobe
N-lobe
HsNedd4_2xbb
HsNedd4-like_2oni
ScRsp5_3olm
HsSmurf2_1zvd
HsWWP1_1nd7
HsE6AP_1c4z
HsNedd4_2xbb
HsNedd4-like_2oni
ScRsp5_3olm
HsSmurf2_1zvd
HsWWP1_1nd7
HsE6AP_1c4z
HsNedd4_2xbb
HsNedd4-like_2oni
ScRsp5_3olm
HsSmurf2_1zvd
HsWWP1_1nd7
HsE6AP_1c4z
HsNedd4_2xbb
HsNedd4-like_2oni
ScRsp5_3olm
HsSmurf2_1zvd
HsWWP1_1nd7
HsE6AP_1c4z
520 530 540 550 560 570 580 590 600 610
α1′ α2β1 α1 α3 β3 β4β2 α3′
620 630 640 650 660 670 680 690 700 710
α6α5α4 β6β5α7 α7′α4′β4
720 730 740 750 760 770 780 790 800 810
α8 β7α10α10′ α11α9 α12 α13
α13 α14β8 β9 β10
Sequence identity
100 0%50
820 830 840 850 860 870 880 890 900
Structure of the HECTNedd4:ubiquitin complex
E. Maspero et al
EMBO reports VOL 12 | NO 4 | 2011 &2011 EUROPEAN MOLECULAR BIOLOGY ORGANIZATION
scientificreport
344
quantification of the results repeated as fold differences between
wild-type HECT and mutants (supplementary Fig S5A online).
Interestingly, F707A and Y605A mutations did not affect self-
ubiquitination of Nedd4 (Fig 3B, lower panels and Fig 3D),
indicating that this in cis reaction is a catalytically distinct
process that cannot be used as a surrogate assay for ligase activity
on substrates.
Most HECT E3s synthesize polyubiquitin chains with specific
linkages (Wang et al, 2006; Kim et al, 2007). To gain insight into
the type of chains synthesized by Nedd4, we tested substrate
ubiquitination using ubiquitin-bearing individual lysine-to-argi-
nine mutations (KR mutants). We found that Nedd4 has a strong
preference for building Lys 63-chains on substrates, a feature
retained by the F707A mutant (Fig 4A). Consistent with previous
data, however, F707A has defective chain elongation on substrate
and shorter free chains, regardless of the type of ubiquitin used
(Fig 4A). Therefore, we conclude that the ubiquitin-binding
surface on the HECT acts to promote substrate polyubiquitination,
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Fig 2 | HECTNedd4:ubiquitin interaction and mutant validation. (A) Close-up view of HECTNedd4 N-lobe:ubiquitin interaction. (B) GST pull-down assay
with the indicated Nedd4 constructs and Lys 63-linked polyubiquitin chains was performed as described in Fig 1A. (C) Fluorescence-polarization assay
with the indicated Nedd4 constructs and monomeric ubiquitin was performed. The HECTNedd4:ubiquitin interaction displays a moderate affinity with a
KD of 11 mM, F707A mutant displays a thirty times lower affinity. Details are described in the supplementary Methods online and similar results for
the Y605A mutant obtained by SPR assay are in supplementary Fig S1 online. IB, immmunoblotting; GST, glutathione S-transferase; SPR, surface
plasmon resonance; Ub, ubiquitin; WT, wild type.
Fig 1 | Structure of the HECTNedd4 domain in apo form and in complex with ubiquitin. (A) GST pull-down assay with the HECT domains of various
Nedd4 family HECT E3 ligases. GST-fusion proteins were incubated for 2 h at 4 1C in YY buffer with synthetic Lys 63-polyubiquitin chains and
analysed by IB as indicated. Coomassie staining shows comparable loading of GST proteins. Similar results were obtained with linear and
Lys 48-polyubiquitin chains (not shown). (B) Overall structure of HECTNedd4 (N-lobe, blue; C-lobe, green). The red dotted line indicates the boundary
between the large and small subdomains of the N-lobe. (C) Overall structure of HECTNedd4 in complex with ubiquitin (yellow). The HECT structure
is represented in the same orientation as in B; N-lobe, light blue; C-lobe, dark green. (D) Superposition on the large subdomain of the N-lobe of
HECTNedd4 and HECTNedd4:ubiquitin. In the complex (light blue), the b5–b6 hairpin of the small subdomain of the N-lobe is closer to the large
subdomain, with respect to the isolated HECT (dark blue). (E) Sequence alignment of the HECTNedd4 domain with other crystallized HECT domains.
Secondary structure elements are depicted. Dotted line indicates that the residues were not visible in the electron density maps. Yellow circles indicate
residues in contact with ubiquitin in the structure of HECTNedd4:ubiquitin (according to PISA; Krissinel & Henrick, 2007). Numbering refers to Nedd4
sequence. GST, glutathione S-transferase; IB, immunoblotting; Ub, ubiquitin.
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but it does not dictate the preference for a specific lysine during
elongation. Indeed, recent observations suggest that the C-lobe,
rather than the ubiquitin-binding N-lobe, is the crucial determi-
nant of lysine selection during elongation (Kim & Huibregtse,
2009).
CONCLUSIONS
Collectively, our results support the hypothesis that the ubiquitin-
binding surface is required for the processivity of the poly-
ubiquitination reaction (Ogunjimi et al, 2010), rather than for
limiting chain elongation, as suggested previously (French et al,
2009). How can this occur? It is tempting to envision a model in
which the distal ubiquitin on the substrate occupies this surface,
promoting retention of the ubiquitinated substrate to the E3, and
also keeping the small subdomain of the N-lobe in a conformation
that favours processive ubiquitin addition. This could be achieved
by either reducing the gap between the catalytic cysteine of the
HECT and the C-terminus of ubiquitin linked to the E2 enzyme
(Kamadurai et al, 2009) or by facilitating the transfer of a
subsequent ubiquitin to the HECT-bound substrate. In support of
this model, we found that the non-covalent ubiquitin-binding
surface that we mapped remains accessible in the complex of the
HECT domain of Nedd4-like with the ubiquitin-loaded E2
(Kamadurai et al, 2009; Fig 4C).
Our data support the notion that Nedd4 adopts a simple
sequential-addition model to build a chain on a substrate; after the
first ubiquitin is attached, the chain is elongated through Lys 63
linkage, because of the ability of the N-lobe to maintain the
growing polyubiquitin chain in close proximity. A similar
conclusion about the role of the HECT ubiquitin-binding site in
promoting chain elongation was reached in the accompanying
study by Kim et al (2011) on Rsp5. Although the position of Lys 63
on bound ubiquitin does not seem to be able to orient the growing
chain towards the E2 catalytic cysteine (Fig 4B), the average B
factors for the ubiquitin molecules are considerably higher than
those of their HECT counterparts (approximately 76A2 for
ubiquitin molecules, approximately 48A2 for HECT domains;
supplementary Table S1 online), suggesting freedom of movement
of ubiquitin on its docking site. This could imply that the binding of
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ubiquitin to the E3 is strong enough to promote polyubiquitination,
yet loose enough to allow chain growth, possibly through a
slippage mechanism by which the ubiquitin-binding surface
specifically binds to the distal ubiquitin at the end of the chain.
The moderate affinity and fast kinetic rates of the HECT:ubiquitin
interaction fit well with such a mechanism. Future structural studies
with Nedd4 in complex with a ubiquitinated substrate might be
required to provide a definitive picture of this dynamic process.
The detailed molecular view provided by our structure allows
the identification of the crucial residues required for binding
(Fig 1E), which can be used to predict the HECT E3 enzymes that
are able to bind to ubiquitin. It remains to be established whether
the presence of this binding surface might determine the
mechanism of chain synthesis adopted by the different HECT
ligases to become processive.
At our level of understanding, generalizing the mechanisms
that underlie polyubiquitination would be premature, but it is
interesting to note from the comparison of the small Nedd4 family
of E3, that nature has used a variety of protein architectures to
ensure specificity.
METHODS
Crystallization and structure determination. Crystals of HECTNedd4
and HECTNedd4:ubiquitin complex were obtained by sitting-drop
vapour diffusion at 20 1C, using a Honeybee Cartesian robot in 96-
well plates. Diffraction-quality crystals were obtained by optimizing
the initial conditions in 24-well plates, hanging drops at 20 1C.
Crystals were all optimized by microseeding. For HECTNedd4, the
optimized conditions were 100mM Na-MES, pH 6.0, 2–4% PEG
400 or PEG 600, 30–60mM CaCl2 or MgCl2, 5mM tris(2-
carboxyethyl)phosphine, with protein concentration in the 2.5–
5mg/ml range. Crystals were cryoprotected in 100mM Na-MES,
pH 6.0, 4% PEG 400, supplemented with 20% ethylene glycol. The
structure was solved with a data set collected at the European
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Synchrotron Radiation Facility (ESRF) at beamline ID14-2. For the
HECTNedd4:ubiquitin complex, initial crystals were obtained in
100mM Na-HEPES, pH 7–8, 10–20% PEG 2000 MME, 5mM
tris(2-carboxyethyl)phosphine, with proteins purified individually,
then mixed in a 1:1molar ratio and a concentration of approximately
30mg/ml. To obtain good-quality diffraction and to overcome
twinning, the complex was crystallized in the presence of excess
ubiquitin (600–900mM of complex, 1.2 –2.3 ubiquitin molar
excess), lower concentration of PEG 2000 MME (2–10%), and the
crystals were carefully frozen by equilibrating them into cryo-buffer
(100mM Na-HEPES, pH 7.5, 10% PEG 2000 MME) with increasing
concentrations of glycerol, reaching a final concentration of
20%. The structure was solved with a data set collected at the
ESRF at beamline ID14-1 on a crystal grown in a 1.9 ubiquitin
molar excess.
X-ray diffraction data were processed with HKL2000
(Otwinowski & Minor, 1997) or XDS (Kabsch, 2010). Both
structures were solved by molecular replacement with Phaser
within the CCP4 suite (CCP4, 1994), using as a search model the
HECT domain of Nedd4-like (Protein Data Bank entry 2oni) in the
case of HECTNedd4, and HECTNedd4 and a high-resolution structure
of ubiquitin (Protein Data Bank entry 1ubi) in the case of
HECTNedd4:ubiquitin complex. Initial models were refined with
the CNS suite (Brunger, 2007), Refmac (Murshudov et al, 1997),
the Phenix suite (Adams et al, 2010) and manual building in Coot
(Emsley et al, 2010). For the HECTNedd4:ubiquitin complex, non-
crystallographic symmetry (NCS) restraints were used in refine-
ment. In the first cycles of refinement carried out with Refmac,
HECT molecules were divided into two NCS groups (the N-lobe
and the C-lobe), and ubiquitin molecules were the third NCS
group. For further refinement cycles carried out with phenix.re-
fine, five NCS groups were used: ubiquitin molecules and HECT
domain residues 522:699, 724:778, 785:828 and 850:891, thus
not subjecting HECT domain loops to NCS restraints. Structure
representations were generated with Pymol (DeLano Scientific
LLC). HECTNedd4 crystallized in spacegroup C2, whereas
HECTNedd4:ubiquitin crystallized in spacegroup P21, with two
complexes per asymmetrical unit. The two complexes differ
slightly in the orientation of the HECTNedd4 C-lobe with respect
to the N-lobe, and the relative orientation of HECTNedd4 with
respect to ubiquitin, but the interactions discussed here are
present in both complexes. Superpositions of pairs of domains of
the asymmetrical unit indicate that they are almost identical (root
mean square deviations of N-lobes: 0.36 A˚ over 260 Ca; C-lobes:
0.63 A˚ over 115 Ca; Ubs: 0.25 A˚ over 76 Ca).
Ubiquitination assay. Ubiquitination assays were performed with
HECT domains produced as glutathione S-transferase (GST) fusion
proteins and cleaved with PreScission protease. The E2 enzyme
Ube2D3, was produced as a His6-fusion protein and eluted from
Ni-NTA Agarose beads (Qiagen). Reaction mixtures contained
purified enzymes (20 nM E1, 250 nM of purified His6-tagged
Ube2D3, 250 nM HECTNedd4), 300 nM of substrate (g epithelial
Naþ channel and LMP2A were produced as GST fusion proteins
and used attached to glutathione beads) and 1 mM of ubiquitin in
ubiquitination buffer (25mM Tris–HCl, pH 7.6, 5mM MgCl2,
100mM NaCl, 0.2 mM dithiothreitol, 2mM ATP). Reactions were
incubated at 37 1C. At the indicated time point, samples were
centrifuged to separate the pellet—containing the ubiquitinated
substrates—and the supernatant—containing the enzymes and the
soluble ubiquitin chains, if produced. The pellet was washed
four times in YY buffer (50 mM Na-HEPES pH 7.5, 150 mM NaCl,
1mM EDTA, 10% glycerol, 1% triton X-100) before loading on
SDS–polyacrylamide gel electrophoresis gel. For self-ubiquitina-
tion reaction, the mixtures contained 20nM E1, 250 nM of
purified His6-tagged Ube2D3, 250 nM of GST-HECTNedd4 and
0.5 mM of ubiquitin in ubiquitination buffer. Detection was
performed by immunoblotting using specific antibody. Coomas-
sie-stained membrane was used to show loading of GST-fusion
protein after immunoblotting.
Reagents and constructs, protein expression and purification,
transthiolation assay, pull-down experiments, fluorescence
polarization assay and SPR are described in the supplementary
Methods online.
Accession codes: Coordinates for HECTNedd4 and the HECTNedd4:
ubiquitin complex have been deposited at the Protein Data Bank
under accession codes 2xbf and 2xbb, respectively.
Supplementary information is available at EMBO reports online
(http://www.emboreports.org).
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